

Frederik Barkhof

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8877219/publications.pdf>

Version: 2024-02-01

1,531
papers

119,803
citations

153

156
h-index

364

282
g-index

1654
all docs

1654
docs citations

1654
times ranked

59768
citing authors

#	ARTICLE	IF	CITATIONS
1	Diagnosis of multiple sclerosis: 2017 revisions of the McDonald criteria. <i>Lancet Neurology</i> , The, 2018, 17, 162-173.	4.9	4,605
2	Neuroimaging standards for research into small vessel disease and its contribution to ageing and neurodegeneration. <i>Lancet Neurology</i> , The, 2013, 12, 822-838.	4.9	3,919
3	Consistent resting-state networks across healthy subjects. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 13848-13853.	3.3	3,817
4	Defining the clinical course of multiple sclerosis. <i>Neurology</i> , 2014, 83, 278-286.	1.5	2,344
5	Oral Fingolimod or Intramuscular Interferon for Relapsing Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2010, 362, 402-415.	13.9	1,983
6	A New Rating Scale for Age-Related White Matter Changes Applicable to MRI and CT. <i>Stroke</i> , 2001, 32, 1318-1322.	1.0	1,506
7	Atrophy of medial temporal lobes on MRI in "probable" Alzheimer's disease and normal ageing: diagnostic value and neuropsychological correlates.. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1992, 55, 967-972.	0.9	1,357
8	Comparison of MRI criteria at first presentation to predict conversion to clinically definite multiple sclerosis. <i>Brain</i> , 1997, 120, 2059-2069.	3.7	1,077
9	Reduced resting-state brain activity in the "default network" in normal aging. <i>Cerebral Cortex</i> , 2008, 18, 1856-1864.	1.6	1,051
10	Effect of early interferon treatment on conversion to definite multiple sclerosis: a randomised study. <i>Lancet</i> , The, 2001, 357, 1576-1582.	6.3	1,025
11	A semiquantitative rating scale for the assessment of signal hyperintensities on magnetic resonance imaging. <i>Journal of the Neurological Sciences</i> , 1993, 114, 7-12.	0.3	870
12	Evaluation of Patients Treated with Natalizumab for Progressive Multifocal Leukoencephalopathy. <i>New England Journal of Medicine</i> , 2006, 354, 924-933.	13.9	744
13	Increased MRI activity and immune activation in two multiple sclerosis patients treated with the monoclonal anti-tumor necrosis factor antibody cA2. <i>Neurology</i> , 1996, 47, 1531-1534.	1.5	705
14	Cortical lesions in multiple sclerosis. <i>Brain</i> , 1999, 122, 17-26.	3.7	703
15	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2006, 67, 1242-1249.	1.5	684
16	MRI criteria for the diagnosis of multiple sclerosis: MAGNIMS consensus guidelines. <i>Lancet Neurology</i> , The, 2016, 15, 292-303.	4.9	679
17	Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study. <i>Human Brain Mapping</i> , 2005, 26, 231-239.	1.9	675
18	Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. <i>Annals of Neurology</i> , 1999, 46, 747-754.	2.8	674

#	ARTICLE	IF	CITATIONS
19	Ocrelizumab in relapsing-remitting multiple sclerosis: a phase 2, randomised, placebo-controlled, multicentre trial. <i>Lancet, The</i> , 2011, 378, 1779-1787.	6.3	636
20	Histopathologic correlate of hypointense lesions on T1-weighted spin-echo MRI in multiple sclerosis. <i>Neurology</i> , 1998, 50, 1282-1288.	1.5	619
21	Heterogeneity of small vessel disease: a systematic review of MRI and histopathology correlations. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 126-135.	0.9	588
22	The clinico-radiological paradox in multiple sclerosis revisited. <i>Current Opinion in Neurology</i> , 2002, 15, 239-245.	1.8	580
23	Measurement of atrophy in multiple sclerosis: pathological basis, methodological aspects and clinical relevance. <i>Brain</i> , 2002, 125, 1676-1695.	3.7	534
24	Loss of "Small-World" Networks in Alzheimer's Disease: Graph Analysis of fMRI Resting-State Functional Connectivity. <i>PLoS ONE</i> , 2010, 5, e13788.	1.1	523
25	Global and local gray matter loss in mild cognitive impairment and Alzheimer's disease. <i>NeuroImage</i> , 2004, 23, 708-716.	2.1	522
26	Clinically isolated syndromes suggestive of multiple sclerosis, part I: natural history, pathogenesis, diagnosis, and prognosis. <i>Lancet Neurology, The</i> , 2005, 4, 281-288.	4.9	513
27	Prevalence of Amyloid PET Positivity in Dementia Syndromes. <i>JAMA - Journal of the American Medical Association</i> , 2015, 313, 1939.	3.8	501
28	Predictive value of gadolinium-enhanced magnetic resonance imaging for relapse rate and changes in disability or impairment in multiple sclerosis: a meta-analysis. <i>Lancet, The</i> , 1999, 353, 964-969.	6.3	476
29	Intracortical Lesions in Multiple Sclerosis: Improved Detection with 3D Double Inversion-Recovery MR Imaging. <i>Radiology</i> , 2005, 236, 254-260.	3.6	470
30	Effect of early versus delayed interferon beta-1b treatment on disability after a first clinical event suggestive of multiple sclerosis: a 3-year follow-up analysis of the BENEFIT study. <i>Lancet, The</i> , 2007, 370, 389-397.	6.3	468
31	Strategic roadmap for an early diagnosis of Alzheimer's disease based on biomarkers. <i>Lancet Neurology, The</i> , 2017, 16, 661-676.	4.9	464
32	Guidelines for the use of magnetic resonance techniques in monitoring the treatment of multiple sclerosis. <i>Annals of Neurology</i> , 1996, 39, 6-16.	2.8	445
33	Accumulation of hypointense lesions ("black holes") on T ₁ spin-echo MRI correlates with disease progression in multiple sclerosis. <i>Neurology</i> , 1996, 47, 1469-1476.	1.5	440
34	Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REBif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial. <i>Lancet Neurology, The</i> , 2008, 7, 903-914.	4.9	437
35	Grey matter pathology in multiple sclerosis. <i>Lancet Neurology, The</i> , 2008, 7, 841-851.	4.9	422
36	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—establishing disease prognosis and monitoring patients. <i>Nature Reviews Neurology</i> , 2015, 11, 597-606.	4.9	422

#	ARTICLE	IF	CITATIONS
37	Genome-wide association analysis of susceptibility and clinical phenotype in multiple sclerosis. <i>Human Molecular Genetics</i> , 2009, 18, 767-778.	1.4	419
38	Vitamin D as an Early Predictor of Multiple Sclerosis Activity and Progression. <i>JAMA Neurology</i> , 2014, 71, 306.	4.5	402
39	The behavioural/dysexecutive variant of Alzheimer's disease: clinical, neuroimaging and pathological features. <i>Brain</i> , 2015, 138, 2732-2749.	3.7	397
40	A phase III randomized trial of gantenerumab in prodromal Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 95.	3.0	396
41	A comprehensive study of gray matter loss in patients with Alzheimer's disease using optimized voxel-based morphometry. <i>NeuroImage</i> , 2003, 18, 895-907.	2.1	388
42	Inter-and Intraobserver Reproducibility of Cerebral Atrophy Assessment on MRI Scans with Hemispheric Infarcts. <i>European Neurology</i> , 1996, 36, 268-272.	0.6	383
43	Arterial Spin Labeling Perfusion of the Brain: Emerging Clinical Applications. <i>Radiology</i> , 2016, 281, 337-356.	3.6	360
44	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. <i>Annals of Neurology</i> , 2000, 47, 831-835.	2.8	356
45	Association between pathological and MRI findings in multiple sclerosis. <i>Lancet Neurology</i> , The, 2012, 11, 349-360.	4.9	356
46	Alzheimer's disease: connecting findings from graph theoretical studies of brain networks. <i>Neurobiology of Aging</i> , 2013, 34, 2023-2036.	1.5	355
47	MAGNIMS consensus guidelines on the use of MRI in multiple sclerosis—clinical implementation in the diagnostic process. <i>Nature Reviews Neurology</i> , 2015, 11, 471-482.	4.9	354
48	Visual assessment of medial temporal lobe atrophy on magnetic resonance imaging: Interobserver reliability. <i>Journal of Neurology</i> , 1995, 242, 557-560.	1.8	352
49	Imaging outcomes for neuroprotection and repair in multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2009, 5, 256-266.	4.9	352
50	Frontal-Striatal Dysfunction During Planning in Obsessive-Compulsive Disorder. <i>Archives of General Psychiatry</i> , 2005, 62, 301.	13.8	351
51	Mechanism of Amyloid Removal in Patients With Alzheimer Disease Treated With Gantenerumab. <i>Archives of Neurology</i> , 2012, 69, 198.	4.9	349
52	Progression of White Matter Hyperintensities and Incidence of New Lacunes Over a 3-Year Period. <i>Stroke</i> , 2008, 39, 1414-1420.	1.0	348
53	Changes in white matter as determinant of global functional decline in older independent outpatients: three year follow-up of LADIS (leukoaraiosis and disability) study cohort. <i>BMJ: British Medical Journal</i> , 2009, 339, b2477-b2477.	2.4	348
54	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis: concerted action guidelines. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1991, 54, 683-688.	0.9	346

#	ARTICLE	IF	CITATIONS
55	Structural magnetic resonance imaging in the practical assessment of dementia: beyond exclusion. <i>Lancet Neurology</i> , The, 2002, 1, 13-21.	4.9	337
56	Regional DTI differences in multiple sclerosis patients. <i>NeuroImage</i> , 2009, 44, 1397-1403.	2.1	337
57	Resting-state fMRI changes in Alzheimer's disease and mild cognitive impairment. <i>Neurobiology of Aging</i> , 2012, 33, 2018-2028.	1.5	337
58	Histopathologic correlates of white matter changes on MRI in Alzheimer's disease and normal aging. <i>Neurology</i> , 1995, 45, 883-888.	1.5	332
59	Brain and spinal cord abnormalities in multiple sclerosis. Correlation between MRI parameters, clinical subtypes and symptoms. <i>Brain</i> , 1998, 121, 687-697.	3.7	331
60	WHITE MATTER LESIONS ON MAGNETIC RESONANCE IMAGING IN CLINICALLY DIAGNOSED ALZHEIMER'S DISEASE: EVIDENCE FOR HETEROGENEITY. <i>Brain</i> , 1992, 115, 735-748.	3.7	325
61	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. <i>Hippocampus</i> , 2000, 10, 398-410.	0.9	323
62	Long-term effect of early treatment with interferon beta-1b after a first clinical event suggestive of multiple sclerosis: 5-year active treatment extension of the phase 3 BENEFIT trial. <i>Lancet Neurology</i> , The, 2009, 8, 987-997.	4.9	322
63	Hippocampal atrophy rates in Alzheimer disease. <i>Neurology</i> , 2009, 72, 999-1007.	1.5	315
64	Small Vessel Disease and General Cognitive Function in Nondisabled Elderly. <i>Stroke</i> , 2005, 36, 2116-2120.	1.0	311
65	Remyelinated Lesions in Multiple Sclerosis. <i>Archives of Neurology</i> , 2003, 60, 1073.	4.9	310
66	Optimizing Patient Care and Research: The Amsterdam Dementia Cohort. <i>Journal of Alzheimer's Disease</i> , 2014, 41, 313-327.	1.2	307
67	Assessment of lesions on magnetic resonance imaging in multiple sclerosis: practical guidelines. <i>Brain</i> , 2019, 142, 1858-1875.	3.7	303
68	2021 MAGNIMSâ€“CMSCâ€“NAIMS consensus recommendations on the use of MRI in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2021, 20, 653-670.	4.9	302
69	Resting-State Functional MR Imaging: A New Window to the Brain. <i>Radiology</i> , 2014, 272, 29-49.	3.6	301
70	Visual assessment of posterior atrophy development of a MRI rating scale. <i>European Radiology</i> , 2011, 21, 2618-2625.	2.3	299
71	MRI in multiple sclerosis: current status and future prospects. <i>Lancet Neurology</i> , The, 2008, 7, 615-625.	4.9	295
72	Deep gray matter volume loss drives disability worsening in multiple sclerosis. <i>Annals of Neurology</i> , 2018, 83, 210-222.	2.8	295

#	ARTICLE	IF	CITATIONS
73	Correlations between changes in disability and T ₂ -weighted brain MRI activity in multiple sclerosis. <i>Neurology</i> , 1995, 45, 255-260.	1.5	292
74	MRI criteria for multiple sclerosis in patients presenting with clinically isolated syndromes: a multicentre retrospective study. <i>Lancet Neurology</i> , The, 2007, 6, 677-686.	4.9	292
75	Cortical lesions in multiple sclerosis: combined postmortem MR imaging and histopathology. <i>American Journal of Neuroradiology</i> , 2005, 26, 572-7.	1.2	292
76	Correlating MRI and clinical disease activity in multiple sclerosis. <i>Neurology</i> , 1995, 45, 1684-1690.	1.5	285
77	Assessing brain atrophy rates in a large population of untreated multiple sclerosis subtypes. <i>Neurology</i> , 2010, 74, 1868-1876.	1.5	284
78	Spinal cord abnormalities in recently diagnosed MS patients. <i>Neurology</i> , 2004, 62, 226-233.	1.5	279
79	The clinical profile of right temporal lobe atrophy. <i>Brain</i> , 2009, 132, 1287-1298.	3.7	277
80	Visual Rating of Age-Related White Matter Changes on Magnetic Resonance Imaging. <i>Stroke</i> , 2003, 34, 441-445.	1.0	271
81	Prevalence and severity of microbleeds in a memory clinic setting. <i>Neurology</i> , 2006, 66, 1356-1360.	1.5	270
82	Impact of White Matter Hyperintensities Scoring Method on Correlations With Clinical Data. <i>Stroke</i> , 2006, 37, 836-840.	1.0	269
83	Progression of regional grey matter atrophy in multiple sclerosis. <i>Brain</i> , 2018, 141, 1665-1677.	3.7	269
84	Axonal loss in multiple sclerosis lesions: Magnetic resonance imaging insights into substrates of disability. <i>Annals of Neurology</i> , 1999, 46, 747-754.	2.8	268
85	Brain atrophy and lesion load predict long term disability in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1082-1091.	0.9	267
86	Standardized evaluation of algorithms for computer-aided diagnosis of dementia based on structural MRI: The CADDementia challenge. <i>NeuroImage</i> , 2015, 111, 562-579.	2.1	266
87	GLP-1 Receptor Activation Modulates Appetite- and Reward-Related Brain Areas in Humans. <i>Diabetes</i> , 2014, 63, 4186-4196.	0.3	264
88	The contribution of magnetic resonance imaging to the diagnosis of multiple sclerosis. <i>Neurology</i> , 1999, 53, 448-448.	1.5	263
89	Consensus recommendations for MS cortical lesion scoring using double inversion recovery MRI. <i>Neurology</i> , 2011, 76, 418-424.	1.5	259
90	Amyloid-PET and 18F-FDG-PET in the diagnostic investigation of Alzheimer's disease and other dementias. <i>Lancet Neurology</i> , The, 2020, 19, 951-962.	4.9	254

#	ARTICLE	IF	CITATIONS
91	Gadolinium enhancement increases the sensitivity of MRI in detecting disease activity in multiple sclerosis. <i>Brain</i> , 1993, 116, 1077-1094.	3.7	252
92	CT and MRI Rating of White Matter Lesions. <i>Cerebrovascular Diseases</i> , 2002, 13, 31-36.	0.8	252
93	Precuneus atrophy in early-onset Alzheimer's disease: a morphometric structural MRI study. <i>Neuroradiology</i> , 2007, 49, 967-976.	1.1	251
94	Post-mortem MRI-guided sampling of multiple sclerosis brain lesions: Increased yield of active demyelinating and (p)reactive lesions. <i>Brain</i> , 2001, 124, 1635-1645.	3.7	250
95	Treatment of multiple sclerosis with the monoclonal anti-CD4 antibody cM-T412: Results of a randomized, double-blind, placebo-controlled MR-monitored phase II trial. <i>Neurology</i> , 1997, 49, 351-357.	1.5	247
96	Decreased interleukin-10 and increased interleukin-12p40 mRNA are associated with disease activity and characterize different disease stages in multiple sclerosis. <i>Annals of Neurology</i> , 1999, 45, 695-703.	2.8	247
97	Magnetic resonance imaging pattern recognition in hypomyelinating disorders. <i>Brain</i> , 2010, 133, 2971-2982.	3.7	247
98	Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial. <i>Lancet, The</i> , 2004, 364, 1489-1496.	6.3	246
99	Heterogeneity of white matter hyperintensities in Alzheimer's disease: post-mortem quantitative MRI and neuropathology. <i>Brain</i> , 2008, 131, 3286-3298.	3.7	246
100	White Matter Changes on CT and MRI: An Overview of Visual Rating Scales. <i>European Neurology</i> , 1998, 39, 80-89.	0.6	244
101	Amyloid-Related Imaging Abnormalities in 2 Phase 3 Studies Evaluating Aducanumab in Patients With Early Alzheimer Disease. <i>JAMA Neurology</i> , 2022, 79, 13.	4.5	244
102	The effect of interferon beta-1b treatment on MRI measures of cerebral atrophy in secondary progressive multiple sclerosis. <i>Brain</i> , 2000, 123, 2256-2263.	3.7	242
103	Extensive Hippocampal Demyelination in Multiple Sclerosis. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 819-827.	0.9	242
104	Lack of Association between Antimyelin Antibodies and Progression to Multiple Sclerosis. <i>New England Journal of Medicine</i> , 2007, 356, 371-378.	13.9	236
105	Treatment with laquinimod reduces development of active MRI lesions in relapsing MS. <i>Neurology</i> , 2005, 64, 987-991.	1.5	232
106	MRI criteria for MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2010, 74, 427-434.	1.5	231
107	White matter tract integrity in aging and Alzheimer's disease. <i>Human Brain Mapping</i> , 2009, 30, 1051-1059.	1.9	227
108	Accumulation of cortical lesions in MS: relation with cognitive impairment. <i>Multiple Sclerosis Journal</i> , 2009, 15, 708-714.	1.4	225

#	ARTICLE	IF	CITATIONS
109	Cortical atrophy patterns in multiple sclerosis are non-random and clinically relevant. <i>Brain</i> , 2016, 139, 115-126.	3.7	223
110	MRI and the diagnosis of multiple sclerosis: expanding the concept of "a better explanation". <i>Lancet Neurology</i> , The, 2006, 5, 841-852.	4.9	217
111	Resting state networks change in clinically isolated syndrome. <i>Brain</i> , 2010, 133, 1612-1621.	3.7	215
112	Spinal-cord MRI in multiple sclerosis. <i>Lancet Neurology</i> , The, 2003, 2, 555-562.	4.9	213
113	Standardized MR imaging protocol for multiple sclerosis: Consortium of MS Centers consensus guidelines. <i>American Journal of Neuroradiology</i> , 2006, 27, 455-61.	1.2	212
114	Frontostriatal system in planning complexity: a parametric functional magnetic resonance version of tower of london task. <i>NeuroImage</i> , 2003, 18, 367-374.	2.1	208
115	Cerebral Microbleeds: Imaging and Clinical Significance. <i>Radiology</i> , 2018, 287, 11-28.	3.6	208
116	Cerebral Blood Flow Measured with 3D Pseudocontinuous Arterial Spin-labeling MR Imaging in Alzheimer Disease and Mild Cognitive Impairment: A Marker for Disease Severity. <i>Radiology</i> , 2013, 267, 221-230.	3.6	206
117	Postmortem verification of MS cortical lesion detection with 3D DIR. <i>Neurology</i> , 2012, 78, 302-308.	1.5	205
118	Comparison of fingolimod with interferon beta-1a in relapsing-remitting multiple sclerosis: a randomised extension of the TRANSFORMS study. <i>Lancet Neurology</i> , The, 2011, 10, 520-529.	4.9	204
119	Imaging markers for Alzheimer disease. <i>Neurology</i> , 2013, 81, 487-500.	1.5	204
120	Patients With Alzheimer Disease With Multiple Microbleeds. <i>Stroke</i> , 2009, 40, 3455-3460.	1.0	202
121	fMRI of visual encoding: Reproducibility of activation. , 2000, 9, 156-164.		201
122	Two Randomized Phase 3 Studies of Aducanumab in Early Alzheimer's Disease. <i>Journal of Prevention of Alzheimer's Disease</i> , The, 2022, 9, 197-210.	1.5	201
123	Pathogenesis of multiple sclerosis: insights from molecular and metabolic imaging. <i>Lancet Neurology</i> , The, 2014, 13, 807-822.	4.9	197
124	Atrophy patterns in early clinical stages across distinct phenotypes of Alzheimer's disease. <i>Human Brain Mapping</i> , 2015, 36, 4421-4437.	1.9	196
125	Automatic segmentation and volumetry of multiple sclerosis brain lesions from MR images. <i>NeuroImage: Clinical</i> , 2015, 8, 367-375.	1.4	196
126	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. <i>Annals of Neurology</i> , 1999, 46, 79-87.	2.8	190

#	ARTICLE	IF	CITATIONS
127	Risk of Rapid Global Functional Decline in Elderly Patients With Severe Cerebral Age-Related White Matter Changes. <i>Archives of Internal Medicine</i> , 2007, 167, 81.	4.3	187
128	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). <i>Multiple Sclerosis Journal</i> , 1999, 5, 283-286.	1.4	186
129	Patterns of lesion development in multiple sclerosis: longitudinal observations with T1-weighted spin-echo and magnetization transfer MR. <i>American Journal of Neuroradiology</i> , 1998, 19, 675-83.	1.2	186
130	Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial. <i>Lancet Neurology</i> , The, 2012, 11, 33-41.	4.9	185
131	Incident lacunes influence cognitive decline. <i>Neurology</i> , 2011, 76, 1872-1878.	1.5	183
132	Patterns of Cerebral Atrophy in Dementia with Lewy Bodies Using Voxel-Based Morphometry. <i>NeuroImage</i> , 2002, 17, 618-630.	2.1	182
133	Noradrenaline mediates amygdala activation in men and women during encoding of emotional material. <i>NeuroImage</i> , 2005, 24, 898-909.	2.1	182
134	MRI T2 lesion burden in multiple sclerosis: A plateauing relationship with clinical disability. <i>Neurology</i> , 2006, 66, 1384-1389.	1.5	182
135	Subcortical atrophy and cognition. <i>Neurology</i> , 2012, 79, 1754-1761.	1.5	181
136	PML in a Patient Treated with Dimethyl Fumarate from a Compounding Pharmacy. <i>New England Journal of Medicine</i> , 2013, 368, 1658-1659.	13.9	181
137	Thalamus structure and function determine severity of cognitive impairment in multiple sclerosis. <i>Neurology</i> , 2015, 84, 776-783.	1.5	180
138	Intravenous immunoglobulin for treatment of mild-to-moderate Alzheimer's disease: a phase 2, randomised, double-blind, placebo-controlled, dose-finding trial. <i>Lancet Neurology</i> , The, 2013, 12, 233-243.	4.9	177
139	Accurate white matter lesion segmentation by k nearest neighbor classification with tissue type priors (kNN-TTPs). <i>NeuroImage: Clinical</i> , 2013, 3, 462-469.	1.4	177
140	Quantitative assessment of MRI lesion load in monitoring the evolution of multiple sclerosis. <i>Brain</i> , 1995, 118, 1601-1612.	3.7	176
141	Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2011, 7, 474.	0.4	176
142	24-month intervention with a specific multinutrient in people with prodromal Alzheimer's disease (LipiDiDiet): a randomised, double-blind, controlled trial. <i>Lancet Neurology</i> , The, 2017, 16, 965-975.	4.9	175
143	The significance of medial temporal lobe atrophy. <i>Neurology</i> , 2007, 69, 1521-1527.	1.5	174
144	MRI visual rating scales in the diagnosis of dementia: evaluation in 184 post-mortem confirmed cases. <i>Brain</i> , 2016, 139, 1211-1225.	3.7	174

#	ARTICLE	IF	CITATIONS
145	Pattern of White Matter Abnormalities at MR Imaging: Use of Polymerase Chain Reaction Testing of Guthrie Cards to Link Pattern with Congenital Cytomegalovirus Infection. <i>Radiology</i> , 2004, 230, 529-536.	3.6	172
146	Primary and transitional progressive MS. <i>Neurology</i> , 1999, 52, 839-839.	1.5	171
147	Combining shape and connectivity analysis: An MRI study of thalamic degeneration in Alzheimer's disease. <i>NeuroImage</i> , 2010, 49, 1-8.	2.1	171
148	Blood-brain barrier alterations in both focal and diffuse abnormalities on postmortem MRI in multiple sclerosis. <i>Neurobiology of Disease</i> , 2005, 20, 953-960.	2.1	169
149	Longitudinal Cognitive Decline in Subcortical Ischemic Vascular Disease – The LADIS Study. <i>Cerebrovascular Diseases</i> , 2009, 27, 384-391.	0.8	167
150	Grey matter volume in a large cohort of MS patients: relation to MRI parameters and disability. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1098-1106.	1.4	167
151	Qualitative Assessment of Cerebral Atrophy on MRI: Inter- and Intra-Observer Reproducibility in Dementia and Normal Aging. <i>European Neurology</i> , 1997, 37, 95-99.	0.6	166
152	Hippocampal atrophy on MRI in frontotemporal lobar degeneration and Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 439-442.	0.9	165
153	Standardized Assessment of Automatic Segmentation of White Matter Hyperintensities and Results of the WMH Segmentation Challenge. <i>IEEE Transactions on Medical Imaging</i> , 2019, 38, 2556-2568.	5.4	165
154	Measuring progression of cerebral white matter lesions on MRI. <i>Neurology</i> , 2004, 62, 1533-1539.	1.5	164
155	Pluriformity of inflammation in multiple sclerosis shown by ultra-small iron oxide particle enhancement. <i>Brain</i> , 2008, 131, 800-807.	3.7	164
156	Within-Subject Reproducibility of Visual Activation Patterns With Functional Magnetic Resonance Imaging Using Multislice Echo Planar Imaging. <i>Magnetic Resonance Imaging</i> , 1998, 16, 105-113.	1.0	163
157	White matter lesion progression. <i>Neurology</i> , 2004, 63, 139-144.	1.5	163
158	Fatigue in multiple sclerosis: Interrelations between fatigue complaints, cerebral MRI abnormalities and neurological disability. <i>Journal of the Neurological Sciences</i> , 1998, 160, 164-170.	0.3	162
159	Whole-Brain T1 Mapping in Multiple Sclerosis: Global Changes of Normal-appearing Gray and White Matter. <i>Radiology</i> , 2006, 240, 811-820.	3.6	162
160	Amnesic Mild Cognitive Impairment: Structural MR Imaging Findings Predictive of Conversion to Alzheimer Disease. <i>American Journal of Neuroradiology</i> , 2008, 29, 944-949.	1.2	162
161	The EADC-ADNI Harmonized Protocol for manual hippocampal segmentation on magnetic resonance: Evidence of validity. <i>Alzheimer's and Dementia</i> , 2015, 11, 111-125.	0.4	162
162	MR venography of multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2000, 21, 1039-42.	1.2	162

#	ARTICLE	IF	CITATIONS
163	Functional MR imaging in Alzheimer's disease during memory encoding. American Journal of Neuroradiology, 2000, 21, 1869-75.	1.2	162
164	Prediction of dementia in MCI patients based on core diagnostic markers for Alzheimer disease. Neurology, 2013, 80, 1048-1056.	1.5	161
165	A new leukoencephalopathy with brainstem and spinal cord involvement and high lactate. Annals of Neurology, 2003, 53, 252-258.	2.8	160
166	CSF biomarkers and medial temporal lobe atrophy predict dementia in mild cognitive impairment. Neurobiology of Aging, 2007, 28, 1070-1074.	1.5	160
167	Operational Definitions for the NINDS-AIREN Criteria for Vascular Dementia. Stroke, 2003, 34, 1907-1912.	1.0	158
168	The current role of MRI in differentiating multiple sclerosis from its imaging mimics. Nature Reviews Neurology, 2018, 14, 199-213.	4.9	157
169	Voxel-based morphometry demonstrates reduced grey matter density on brain MRI in patients with diabetic retinopathy. Diabetologia, 2006, 49, 2474-2480.	2.9	156
170	Different patterns of gray matter atrophy in early- and late-onset Alzheimer's disease. Neurobiology of Aging, 2013, 34, 2014-2022.	1.5	156
171	Cognitive impairment in MS. Neurology, 2013, 80, 1025-1032.	1.5	155
172	Diagnostic algorithm for relapsing acquired demyelinating syndromes in children. Neurology, 2017, 89, 269-278.	1.5	155
173	Post-mortem high-resolution MRI of the spinal cord in multiple sclerosis. Brain, 2001, 124, 154-166.	3.7	154
174	Guidelines for using quantitative measures of brain magnetic resonance imaging abnormalities in monitoring the treatment of multiple sclerosis. Annals of Neurology, 1998, 43, 499-506.	2.8	152
175	Correlations between monthly enhanced MRI Lesion rate and changes in T2 Lesion volume in multiple sclerosis. Annals of Neurology, 1998, 43, 332-339.	2.8	150
176	MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice. Nature Reviews Neurology, 2020, 16, 171-182.	4.9	150
177	Differentiation of Multiple Sclerosis from Other Inflammatory Disorders and Cerebrovascular Disease: Value of Spinal MR Imaging. Radiology, 2002, 223, 46-56.	3.6	149
178	l-budilast in relapsing-remitting multiple sclerosis. Neurology, 2010, 74, 1033-1040.	1.5	148
179	Cerebrotendinous Xanthomatosis: The Spectrum of Imaging Findings and the Correlation with Neuropathologic Findings. Radiology, 2000, 217, 869-876.	3.6	147
180	Endogenous cortisol level interacts with noradrenergic activation in the human amygdala. Neurobiology of Learning and Memory, 2007, 87, 57-66.	1.0	146

#	ARTICLE	IF	CITATIONS
181	Diffusely Abnormal White Matter in Chronic Multiple Sclerosis. Archives of Neurology, 2009, 66, 601-9.	4.9	146
182	Selection of Patients for Resection of Colorectal Metastases to the Liver Using Diagnostic Laparoscopy and Laparoscopic Ultrasonography. Annals of Surgery, 1999, 230, 31.	2.1	146
183	Normal gyration and sulcation in preterm and term neonates: appearance on MR images.. Radiology, 1996, 200, 389-396.	3.6	145
184	Unbiased whole-brain analysis of gray matter loss in Alzheimer's disease. Neuroscience Letters, 2000, 285, 231-233.	1.0	145
185	Optimizing parameter choice for FSL-Brain Extraction Tool (BET) on 3D T1 images in multiple sclerosis. NeuroImage, 2012, 61, 1484-1494.	2.1	145
186	Longitudinal imaging of Alzheimer pathology using [11C]PIB, [18F]FDDNP and [18F]FDG PET. European Journal of Nuclear Medicine and Molecular Imaging, 2012, 39, 990-1000.	3.3	145
187	Microglial activation in Alzheimer's disease: an (R)-[11C]PK11195 positron emission tomography study. Neurobiology of Aging, 2013, 34, 128-136.	1.5	145
188	Alterations in brain activation during cholinergic enhancement with rivastigmine in Alzheimer's disease. Journal of Neurology, Neurosurgery and Psychiatry, 2002, 73, 665-671.	0.9	142
189	Longitudinal Brain Volume Measurement in Multiple Sclerosis. Archives of Neurology, 2002, 59, 1572.	4.9	141
190	POSTWITHDRAWAL REBOUND INCREASE IN T2 LESIONAL ACTIVITY IN NATALIZUMAB-TREATED MS PATIENTS. Neurology, 2008, 70, 1150-1151.	1.5	141
191	Relapsing-remitting multiple sclerosis: sequential enhanced MR imaging vs clinical findings in determining disease activity.. American Journal of Roentgenology, 1992, 159, 1041-1047.	1.0	140
192	Neonatal porencephaly and adult stroke related to mutations in collagen IV A1. Annals of Neurology, 2006, 59, 504-511.	2.8	140
193	Improved in vivo detection of cortical lesions in multiple sclerosis using double inversion recovery MR imaging at 3 Tesla. European Radiology, 2010, 20, 1675-1683.	2.3	140
194	Spinal cord lesions in patients with clinically isolated syndrome. Neurology, 2013, 80, 69-75.	1.5	140
195	Associations Between Cerebral Small-Vessel Disease and Alzheimer Disease Pathology as Measured by Cerebrospinal Fluid Biomarkers. JAMA Neurology, 2014, 71, 855.	4.5	140
196	Axonal damage in the spinal cord of MS patients occurs largely independent of T2 MRI lesions. Neurology, 2002, 59, 1766-1771.	1.5	139
197	Differential diagnosis of neurodegenerative diseases using structural MRI data. NeuroImage: Clinical, 2016, 11, 435-449.	1.4	137
198	Long-term (up to 4.5 years) treatment with fingolimod in multiple sclerosis: results from the extension of the randomised TRANSFORMS study. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, 468-475.	0.9	137

#	ARTICLE	IF	CITATIONS
199	Altered diffusion tensor in multiple sclerosis normal-appearing brain tissue: Cortical diffusion changes seem related to clinical deterioration. <i>Journal of Magnetic Resonance Imaging</i> , 2006, 23, 628-636.	1.9	136
200	Chronic white matter lesion activity predicts clinical progression in primary progressive multiple sclerosis. <i>Brain</i> , 2019, 142, 2787-2799.	3.7	136
201	Functional connectivity and cognitive decline over 3 years in Parkinson disease. <i>Neurology</i> , 2014, 83, 2046-2053.	1.5	135
202	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997, 7, 594-601.	0.9	134
203	Chronic cerebrospinal venous insufficiency and multiple sclerosis. <i>Annals of Neurology</i> , 2010, 67, 286-290.	2.8	134
204	Inflammatory biomarkers in Alzheimer's disease plasma. <i>Alzheimer's and Dementia</i> , 2019, 15, 776-787.	0.4	134
205	Whole-Brain Atrophy Rate and Cognitive Decline: Longitudinal MR Study of Memory Clinic Patients. <i>Radiology</i> , 2008, 248, 590-598.	3.6	133
206	Increased cortical grey matter lesion detection in multiple sclerosis with 7 T MRI: a post-mortem verification study. <i>Brain</i> , 2016, 139, 1472-1481.	3.7	133
207	Lack of Correlation Between Cortical Demyelination and White Matter Pathologic Changes in Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 76.	4.9	132
208	The Spinal Cord in Multiple Sclerosis: Relationship of High-Spatial-Resolution Quantitative MR Imaging Findings to Histopathologic Results. <i>Radiology</i> , 2004, 233, 531-540.	3.6	131
209	Resting-state networks in awake five- to eight-year old children. <i>Human Brain Mapping</i> , 2012, 33, 1189-1201.	1.9	131
210	MR spectroscopic evidence for glial increase but not for neuro-axonal damage in MS normal-appearing white matter. <i>Magnetic Resonance in Medicine</i> , 2005, 53, 256-266.	1.9	130
211	The effect of the neuroprotective agent riluzole on MRI parameters in primary progressive multiple sclerosis: a pilot study. <i>Multiple Sclerosis Journal</i> , 2002, 8, 532-533.	1.4	129
212	Clinically isolated syndromes suggestive of multiple sclerosis, part 2: non-conventional MRI, recovery processes, and management. <i>Lancet Neurology</i> , The, 2005, 4, 341-348.	4.9	129
213	Delayed rather than decreased BOLD response as a marker for early Alzheimer's disease. <i>NeuroImage</i> , 2005, 26, 1078-1085.	2.1	129
214	Model-free group analysis shows altered BOLD fMRI networks in dementia. <i>Human Brain Mapping</i> , 2009, 30, 256-266.	1.9	129
215	Injury markers predict time to dementia in subjects with MCI and amyloid pathology. <i>Neurology</i> , 2012, 79, 1809-1816.	1.5	129
216	Combination of plasma amyloid beta(1-42/1-40) and glial fibrillary acidic protein strongly associates with cerebral amyloid pathology. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 118.	3.0	129

#	ARTICLE	IF	CITATIONS
217	Imaging of White Matter Lesions. <i>Cerebrovascular Diseases</i> , 2002, 13, 21-30.	0.8	128
218	Progression of Mild Cognitive Impairment to Dementia. <i>Stroke</i> , 2009, 40, 1269-1274.	1.0	128
219	Neuroplasticity and functional recovery in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2012, 8, 635-646.	4.9	128
220	Hippocampal atrophy in Alzheimer disease: Age matters. <i>Neurology</i> , 2006, 66, 236-238.	1.5	127
221	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. <i>Radiology</i> , 2013, 269, 542-552.	3.6	126
222	Functional brain network analysis using minimum spanning trees in Multiple Sclerosis: An MEG source-space study. <i>NeuroImage</i> , 2014, 88, 308-318.	2.1	126
223	Quantitative MRI changes in gadolinium-€DTPA enhancement after high-€dose intravenous methylprednisolone in multiple sclerosis. <i>Neurology</i> , 1991, 41, 1219-1219.	1.5	126
224	Microglial activation in healthy aging. <i>Neurobiology of Aging</i> , 2012, 33, 1067-1072.	1.5	125
225	Brain atrophy accelerates cognitive decline in cerebral small vessel disease. <i>Neurology</i> , 2012, 78, 1785-1792.	1.5	125
226	Structural degree predicts functional network connectivity: A multimodal resting-state fMRI and MEG study. <i>NeuroImage</i> , 2014, 97, 296-307.	2.1	125
227	Efficacy, safety and tolerability of rivastigmine capsules in patients with probable vascular dementia: the VantagE study. <i>Current Medical Research and Opinion</i> , 2008, 24, 2561-2574.	0.9	124
228	Clinical Relevance of Improved Microbleed Detection by Susceptibility-Weighted Magnetic Resonance Imaging. <i>Stroke</i> , 2011, 42, 1894-1900.	1.0	124
229	Survival prediction model of children with diffuse intrinsic pontine glioma based on clinical and radiological criteria. <i>Neuro-Oncology</i> , 2015, 17, 160-166.	0.6	124
230	Multiple sclerosis. <i>Neurology</i> , 2003, 60, 219-223.	1.5	123
231	Mild cognitive impairment with suspected nonamyloid pathology (SNAP). <i>Neurology</i> , 2015, 84, 508-515.	1.5	122
232	Slowly expanding/evolving lesions as a magnetic resonance imaging marker of chronic active multiple sclerosis lesions. <i>Multiple Sclerosis Journal</i> , 2019, 25, 1915-1925.	1.4	122
233	Brain atrophy and lesion load as explaining parameters for cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2005, 11, 524-531.	1.4	121
234	Diagnostic Imaging of Patients in a Memory Clinic: Comparison of MR Imaging and 64-€Detector Row CT. <i>Radiology</i> , 2009, 253, 174-183.	3.6	121

#	ARTICLE	IF	CITATIONS
235	Optimizing the association between disability and biological markers in MS. <i>Neurology</i> , 2001, 57, 1253-1258.	1.5	120
236	Validation of diagnostic magnetic resonance imaging criteria for multiple sclerosis and response to interferon β1a. <i>Annals of Neurology</i> , 2003, 53, 718-724.	2.8	120
237	Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Imaging. <i>Archives of Neurology</i> , 2001, 58, 76-81.	4.9	119
238	White matter lesions and hippocampal atrophy in Alzheimer's disease. <i>Neurology</i> , 2004, 62, 310-312.	1.5	119
239	MR spectroscopic evidence for thalamic and hippocampal, but not cortical, damage in multiple sclerosis. <i>Magnetic Resonance in Medicine</i> , 2006, 55, 478-483.	1.9	119
240	Detection of Alzheimer Pathology In Vivo Using Both ¹¹ C-PIB and ¹⁸ F-FDDNP PET. <i>Journal of Nuclear Medicine</i> , 2009, 50, 191-197.	2.8	119
241	No association of abnormal cranial venous drainage with multiple sclerosis: a magnetic resonance venography and flow-quantification study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 429-435.	0.9	119
242	Correlation between brain volume loss and clinical and MRI outcomes in multiple sclerosis. <i>Neurology</i> , 2015, 84, 784-793.	1.5	119
243	Diagnostic criteria for primary progressive multiple sclerosis: a position paper. <i>Annals of Neurology</i> , 2000, 47, 831-5.	2.8	119
244	MRI Biomarkers of Vascular Damage and Atrophy Predicting Mortality in a Memory Clinic Population. <i>Stroke</i> , 2009, 40, 492-498.	1.0	118
245	Arterial Spin Labeling May Contribute to the Prediction of Cognitive Deterioration in Healthy Elderly Individuals. <i>Radiology</i> , 2015, 274, 490-499.	3.6	118
246	Unusual variants of Alexander's disease. <i>Annals of Neurology</i> , 2005, 57, 327-338.	2.8	117
247	Hippocampal volume change measurement: Quantitative assessment of the reproducibility of expert manual outlining and the automated methods FreeSurfer and FIRST. <i>NeuroImage</i> , 2014, 92, 169-181.	2.1	117
248	Automated segmentation of multiple sclerosis lesion subtypes with multichannel MRI. <i>NeuroImage</i> , 2006, 32, 1205-1215.	2.1	115
249	Incidence of cerebral microbleeds. <i>Neurology</i> , 2010, 74, 1954-1960.	1.5	115
250	Assessing treatment outcomes in multiple sclerosis trials and in the clinical setting. <i>Nature Reviews Neurology</i> , 2018, 14, 75-93.	4.9	115
251	Global Burden of Small Vessel Disease-Related Brain Changes on MRI Predicts Cognitive and Functional Decline. <i>Stroke</i> , 2020, 51, 170-178.	1.0	115
252	Using visual rating to diagnose dementia: a critical evaluation of MRI atrophy scales. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 1225-1233.	0.9	114

#	ARTICLE	IF	CITATIONS
253	Structural and Functional Hippocampal Changes in Multiple Sclerosis Patients with Intact Memory Function. <i>Radiology</i> , 2010, 255, 595-604.	3.6	113
254	Predicting cognitive decline in multiple sclerosis: a 5-year follow-up study. <i>Brain</i> , 2018, 141, 2605-2618.	3.7	113
255	Early imaging predictors of long-term outcomes in relapse-onset multiple sclerosis. <i>Brain</i> , 2019, 142, 2276-2287.	3.7	113
256	MRI criteria for dissemination in space in patients with clinically isolated syndromes: a multicentre follow-up study. <i>Lancet Neurology</i> , The, 2006, 5, 221-227.	4.9	112
257	<scp>EFNS</scp> task force: the use of neuroimaging in the diagnosis of dementia. <i>European Journal of Neurology</i> , 2012, 19, 1487-1501.	1.7	112
258	Bidirectional trans-synaptic axonal degeneration in the visual pathway in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 419-424.	0.9	112
259	Identifying multiple sclerosis subtypes using unsupervised machine learning and MRI data. <i>Nature Communications</i> , 2021, 12, 2078.	5.8	112
260	Retinoblastoma: MR Imaging Parameters in Detection of Tumor Extent. <i>Radiology</i> , 2005, 235, 197-207.	3.6	111
261	Randomized phase I trials of the safety/tolerability of anti-LINGO-1 monoclonal antibody BIIB033. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2014, 1, e18.	3.1	111
262	Cervical spinal cord volume loss is related to clinical disability progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 410-418.	0.9	111
263	Cholinergic challenge in Alzheimer patients and mild cognitive impairment differentially affects hippocampal activation—a pharmacological fMRI study. <i>Brain</i> , 2006, 129, 141-157.	3.7	110
264	Spinal cord involvement in multiple sclerosis and neuromyelitis optica spectrum disorders. <i>Lancet Neurology</i> , The, 2019, 18, 185-197.	4.9	110
265	Simple versus complex assessment of white matter hyperintensities in relation to physical performance and cognition: the LADIS study. <i>Journal of Neurology</i> , 2006, 253, 1189-1196.	1.8	109
266	Amyloid burden and metabolic function in early-onset Alzheimer's disease: parietal lobe involvement. <i>Brain</i> , 2012, 135, 2115-2125.	3.7	109
267	Resting-State Brain Networks in Type 1 Diabetic Patients With and Without Microangiopathy and Their Relation to Cognitive Functions and Disease Variables. <i>Diabetes</i> , 2012, 61, 1814-1821.	0.3	109
268	Clinical relevance of serum natalizumab concentration and anti-natalizumab antibodies in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 593-600.	1.4	109
269	Nonconventional MRI and microstructural cerebral changes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2015, 11, 676-686.	4.9	109
270	The 11-year long-term follow-up study from the randomized BENEFIT CIS trial. <i>Neurology</i> , 2016, 87, 978-987.	1.5	109

#	ARTICLE	IF	CITATIONS
271	Brain network alterations in Alzheimer's disease measured by Eigenvector centrality in fMRI are related to cognition and CSF biomarkers. <i>Human Brain Mapping</i> , 2014, 35, 2383-2393.	1.9	108
272	The role of MRI as a surrogate outcome measure in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 40-51.	1.4	107
273	The Contribution of Medial Temporal Lobe Atrophy and Vascular Pathology to Cognitive Impairment in Vascular Dementia. <i>Stroke</i> , 2007, 38, 3182-3185.	1.0	107
274	Single-Subject Grey Matter Graphs in Alzheimer's Disease. <i>PLoS ONE</i> , 2013, 8, e58921.	1.1	107
275	One year follow up study of primary and transitional progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2000, 68, 713-718.	0.9	106
276	Functional connectivity changes in multiple sclerosis patients: A graph analytical study of MEG resting state data. <i>Human Brain Mapping</i> , 2013, 34, 52-61.	1.9	106
277	The functional basis of ocular dominance: functional MRI (fMRI) findings. <i>Neuroscience Letters</i> , 1996, 221, 1-4.	1.0	105
278	Cognitive performance in type 1 diabetes patients is associated with cerebral white matter volume. <i>Diabetologia</i> , 2007, 50, 1763-1769.	2.9	105
279	Fast Eigenvector Centrality Mapping of Voxel-Wise Connectivity in Functional Magnetic Resonance Imaging: Implementation, Validation, and Interpretation. <i>Brain Connectivity</i> , 2012, 2, 265-274.	0.8	105
280	Accelerated Aging, Decreased White Matter Integrity, and Associated Neuropsychological Dysfunction 25 Years After Pediatric Lymphoid Malignancies. <i>Journal of Clinical Oncology</i> , 2013, 31, 3378-3388.	0.8	105
281	MRI monitoring of pathological changes in the spinal cord in patients with multiple sclerosis. <i>Lancet Neurology</i> , The, 2015, 14, 443-454.	4.9	105
282	Challenging the cholinergic system in mild cognitive impairment: a pharmacological fMRI study. <i>NeuroImage</i> , 2004, 23, 1450-1459.	2.1	104
283	The limits of functional reorganization in multiple sclerosis. <i>Neurology</i> , 2010, 74, 1246-1247.	1.5	104
284	Improving interobserver variation in reporting gadolinium-enhanced MRI lesions in multiple sclerosis. <i>Neurology</i> , 1997, 49, 1682-1688.	1.5	103
285	CSF and MRI markers independently contribute to the diagnosis of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2008, 29, 669-675.	1.5	103
286	Behavioural and psychological symptoms in vascular dementia; differences between small- and large-vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 547-551.	0.9	103
287	Efficacy of vitamin D3 as add-on therapy in patients with relapsing/remitting multiple sclerosis receiving subcutaneous interferon beta-1a: A Phase II, multicenter, double-blind, randomized, placebo-controlled trial. <i>Journal of the Neurological Sciences</i> , 2011, 311, 44-49.	0.3	103
288	Differential effects of cognitive reserve and brain reserve on cognition in Alzheimer disease. <i>Neurology</i> , 2018, 90, e149-e156.	1.5	103

#	ARTICLE	IF	CITATIONS
289	Location of lacunar infarcts correlates with cognition in a sample of non-disabled subjects with age-related white-matter changes: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 478-483.	0.9	102
290	Atrophy subtypes in prodromal Alzheimer's disease are associated with cognitive decline. <i>Brain</i> , 2018, 141, 3443-3456.	3.7	102
291	Association of Amyloid Positron Emission Tomography With Changes in Diagnosis and Patient Treatment in an Unselected Memory Clinic Cohort. <i>JAMA Neurology</i> , 2018, 75, 1062.	4.5	102
292	Visual Rating Scales for Age-Related White Matter Changes (Leukoaraiosis). <i>Stroke</i> , 2002, 33, 2827-2833.	1.0	101
293	Predicting progression in primary progressive multiple sclerosis: A 10-year multicenter study. <i>Annals of Neurology</i> , 2008, 63, 790-793.	2.8	101
294	The pedunclopontine nucleus is related to visual hallucinations in Parkinson's disease: preliminary results of a voxel-based morphometry study. <i>Journal of Neurology</i> , 2012, 259, 147-154.	1.8	101
295	A multicenter measurement of magnetization transfer ratio in normal white matter. <i>Journal of Magnetic Resonance Imaging</i> , 1999, 9, 441-446.	1.9	99
296	Differential effect of APOE genotype on amyloid load and glucose metabolism in AD dementia. <i>Neurology</i> , 2013, 80, 359-365.	1.5	99
297	Structural MRI correlates of cognitive impairment in patients with multiple sclerosis. <i>Human Brain Mapping</i> , 2016, 37, 1627-1644.	1.9	99
298	Cerebral perfusion in the prodementia stages of Alzheimer's disease. <i>European Radiology</i> , 2016, 26, 506-514.	2.3	99
299	Lower cerebral blood flow is associated with impairment in multiple cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2017, 13, 531-540.	0.4	99
300	A correlative triad of gadolinium-TPA MRI, EDSS, and CSF-MBP in relapsing multiple sclerosis patients treated with high-dose intravenous methylprednisolone. <i>Neurology</i> , 1992, 42, 63-63.	1.5	99
301	Improved vision after intravenous immunoglobulin in stable demyelinating optic neuritis. <i>Annals of Neurology</i> , 1992, 32, 834-835.	2.8	98
302	Imaging the tip of the iceberg: visualization of cortical lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2011, 17, 1202-1210.	1.4	98
303	An algorithmic approach to structural imaging in dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 692-698.	0.9	98
304	Prediction of a multiple sclerosis diagnosis in patients with clinically isolated syndrome using the 2016 MAGNIMS and 2010 McDonald criteria: a retrospective study. <i>Lancet Neurology</i> , The, 2018, 17, 133-142.	4.9	98
305	Test-retest analysis with functional MR of the activated area in the human visual cortex. <i>American Journal of Neuroradiology</i> , 1997, 18, 1317-22.	1.2	98
306	Lower cerebral blood flow is associated with faster cognitive decline in Alzheimer's disease. <i>European Radiology</i> , 2017, 27, 1169-1175.	2.3	97

#	ARTICLE	IF	CITATIONS
307	ATN classification and clinical progression in subjective cognitive decline. <i>Neurology</i> , 2020, 95, e46-e58.	1.5	97
308	Medial temporal lobe atrophy and white matter hyperintensities are associated with mild cognitive deficits in non-disabled elderly people: the LADIS study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1497-1500.	0.9	96
309	Recommendations to improve imaging and analysis of brain lesion load and atrophy in longitudinal studies of multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2458-2471.	1.8	96
310	Functional brain networks: Linking thalamic atrophy to clinical disability in multiple sclerosis, a multimodal fMRI and MEG Study. <i>Human Brain Mapping</i> , 2015, 36, 603-618.	1.9	96
311	Hyperglycaemia as a determinant of cognitive decline in patients with type 1 diabetes. <i>European Journal of Pharmacology</i> , 2008, 585, 88-96.	1.7	95
312	Magnetic resonance imaging correlates of physical disability in relapse onset multiple sclerosis of long disease duration. <i>Multiple Sclerosis Journal</i> , 2014, 20, 72-80.	1.4	95
313	Treatment with interferon beta-1b delays conversion to clinically definite and McDonald MS in patients with clinically isolated syndromes. <i>Neurology</i> , 2007, 68, 1163-1164.	1.5	94
314	Whole-brain atrophy rate in Alzheimer disease. <i>Neurology</i> , 2008, 70, 1836-1841.	1.5	94
315	What drives MRI-measured cortical atrophy in multiple sclerosis?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1280-1290.	1.4	94
316	Magnetic resonance imaging in monitoring the treatment of multiple sclerosis patients: Statistical power of parallel-groups and crossover designs. <i>Journal of the Neurological Sciences</i> , 1994, 122, 6-14.	0.3	93
317	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. <i>Multiple Sclerosis Journal</i> , 2000, 6, 280-285.	1.4	93
318	Susceptibility-weighted Imaging: Technical Essentials and Clinical Neurologic Applications. <i>Radiology</i> , 2021, 299, 3-26.	3.6	92
319	MS Functional Composite. <i>Neurology</i> , 2000, 54, 1233-1239.	1.5	91
320	Sample sizes for brain atrophy outcomes in trials for secondary progressive multiple sclerosis. <i>Neurology</i> , 2009, 72, 595-601.	1.5	91
321	Increased default-mode network centrality in cognitively impaired multiple sclerosis patients. <i>Neurology</i> , 2017, 88, 952-960.	1.5	91
322	Corpus callosum atrophy is associated with mental slowing and executive deficits in subjects with age-related white matter hyperintensities: the LADIS Study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 78, 491-496.	0.9	90
323	Multi-contrast, isotropic, single-slab 3D MR imaging in multiple sclerosis. <i>European Radiology</i> , 2008, 18, 2311-2320.	2.3	90
324	Regional White Matter Integrity Differentiates Between Vascular Dementia and Alzheimer Disease. <i>Stroke</i> , 2009, 40, 773-779.	1.0	90

#	ARTICLE	IF	CITATIONS
325	Whole-brain atrophy rate and CSF biomarker levels in MCI and AD: A longitudinal study. <i>Neurobiology of Aging</i> , 2010, 31, 758-764.	1.5	90
326	Brain reward system activation in response to anticipation and consumption of palatable food is altered by glucagon-like peptide-1 receptor activation in humans. <i>Diabetes, Obesity and Metabolism</i> , 2015, 17, 878-886.	2.2	90
327	The hippocampus in multiple sclerosis. <i>Lancet Neurology</i> , The, 2018, 17, 918-926.	4.9	90
328	Cerebrospinal fluid biomarkers of neurodegeneration, synaptic integrity, and astroglial activation across the clinical Alzheimer's disease spectrum. <i>Alzheimer's and Dementia</i> , 2019, 15, 644-654.	0.4	90
329	Effect of simvastatin in addition to chenodeoxycholic acid in patients with cerebrotendinous xanthomatosis. <i>Metabolism: Clinical and Experimental</i> , 1999, 48, 233-238.	1.5	89
330	Interobserver variability in the radiological assessment of response to chemotherapy in glioma. <i>Neurology</i> , 2003, 60, 826-830.	1.5	89
331	Gender-related differences in functional connectivity in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 164-173.	1.4	89
332	The identification of cognitive subtypes in Alzheimer's disease dementia using latent class analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 235-243.	0.9	89
333	Pathophysiological subtypes of Alzheimer's disease based on cerebrospinal fluid proteomics. <i>Brain</i> , 2020, 143, 3776-3792.	3.7	89
334	Characterization of tissue damage in multiple sclerosis by nuclear magnetic resonance. <i>Philosophical Transactions of the Royal Society B: Biological Sciences</i> , 1999, 354, 1675-1686.	1.8	88
335	Increased cortical atrophy in patients with Alzheimer's disease and type 2 diabetes mellitus. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 77, 304-307.	0.9	88
336	Diabetes mellitus, hypertension and medial temporal lobe atrophy: the LADIS study. <i>Diabetic Medicine</i> , 2007, 24, 166-171.	1.2	88
337	Accelerating regional atrophy rates in the progression from normal aging to Alzheimer's disease. <i>European Radiology</i> , 2009, 19, 2826-2833.	2.3	88
338	White Matter Lesion Progression in LADIS. <i>Stroke</i> , 2012, 43, 2643-2647.	1.0	88
339	The chameleon of neuroinflammation: magnetic resonance imaging characteristics of natalizumab-associated progressive multifocal leukoencephalopathy. <i>Multiple Sclerosis Journal</i> , 2013, 19, 1826-1840.	1.4	88
340	Improved differentiation between MS and vascular brain lesions using FLAIR* at 7 Tesla. <i>European Radiology</i> , 2014, 24, 841-849.	2.3	88
341	Relation between subcortical grey matter atrophy and conversion from mild cognitive impairment to Alzheimer's disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 425-432.	0.9	88
342	Randomized trial of daily high-dose vitamin D ₃ in patients with RRMS receiving subcutaneous interferon β-1a. <i>Neurology</i> , 2019, 93, e1906-e1916.	1.5	88

#	ARTICLE	IF	CITATIONS
343	Unraveling treatment response in multiple sclerosis. <i>Neurology</i> , 2019, 92, 180-192.	1.5	88
344	Subjective Cognitive Impairment Cohort (SCIENCe): study design and first results. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 76.	3.0	87
345	Periventricular white matter hyperintensities increase the likelihood of progression from amnesic mild cognitive impairment to dementia. <i>Journal of Neurology</i> , 2008, 255, 1302-8.	1.8	86
346	Measurements of medial temporal lobe atrophy for prediction of Alzheimer's disease in subjects with mild cognitive impairment. <i>Neurobiology of Aging</i> , 2013, 34, 2003-2013.	1.5	86
347	T1 hypointense lesions in secondary progressive multiple sclerosis: effect of interferon beta-1b treatment. <i>Brain</i> , 2001, 124, 1396-1402.	3.7	85
348	In vivo MR imaging of hippocampal lesions in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 27, 726-731.	1.9	85
349	The spatial distribution of age-related white matter changes as a function of vascular risk factors—Results from the LADIS study. <i>NeuroImage</i> , 2012, 60, 1597-1607.	2.1	85
350	Functional segmentation of the hippocampus in the healthy human brain and in Alzheimer's disease. <i>NeuroImage</i> , 2013, 66, 28-35.	2.1	85
351	Longitudinal reproducibility of default-mode network connectivity in healthy elderly participants: A multicentric resting-state fMRI study. <i>NeuroImage</i> , 2016, 124, 442-454.	2.1	85
352	Cognitive reserve and clinical progression in Alzheimer disease. <i>Neurology</i> , 2019, 93, e334-e346.	1.5	85
353	Biomarker-based prognosis for people with mild cognitive impairment (ABIDE): a modelling study. <i>Lancet Neurology</i> , The, 2019, 18, 1034-1044.	4.9	85
354	Management of obstetric brachial plexus lesions: state of the art and future developments. <i>Child's Nervous System</i> , 2000, 16, 638-644.	0.6	84
355	The effect of interferon β -1b on quantities derived from MT MRI in secondary progressive MS. <i>Neurology</i> , 2003, 60, 853-860.	1.5	84
356	Human Gray Matter: Feasibility of Single-Slab 3D Double Inversion-Recovery High-Spatial-Resolution MR Imaging. <i>Radiology</i> , 2006, 241, 873-879.	3.6	84
357	MRI assessment of iron deposition in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2011, 34, 13-21.	1.9	84
358	Altered cerebrovascular reactivity velocity in mild cognitive impairment and Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 33-41.	1.5	84
359	Leukoaraiosis Predicts Hidden Global Functioning Impairment in Nondisabled Older People: The LADIS (Leukoaraiosis and Disability in the Elderly) Study. <i>Journal of the American Geriatrics Society</i> , 2006, 54, 1095-1101.	1.3	83
360	Visual activation patterns in patients with optic neuritis. <i>Neurology</i> , 1998, 50, 1896-1899.	1.5	82

#	ARTICLE	IF	CITATIONS
361	Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy. <i>Journal of the Neurological Sciences</i> , 2001, 184, 155-162.	0.3	82
362	A paced visual serial addition test for fMRI. <i>Journal of the Neurological Sciences</i> , 2003, 213, 29-34.	0.3	82
363	Diffusion-Weighted Imaging and Cognition in the Leukoariosis and Disability in the Elderly Study. <i>Stroke</i> , 2010, 41, e402-8.	1.0	82
364	Fingolimod versus intramuscular interferon in patient subgroups from TRANSFORMS. <i>Journal of Neurology</i> , 2013, 260, 2023-2032.	1.8	82
365	Identifying confounds to increase specificity during a "no task condition". <i>NeuroImage</i> , 2003, 20, 1236-1245.	2.1	81
366	Osteopontin levels and increased disease activity in relapsing-remitting multiple sclerosis patients. <i>Journal of Neuroimmunology</i> , 2004, 155, 155-160.	1.1	81
367	Most Patients With Multiple Sclerosis or a Clinically Isolated Demyelinating Syndrome Should Be Treated at the Time of Diagnosis. <i>Archives of Neurology</i> , 2006, 63, 614.	4.9	81
368	Intercenter differences in diffusion tensor MRI acquisition. <i>Journal of Magnetic Resonance Imaging</i> , 2010, 31, 1458-1468.	1.9	81
369	"Leukodystrophy-like" phenotype in children with myelin oligodendrocyte glycoprotein antibody-associated disease. <i>Developmental Medicine and Child Neurology</i> , 2018, 60, 417-423.	1.1	81
370	Early adaptive immune activation detected in monozygotic twins with prodromal multiple sclerosis. <i>Journal of Clinical Investigation</i> , 2019, 129, 4758-4768.	3.9	81
371	Efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis (MS-SMART): a phase 2b, multiarm, double-blind, randomised placebo-controlled trial. <i>Lancet Neurology</i> , 2020, 19, 214-225.	4.9	81
372	Quantitative magnetic resonance imaging towards clinical application in multiple sclerosis. <i>Brain</i> , 2021, 144, 1296-1311.	3.7	81
373	Phase-Contrast Cine Mr Imaging of Normal Aqueductal CSF Flow. <i>Acta Radiologica</i> , 1994, 35, 123-130.	0.5	80
374	Effect of training and different measurement strategies on the reproducibility of brain MRI lesion load measurements in multiple sclerosis. <i>Neurology</i> , 1998, 50, 238-244.	1.5	80
375	MRI characteristics of atypical idiopathic inflammatory demyelinating lesions of the brain. <i>Journal of Neurology</i> , 2008, 255, 1-10.	1.8	80
376	Neurological Signs in Relation to Type of Cerebrovascular Disease in Vascular Dementia. <i>Stroke</i> , 2008, 39, 317-322.	1.0	80
377	Cerebral perfusion and glucose metabolism in Alzheimer's disease and frontotemporal dementia: two sides of the same coin?. <i>European Radiology</i> , 2015, 25, 3050-3059.	2.3	80
378	ExploreASL: An image processing pipeline for multi-center ASL perfusion MRI studies. <i>NeuroImage</i> , 2020, 219, 117031.	2.1	80

#	ARTICLE	IF	CITATIONS
379	Reliability and Sensitivity of Visual Scales versus Volumetry for Evaluating White Matter Hyperintensity Progression. <i>Cerebrovascular Diseases</i> , 2008, 25, 247-253.	0.8	79
380	Disruption of structural and functional networks in long-standing multiple sclerosis. <i>Human Brain Mapping</i> , 2014, 35, 5946-5961.	1.9	79
381	Predicting Prodromal Alzheimer's Disease in Subjects with Mild Cognitive Impairment Using Machine Learning Classification of Multimodal Multicenter Diffusionâ€Tensor and Magnetic Resonance Imaging Data. <i>Journal of Neuroimaging</i> , 2015, 25, 738-747.	1.0	79
382	Alzheimer Disease and Behavioral Variant Frontotemporal Dementia: Automatic Classification Based on Cortical Atrophy for Single-Subject Diagnosis. <i>Radiology</i> , 2016, 279, 838-848.	3.6	79
383	Longitudinal Assessment of Multiple Sclerosis with the Brainâ€Age Paradigm. <i>Annals of Neurology</i> , 2020, 88, 93-105.	2.8	79
384	Childhood White Matter Disorders: Quantitative MR Imaging and Spectroscopy. <i>Radiology</i> , 2006, 241, 510-517.	3.6	78
385	MRI-Defined Subcortical Ischemic Vascular Disease: Baseline Clinical and Neuropsychological Findings. <i>Cerebrovascular Diseases</i> , 2009, 27, 336-344.	0.8	78
386	Frontal lobe white matter hyperintensities and neurofibrillary pathology in the oldest old. <i>Neurology</i> , 2010, 75, 2071-2078.	1.5	78
387	Patterns of atrophy in pathologically confirmed dementias: a voxelwise analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 908-916.	0.9	78
388	Interscanner variation in brain MRI lesion load measurements in MS: Implications for clinical trials. <i>Neurology</i> , 1997, 49, 371-377.	1.5	77
389	Spinal xanthomatosis: a variant of cerebrotendinous xanthomatosis. <i>Brain</i> , 1999, 122, 1589-1595.	3.7	77
390	Baseline predictors of rates of hippocampal atrophy in mild cognitive impairment. <i>Neurology</i> , 2007, 69, 1491-1497.	1.5	77
391	Tumor-Volume Changes after Radiosurgery for Vestibular Schwannoma: Implications for Follow-Up MR Imaging Protocol. <i>American Journal of Neuroradiology</i> , 2008, 29, 906-910.	1.2	77
392	Interpreting Biomarker Results in Individual Patients With Mild Cognitive Impairment in the Alzheimerâ€™s Biomarkers in Daily Practice (ABIDE) Project. <i>JAMA Neurology</i> , 2017, 74, 1481.	4.5	77
393	MR of the spinal cord in multiple sclerosis: relation to clinical subtype and disability. <i>American Journal of Neuroradiology</i> , 1997, 18, 1041-8.	1.2	77
394	On the Etiology of Incident Brain Lacunes. <i>Stroke</i> , 2008, 39, 3083-3085.	1.0	76
395	A clinical-radiological framework of the right temporal variant of frontotemporal dementia. <i>Brain</i> , 2020, 143, 2831-2843.	3.7	76
396	Relating functional changes during hand movement to clinical parameters in patients with multiple sclerosis in a multiâ€centre fMRI study. <i>European Journal of Neurology</i> , 2008, 15, 113-122.	1.7	75

#	ARTICLE	IF	CITATIONS
397	High field MRI in the diagnosis of multiple sclerosis: high fieldâ€“high yield?. <i>Neuroradiology</i> , 2009, 51, 279-292.	1.1	75
398	Test sequence of CSF and MRI biomarkers for prediction of AD in subjects with MCI. <i>Neurobiology of Aging</i> , 2012, 33, 2272-2281.	1.5	75
399	MRI pattern in asymptomatic natalizumab-associated PML. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2015, 86, 793-798.	0.9	75
400	Inter-rater agreement in glioma segmentations on longitudinal MRI. <i>NeuroImage: Clinical</i> , 2019, 22, 101727.	1.4	75
401	Visualizing brain activation during planning: the tower of London test adapted for functional MR imaging. <i>American Journal of Neuroradiology</i> , 2000, 21, 1407-14.	1.2	75
402	Loss of frontal fMRI activation in early frontotemporal dementia compared to early AD. <i>Neurology</i> , 2003, 60, 1904-1908.	1.5	74
403	Posterior cerebral atrophy in the absence of medial temporal lobe atrophy in pathologically-confirmed Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 627.e1-627.e12.	1.5	74
404	Functional correlates of callosal atrophy in relapsing-remitting multiple sclerosis patients. A preliminary MRI study. <i>Journal of Neurology</i> , 1998, 245, 153-158.	1.8	73
405	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. <i>Multiple Sclerosis Journal</i> , 2000, 6, 99-104.	1.4	73
406	Injury Markers but not Amyloid Markers are Associated with Rapid Progression from Mild Cognitive Impairment to Dementia in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 319-327.	1.2	73
407	Lesion detection at seven Tesla in multiple sclerosis using magnetisation prepared 3D-FLAIR and 3D-DIR. <i>European Radiology</i> , 2012, 22, 221-231.	2.3	73
408	Long-term impact of interferon beta-1b in patients with CIS: 8-year follow-up of BENEFIT. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 1183-1189.	0.9	73
409	Functional correlates of cognitive dysfunction in multiple sclerosis: A multicenter fMRI Study. <i>Human Brain Mapping</i> , 2014, 35, 5799-5814.	1.9	73
410	White Matter Hyperintensities Relate to Clinical Progression in Subjective Cognitive Decline. <i>Stroke</i> , 2015, 46, 2661-2664.	1.0	73
411	Cerebral Blood Flow by Using Pulsed Arterial Spin-Labeling in Elderly Subjects with White Matter Hyperintensities. <i>American Journal of Neuroradiology</i> , 2008, 29, 1296-1301.	1.2	72
412	Microbleeds do not affect rate of cognitive decline in Alzheimer disease. <i>Neurology</i> , 2012, 79, 763-769.	1.5	72
413	Increased Number of Microinfarcts in Alzheimer Disease at 7-T MR Imaging. <i>Radiology</i> , 2014, 270, 205-211.	3.6	72
414	Endogenous GLP-1 mediates postprandial reductions in activation in central reward and satiety areas in patients with type 2 diabetes. <i>Diabetologia</i> , 2015, 58, 2688-2698.	2.9	72

#	ARTICLE	IF	CITATIONS
415	Concurrent validity of the MS Functional Composite using MRI as a biological disease marker. <i>Neurology</i> , 2001, 56, 215-219.	1.5	71
416	Prevalence of cortical superficial siderosis in a memory clinic population. <i>Neurology</i> , 2014, 82, 698-704.	1.5	71
417	Matrix Metalloproteinases in Alzheimer's Disease and Concurrent Cerebral Microbleeds. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 711-720.	1.2	71
418	Prediction of AD dementia by biomarkers following the NIA-AA and IWG diagnostic criteria in MCI patients from three European memory clinics. <i>Alzheimer's and Dementia</i> , 2015, 11, 1191-1201.	0.4	71
419	MRI Visual Ratings of Brain Atrophy and White Matter Hyperintensities across the Spectrum of Cognitive Decline Are Differently Affected by Age and Diagnosis. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 117.	1.7	71
420	Value of the central vein sign at 3T to differentiate MS from seropositive NMOSD. <i>Neurology</i> , 2018, 90, e1183-e1190.	1.5	71
421	Strategies for optimizing MRI techniques aimed at monitoring disease activity in multiple sclerosis treatment trials. <i>Journal of Neurology</i> , 1997, 244, 76-84.	1.8	70
422	Quantitative 1H-MRS of healthy human cortex, hippocampus, and thalamus: Metabolite concentrations, quantification precision, and reproducibility. <i>Journal of Magnetic Resonance Imaging</i> , 2004, 20, 366-371.	1.9	70
423	Baseline CSF p-tau levels independently predict progression of hippocampal atrophy in Alzheimer disease. <i>Neurology</i> , 2009, 73, 935-940.	1.5	70
424	Improved Detection of Active Multiple Sclerosis Lesions: 3D Subtraction Imaging. <i>Radiology</i> , 2010, 255, 154-163.	3.6	70
425	Oxysterols and cholesterol precursors correlate to magnetic resonance imaging measures of neurodegeneration in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 412-417.	1.4	70
426	Differential patterns of spinal cord and brain atrophy in NMO and MS. <i>Neurology</i> , 2015, 84, 1465-1472.	1.5	70
427	Changes in brain electrical activity during extended continuous word recognition. <i>NeuroImage</i> , 2005, 26, 952-959.	2.1	69
428	Single-Subject Gray Matter Graph Properties and Their Relationship with Cognitive Impairment in Early- and Late-Onset Alzheimer's Disease. <i>Brain Connectivity</i> , 2014, 4, 337-346.	0.8	69
429	What Explains Gray Matter Atrophy in Long-standing Multiple Sclerosis?. <i>Radiology</i> , 2014, 272, 832-842.	3.6	69
430	Changes in functional network centrality underlie cognitive dysfunction and physical disability in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1058-1065.	1.4	69
431	Connectivity-based parcellation of the thalamus in multiple sclerosis and its implications for cognitive impairment: A multicenter study. <i>Human Brain Mapping</i> , 2015, 36, 2809-2825.	1.9	69
432	Patterns of cerebral atrophy in dementia with Lewy bodies using voxel-based morphometry. <i>NeuroImage</i> , 2002, 17, 618-30.	2.1	69

#	ARTICLE	IF	CITATIONS
433	Modelling MRI enhancing lesion counts in multiple sclerosis using a negative binomial model: implications for clinical trials. <i>Journal of the Neurological Sciences</i> , 1999, 163, 74-80.	0.3	68
434	Clinical correlations of brain lesion distribution in multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 768-773.	1.9	68
435	Functional adaptive changes within the hippocampal memory system of patients with multiple sclerosis. <i>Human Brain Mapping</i> , 2012, 33, 2268-2280.	1.9	68
436	Mean upper cervical cord area (MUCCA) measurement in long-standing multiple sclerosis: Relation to brain findings and clinical disability. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1860-1865.	1.4	68
437	Cognitive and Clinical Dysfunction, Altered MEG Resting-State Networks and Thalamic Atrophy in Multiple Sclerosis. <i>PLoS ONE</i> , 2013, 8, e69318.	1.1	68
438	Magnetic Resonance Imaging Predictors of Cognition in Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2007, 64, 1023.	4.9	67
439	Clinical significance of corpus callosum atrophy in a mixed elderly population. <i>Neurobiology of Aging</i> , 2007, 28, 955-963.	1.5	67
440	MRI monitoring of immunomodulation in relapse-onset multiple sclerosis trials. <i>Nature Reviews Neurology</i> , 2012, 8, 13-21.	4.9	67
441	Equivalence of Generic Glatiramer Acetate in Multiple Sclerosis. <i>JAMA Neurology</i> , 2015, 72, 1433.	4.5	67
442	A 30-Year Clinical and Magnetic Resonance Imaging Observational Study of Multiple Sclerosis and Clinically Isolated Syndromes. <i>Annals of Neurology</i> , 2020, 87, 63-74.	2.8	67
443	Guidelines for using quantitative magnetization transfer magnetic resonance imaging for monitoring treatment of multiple sclerosis. <i>Journal of Magnetic Resonance Imaging</i> , 2003, 17, 389-397.	1.9	66
444	Corpus callosum size correlates with asymmetric performance on a dichotic listening task in healthy aging but not in Alzheimer's disease. <i>Neuropsychologia</i> , 2006, 44, 208-217.	0.7	66
445	Specific risk factors for microbleeds and white matter hyperintensities in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2013, 34, 2488-2494.	1.5	66
446	Diffusion changes predict cognitive and functional outcome: The LADIS study. <i>Annals of Neurology</i> , 2013, 73, 576-583.	2.8	66
447	Sex-specific extent and severity of white matter damage in multiple sclerosis: Implications for cognitive decline. <i>Human Brain Mapping</i> , 2014, 35, 2348-2358.	1.9	66
448	The effect of IFN β -1b on the evolution of enhancing lesions in secondary progressive MS. <i>Neurology</i> , 2001, 57, 2185-2190.	1.5	65
449	An fMRI study of planning-related brain activity in patients with moderately advanced multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 549-555.	1.4	65
450	MRI and CT in the diagnosis of vascular dementia. <i>Journal of the Neurological Sciences</i> , 2004, 226, 9-12.	0.3	65

#	ARTICLE	IF	CITATIONS
451	Outcome measures for multiple sclerosis clinical trials: relative measurement precision of the Expanded Disability Status Scale and Multiple Sclerosis Functional Composite. <i>Multiple Sclerosis Journal</i> , 2004, 10, 41-46.	1.4	65
452	A three-year, multi-parametric MRI study in patients at presentation with CIS. <i>Journal of Neurology</i> , 2008, 255, 683-691.	1.8	65
453	Ethics of placebo-controlled clinical trials in multiple sclerosis. <i>Neurology</i> , 2008, 70, 1134-1140.	1.5	65
454	Spinal cord grey matter lesions in multiple sclerosis detected by post-mortem high field MR imaging. <i>Multiple Sclerosis Journal</i> , 2009, 15, 180-188.	1.4	65
455	Resection Probability Maps for Quality Assessment of Glioma Surgery without Brain Location Bias. <i>PLoS ONE</i> , 2013, 8, e73353.	1.1	65
456	Liraglutide Reduces CNS Activation in Response to Visual Food Cues Only After Short-term Treatment in Patients With Type 2 Diabetes. <i>Diabetes Care</i> , 2016, 39, 214-221.	4.3	65
457	Disrupted topological organization of structural and functional brain connectomes in clinically isolated syndrome and multiple sclerosis. <i>Scientific Reports</i> , 2016, 6, 29383.	1.6	65
458	Magnetic resonance imaging as a tool to examine the neuropathology of multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2004, 30, 106-117.	1.8	64
459	Early central atrophy rate predicts 5 year clinical outcome in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 1351-1356.	0.9	64
460	Clinical application of multi-contrast 7-T MR imaging in multiple sclerosis: increased lesion detection compared to 3T confined to grey matter. <i>European Radiology</i> , 2013, 23, 528-540.	2.3	64
461	Resting state functional connectivity differences between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Frontiers in Human Neuroscience</i> , 2015, 9, 474.	1.0	64
462	Alterations in white matter volume and integrity in obesity and type 2 diabetes. <i>Metabolic Brain Disease</i> , 2016, 31, 621-629.	1.4	64
463	Connectomic profile and clinical phenotype in newly diagnosed glioma patients. <i>NeuroImage: Clinical</i> , 2017, 14, 87-96.	1.4	64
464	In vivo assessment of neuroinflammation in progressive multiple sclerosis: a proof of concept study with [18F]DPA714 PET. <i>Journal of Neuroinflammation</i> , 2018, 15, 314.	3.1	64
465	MRI predictors of amyloid pathology: results from the EMIF-AD Multimodal Biomarker Discovery study. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 100.	3.0	64
466	Development of Hypointense Lesions on T1-Weighted Spin-Echo Magnetic Resonance Images in Multiple Sclerosis. <i>Archives of Neurology</i> , 1999, 56, 345.	4.9	63
467	Anterior Medial Temporal Lobe Activation during Attempted Retrieval of Encoded Visuospatial Scenes: An Event-Related fMRI Study. <i>NeuroImage</i> , 2001, 14, 67-76.	2.1	63
468	Microvascular Disease in Type 1 Diabetes Alters Brain Activation: A Functional Magnetic Resonance Imaging Study. <i>Diabetes</i> , 2006, 55, 334-340.	0.3	63

#	ARTICLE	IF	CITATIONS
469	Subgroups of the BENEFIT study: Risk of developing MS and treatment effect of interferon beta-1b. <i>Journal of Neurology</i> , 2008, 255, 480-487.	1.8	63
470	Intracranial Aneurysms Treated with Coil Placement: Test Characteristics of Follow-up MR Angiographyâ€™ Multicenter Study. <i>Radiology</i> , 2010, 256, 209-218.	3.6	63
471	Atypical idiopathic inflammatory demyelinating lesions: prognostic implications and relation to multiple sclerosis. <i>Journal of Neurology</i> , 2013, 260, 2016-2022.	1.8	63
472	Structural MRI substrates of cognitive impairment in neuromyelitis optica. <i>Neurology</i> , 2015, 85, 1491-1499.	1.5	63
473	Overdiagnosis of multiple sclerosis and magnetic resonance imaging criteria. <i>Annals of Neurology</i> , 2005, 58, 781-783.	2.8	62
474	Does high-field MR imaging improve cortical lesion detection in multiple sclerosis?. <i>Journal of Neurology</i> , 2008, 255, 183-191.	1.8	62
475	Memory impairment in multiple sclerosis: Relevance of hippocampal activation and hippocampal connectivity. <i>Multiple Sclerosis Journal</i> , 2015, 21, 1705-1712.	1.4	62
476	Increased connectivity of hub networks and cognitive impairment in multiple sclerosis. <i>Neurology</i> , 2017, 88, 2107-2114.	1.5	62
477	Imaging outcome measures for progressive multiple sclerosis trials. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1614-1626.	1.4	62
478	The EMIF-AD Multimodal Biomarker Discovery study: design, methods and cohort characteristics. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 64.	3.0	62
479	Primary fatty amides in plasma associated with brain amyloid burden, hippocampal volume, and memory in the European Medical Information Framework for Alzheimer's Disease biomarker discovery cohort. <i>Alzheimer's and Dementia</i> , 2019, 15, 817-827.	0.4	62
480	Phase-contrast cine MR imaging of normal aqueductal CSF flow. <i>Acta Radiologica</i> , 1994, 35, 123-130.	0.5	61
481	Diffuse signal abnormalities in the spinal cord in multiple sclerosis: Direct postmortem in situ magnetic resonance imaging correlated with in vitro high-resolution magnetic resonance imaging and histopathology. <i>Annals of Neurology</i> , 2002, 51, 652-656.	2.8	61
482	EFNS guidelines on the use of neuroimaging in the management of multiple sclerosis. <i>European Journal of Neurology</i> , 2006, 13, 313-325.	1.7	61
483	Diagnosis of natalizumab-associated progressive multifocal leukoencephalopathy using MRI. <i>Current Opinion in Neurology</i> , 2014, 27, 260-270.	1.8	61
484	Proliferative Retinopathy in Type 1 Diabetes Is Associated With Cerebral Microbleeds, Which Is Part of Generalized Microangiopathy. <i>Diabetes Care</i> , 2014, 37, 1165-1168.	4.3	61
485	Cerebral Blood Flow and Cognitive Functioning in a Community-Based, Multi-Ethnic Cohort: The SABRE Study. <i>Frontiers in Aging Neuroscience</i> , 2018, 10, 279.	1.7	61
486	Histopathologic correlates of radial stripes on MR images in lysosomal storage disorders. <i>American Journal of Neuroradiology</i> , 2005, 26, 442-6.	1.2	61

#	ARTICLE	IF	CITATIONS
487	Increased Production of Tumor Necrosis Factor $\hat{1}\pm$, and Not of Interferon $\hat{1}3$, Preceding Disease Activity in Patients With Multiple Sclerosis. <i>Archives of Neurology</i> , 1998, 55, 793.	4.9	60
488	Visual analysis of serial T2-weighted MRI in multiple sclerosis: intra- and interobserver reproducibility. <i>Neuroradiology</i> , 1999, 41, 882-888.	1.1	60
489	Pathological Aging of the Brain. <i>Topics in Magnetic Resonance Imaging</i> , 2004, 15, 369-389.	0.7	60
490	Diffusion-weighted and Conventional MR Imaging in Neonatal Hypoxic Ischemia: Two-year Follow-up Study. <i>Radiology</i> , 2008, 249, 631-639.	3.6	60
491	Clinical validity of medial temporal atrophy as a biomarker for Alzheimer's disease in the context of a structured 5-phase development framework. <i>Neurobiology of Aging</i> , 2017, 52, 167-182.e1.	1.5	60
492	Long-term clinical outcome of primary progressive MS: Predictive value of clinical and MRI data. <i>Neurology</i> , 2005, 65, 633-635.	1.5	59
493	Spinal-Cord MRI in Multiple Sclerosis: Conventional and Nonconventional MR Techniques. <i>Neuroimaging Clinics of North America</i> , 2009, 19, 81-99.	0.5	59
494	Unraveling the relationship between regional gray matter atrophy and pathology in connected white matter tracts in long-standing multiple sclerosis. <i>Human Brain Mapping</i> , 2015, 36, 1796-1807.	1.9	59
495	MRI criteria differentiating asymptomatic PML from new MS lesions during natalizumab pharmacovigilance. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1138-1145.	0.9	59
496	Cognitive subtypes of probable Alzheimer's disease robustly identified in four cohorts. <i>Alzheimer's and Dementia</i> , 2017, 13, 1226-1236.	0.4	59
497	A neuroimaging approach to capture cognitive reserve: Application to Alzheimer's disease. <i>Human Brain Mapping</i> , 2017, 38, 4703-4715.	1.9	59
498	Early- and Late-Onset Depression in Late Life: A Prospective Study on Clinical and Structural Brain Characteristics and Response to Electroconvulsive Therapy. <i>American Journal of Geriatric Psychiatry</i> , 2017, 25, 178-189.	0.6	59
499	Improved detection of diffuse glioma infiltration with imaging combinations: a diagnostic accuracy study. <i>Neuro-Oncology</i> , 2020, 22, 412-422.	0.6	59
500	Neuronal damage in T1-hypointense multiple sclerosis lesions demonstrated in vivo using proton magnetic resonance spectroscopy. <i>Annals of Neurology</i> , 1999, 46, 79-87.	2.8	59
501	Does high field MRI allow an earlier diagnosis of multiple sclerosis?. <i>Journal of Neurology</i> , 2008, 255, 1159-1163.	1.8	58
502	Large-scale, multicentre, quantitative MRI study of brain and cord damage in primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 455-464.	1.4	58
503	Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1466-1471.	1.4	58
504	Diffusion tensor imaging in type 1 diabetes: decreased white matter integrity relates to cognitive functions. <i>Diabetologia</i> , 2012, 55, 1218-1220.	2.9	58

#	ARTICLE	IF	CITATIONS
505	Application of Machine Learning to Arterial Spin Labeling in Mild Cognitive Impairment and Alzheimer Disease. <i>Radiology</i> , 2016, 281, 865-875.	3.6	58
506	Diagnostic Accuracy of MRI and Additional [18F]FDG-PET for Behavioral Variant Frontotemporal Dementia in Patients with Late Onset Behavioral Changes. <i>Journal of Alzheimer's Disease</i> , 2016, 53, 1287-1297.	1.2	58
507	Atrophy, hypometabolism and clinical trajectories in patients with amyloid-negative Alzheimer's disease. <i>Brain</i> , 2016, 139, 2528-2539.	3.7	58
508	Diffusion-Weighted MRI in Severe Neonatal Hypoxic Ischaemia: The White Cerebrum. <i>Neuropediatrics</i> , 2003, 34, 72-76.	0.3	57
509	Assessment and correction of B1-induced errors in magnetization transfer ratio measurements. <i>Magnetic Resonance in Medicine</i> , 2005, 53, 134-140.	1.9	57
510	Corpus callosum atrophy as a predictor of age-related cognitive and motor impairment: A 3-year follow-up of the LADIS study cohort. <i>Journal of the Neurological Sciences</i> , 2011, 307, 100-105.	0.3	57
511	Multicontrast MR Imaging at 7T in Multiple Sclerosis: Highest Lesion Detection in Cortical Gray Matter with 3D-FLAIR. <i>American Journal of Neuroradiology</i> , 2013, 34, 791-796.	1.2	57
512	The Dutch Parelinoer Institute - Neurodegenerative diseases; methods, design and baseline results. <i>BMC Neurology</i> , 2014, 14, 254.	0.8	57
513	Moving toward earlier treatment of multiple sclerosis: Findings from a decade of clinical trials and implications for clinical practice. <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 147-155.	0.9	57
514	Alzheimer's biomarkers in daily practice (ABIDE) project: Rationale and design. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 6, 143-151.	1.2	57
515	Gut Microbiota Composition Is Related to AD Pathology. <i>Frontiers in Immunology</i> , 2021, 12, 794519.	2.2	57
516	Clinical MRI correlations in a European trial of interferon beta-1b in secondary progressive MS. <i>Neurology</i> , 2001, 57, 2191-2197.	1.5	56
517	Molecular imaging in the diagnosis of Alzheimer's disease: visual assessment of [11C]PIB and [18F]FDG PET images. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2010, 81, 882-884.	0.9	56
518	Cognitive Dysfunction in Early Multiple Sclerosis: Altered Centrality Derived from Resting-State Functional Connectivity Using Magneto-Encephalography. <i>PLoS ONE</i> , 2012, 7, e42087.	1.1	56
519	Widespread Disruption of Functional Brain Organization in Early-Onset Alzheimer's Disease. <i>PLoS ONE</i> , 2014, 9, e102995.	1.1	56
520	Basal Forebrain and Hippocampus as Predictors of Conversion to Alzheimer's Disease in Patients with Mild Cognitive Impairment - A Multicenter DTI and Volumetry Study. <i>Journal of Alzheimer's Disease</i> , 2015, 48, 197-204.	1.2	56
521	The Diagnostic Value of Magnetic Resonance Imaging and Technetium 99m-HMPAO Single-Photon-Emission Computed Tomography for the Diagnosis of Alzheimer Disease in a Community-Dwelling Elderly Population. <i>Alzheimer Disease and Associated Disorders</i> , 1997, 11, 63-70.	0.6	55
522	Neurophysiological correlates of increased verbal working memory in high-dissociative participants: a functional MRI study. <i>Psychological Medicine</i> , 2005, 35, 175-185.	2.7	55

#	ARTICLE	IF	CITATIONS
523	Small vessel versus large vessel vascular dementia. <i>Journal of Neurology</i> , 2008, 255, 1644-1651.	1.8	55
524	Grid infrastructures for computational neuroscience: the neuGRID example. <i>Future Neurology</i> , 2009, 4, 703-722.	0.9	55
525	Microbleeds relate to altered amyloid-beta metabolism in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2012, 33, 1011.e1-1011.e9.	1.5	55
526	No association of multiple sclerosis activity and progression with EBV or tobacco use in BENEFIT. <i>Neurology</i> , 2015, 85, 1694-1701.	1.5	55
527	rTMS affects working memory performance, brain activation and functional connectivity in patients with multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 386-394.	0.9	55
528	Multitracer model for staging cortical amyloid deposition using PET imaging. <i>Neurology</i> , 2020, 95, e1538-e1553.	1.5	55
529	Clinical trials of multiple sclerosis monitored with enhanced MRI: new sample size calculations based on large data sets. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2001, 70, 494-499.	0.9	54
530	Brain atrophy in multiple sclerosis: impact of lesions and of damage of whole brain tissue. <i>Multiple Sclerosis Journal</i> , 2002, 8, 410-414.	1.4	54
531	Normal CSF ferritin levels in MS suggest against etiologic role of chronic venous insufficiency. <i>Neurology</i> , 2010, 75, 1617-1622.	1.5	54
532	Reduced dynamics of functional connectivity and cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2020, 26, 476-488.	1.4	54
533	Limited duration of the effect of methylprednisolone on changes on MRI in multiple sclerosis. <i>Neuroradiology</i> , 1994, 36, 382-387.	1.1	53
534	Cognitive slowing in multiple sclerosis is strongly associated with brain volume reduction. <i>Multiple Sclerosis Journal</i> , 2006, 12, 760-768.	1.4	53
535	CCL5 and CCR5 genotypes modify clinical, radiological and pathological features of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2007, 190, 157-164.	1.1	53
536	T2 lesion location really matters: a 10 year follow-up study in primary progressive multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 72-77.	0.9	53
537	Location of brain lesions predicts conversion of clinically isolated syndromes to multiple sclerosis. <i>Neurology</i> , 2013, 80, 234-241.	1.5	53
538	Cortical atrophy accelerates as cognitive decline worsens in multiple sclerosis. <i>Neurology</i> , 2019, 93, e1348-e1359.	1.5	53
539	Is retinal vasculature a biomarker in amyloid proven Alzheimer's disease?. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 383-391.	1.2	53
540	Head-to-Head Comparison of Two Popular Cortical Thickness Extraction Algorithms: A Cross-Sectional and Longitudinal Study. <i>PLoS ONE</i> , 2015, 10, e0117692.	1.1	53

#	ARTICLE	IF	CITATIONS
541	Thalamic Lesions in Vascular Dementia. <i>Stroke</i> , 2004, 35, 415-419.	1.0	52
542	Impairment of movement-associated brain deactivation in multiple sclerosis: further evidence for a functional pathology of interhemispheric neuronal inhibition. <i>Experimental Brain Research</i> , 2008, 187, 25-31.	0.7	52
543	Shifting imaging targets in multiple sclerosis: From inflammation to neurodegeneration. <i>Journal of Magnetic Resonance Imaging</i> , 2012, 36, 1-19.	1.9	52
544	Emotional eating is associated with increased brain responses to food cues and reduced sensitivity to GLP-1 receptor activation. <i>Obesity</i> , 2015, 23, 2075-2082.	1.5	52
545	Gray matter networks and clinical progression in subjects with predementia Alzheimer's disease. <i>Neurobiology of Aging</i> , 2018, 61, 75-81.	1.5	52
546	Relevance of Spinal Cord Abnormalities to Clinical Disability in Multiple Sclerosis: MR Imaging Findings in a Large Cohort of Patients. <i>Radiology</i> , 2013, 269, 542-552.	3.6	52
547	Normal-appearing white matter changes vary with distance to lesions in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 2006, 27, 2005-11.	1.2	52
548	Cerebral volume changes in multiple sclerosis patients treated with high-dose intravenous methylprednisolone. <i>Multiple Sclerosis Journal</i> , 2002, 8, 415-419.	1.4	51
549	Segmentation of age-related white matter changes in a clinical multi-center study. <i>NeuroImage</i> , 2008, 41, 335-345.	2.1	51
550	White Matter Changes Contribute to Corpus Callosum Atrophy in the Elderly: The LADIS Study. <i>American Journal of Neuroradiology</i> , 2008, 29, 1498-1504.	1.2	51
551	Abnormal connectivity of the sensorimotor network in patients with MS: A multicenter fMRI study. <i>Human Brain Mapping</i> , 2009, 30, 2412-2425.	1.9	51
552	Long-term effects of amyloid, hypometabolism, and atrophy on neuropsychological functions. <i>Neurology</i> , 2014, 82, 1768-1775.	1.5	51
553	Gray matter network disruptions and amyloid beta in cognitively normal adults. <i>Neurobiology of Aging</i> , 2016, 37, 154-160.	1.5	51
554	Applying the ATN scheme in a memory clinic population. <i>Neurology</i> , 2019, 93, e1635-e1646.	1.5	51
555	White Matter Lesions Are Associated With Progression of Medial Temporal Lobe Atrophy in Alzheimer Disease. <i>Stroke</i> , 2006, 37, 2248-2252.	1.0	50
556	Distinct perfusion patterns in Alzheimer's disease, frontotemporal dementia and dementia with Lewy bodies. <i>European Radiology</i> , 2014, 24, 2326-2333.	2.3	50
557	Perivascular spaces in MS patients at 7 Tesla MRI: A marker of neurodegeneration?. <i>Multiple Sclerosis Journal</i> , 2015, 21, 155-162.	1.4	50
558	Elevated Postoperative Endogenous GLP-1 Levels Mediate Effects of Roux-en-Y Gastric Bypass on Neural Responsivity to Food Cues. <i>Diabetes Care</i> , 2017, 40, 1522-1529.	4.3	50

#	ARTICLE	IF	CITATIONS
559	Dementia imaging in clinical practice: a European-wide survey of 193 centres and conclusions by the ESNR working group. <i>Neuroradiology</i> , 2019, 61, 633-642.	1.1	50
560	Global and Regional Differences in Brain Anatomy of Young Children Born Small for Gestational Age. <i>PLoS ONE</i> , 2011, 6, e24116.	1.1	50
561	Reproducibility of fMRI in the clinical setting: Implications for trial designs. <i>NeuroImage</i> , 2008, 42, 603-610.	2.1	49
562	Fetal Origin of Brain Damage in 2 Infants with a <i>COL4A1</i> Mutation: Fetal and Neonatal MRI. <i>Neuropediatrics</i> , 2011, 42, 1-3.	0.3	49
563	MRI mimics of multiple sclerosis. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2014, 122, 291-316.	1.0	49
564	Cerebrospinal fluid biomarkers and cerebral atrophy in distinct clinical variants of probable Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 2340-2347.	1.5	49
565	Endogenous GLP1 and GLP1 analogue alter CNS responses to palatable food consumption. <i>Journal of Endocrinology</i> , 2016, 229, 1-12.	1.2	49
566	Image registration and subtraction to detect active T2 lesions in MS: an interobserver study. <i>Journal of Neurology</i> , 2002, 249, 767-773.	1.8	48
567	MRI features of benign multiple sclerosis. <i>Neurology</i> , 2009, 72, 1693-1701.	1.5	48
568	New Research Criteria for the Diagnosis of Alzheimer's Disease Applied in a Memory Clinic Population. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 30, 1-7.	0.7	48
569	Microbleeds, Mortality, and Stroke in Alzheimer Disease. <i>JAMA Neurology</i> , 2015, 72, 539.	4.5	48
570	A Longitudinal Study on Resting State Functional Connectivity in Behavioral Variant Frontotemporal Dementia and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 521-537.	1.2	48
571	Differences in structural covariance brain networks between behavioral variant frontotemporal dementia and Alzheimer's disease. <i>Human Brain Mapping</i> , 2016, 37, 978-988.	1.9	48
572	The EMIF-AD PreclinAD study: study design and baseline cohort overview. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 75.	3.0	48
573	Sex differences in CSF biomarkers vary by Alzheimer disease stage and <i>APOE</i> ϵ 4 genotype. <i>Neurology</i> , 2020, 95, e2378-e2388.	1.5	48
574	CSF myelin basic protein, IgG and IgM levels in 101 MS patients before and after treatment with high-dose intravenous methylprednisolone. <i>Acta Neurologica Scandinavica</i> , 1992, 86, 291-297.	1.0	47
575	Predicting gadolinium enhancement status in MS patients eligible for randomized clinical trials. <i>Neurology</i> , 2005, 65, 1447-1454.	1.5	47
576	Predicting short-term disability progression in early multiple sclerosis: added value of MRI parameters. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2008, 79, 917-923.	0.9	47

#	ARTICLE	IF	CITATIONS
577	Subtraction MR Images in a Multiple Sclerosis Multicenter Clinical Trial Setting. <i>Radiology</i> , 2009, 250, 506-514.	3.6	47
578	Diffusely Abnormal White Matter in Progressive Multiple Sclerosis: In Vivo Quantitative MR Imaging Characterization and Comparison between Disease Types. <i>American Journal of Neuroradiology</i> , 2010, 31, 541-548.	1.2	47
579	Determinants of iron accumulation in deep grey matter of multiple sclerosis patients. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1692-1698.	1.4	47
580	Urgent challenges in quantification and interpretation of brain grey matter atrophy in individual MS patients using MRI. <i>NeuroImage: Clinical</i> , 2018, 19, 466-475.	1.4	47
581	Assessing Amyloid Pathology in Cognitively Normal Subjects Using ¹⁸ F-Flutemetamol PET: Comparing Visual Reads and Quantitative Methods. <i>Journal of Nuclear Medicine</i> , 2019, 60, 541-547.	2.8	47
582	In vivo tau pathology is associated with synaptic loss and altered synaptic function. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 35.	3.0	47
583	Medial temporal lobe atrophy in an open population of very old persons. <i>Neurology</i> , 1995, 45, 747-752.	1.5	46
584	Magnetization Transfer Ratio of the Spinal Cord in Multiple Sclerosis: Relationship to Atrophy and Neurologic Disability. <i>Journal of Neuroimaging</i> , 2000, 10, 67-72.	1.0	46
585	Patterns of enhancing lesion evolution in multiple sclerosis are uniform within patients. <i>Neurology</i> , 2005, 65, 56-61.	1.5	46
586	Magnetic Resonance Imaging Effects of Interferon Beta-1b in the BENEFIT Study. <i>Archives of Neurology</i> , 2007, 64, 1292.	4.9	46
587	Cerebrospinal fluid ATP metabolites in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 549-554.	1.4	46
588	Early postoperative MRI overestimates residual tumour after resection of gliomas with no or minimal enhancement. <i>European Radiology</i> , 2011, 21, 1526-1534.	2.3	46
589	More Atrophy of Deep Gray Matter Structures in Frontotemporal Dementia Compared to Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2015, 44, 635-647.	1.2	46
590	MRI characteristics of early PML-IRIS after natalizumab treatment in patients with MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 879-884.	0.9	46
591	Secondary prevention of Alzheimer's dementia: neuroimaging contributions. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 112.	3.0	46
592	Clinical phenotype, atrophy, and small vessel disease in $\epsilon 2$ carriers with Alzheimer disease. <i>Neurology</i> , 2018, 91, e1851-e1859.	1.5	46
593	Discovery and validation of plasma proteomic biomarkers relating to brain amyloid burden by SOMAscan assay. <i>Alzheimer's and Dementia</i> , 2019, 15, 1478-1488.	0.4	46
594	Spatial patterns of white matter hyperintensities associated with Alzheimer's disease risk factors in a cognitively healthy middle-aged cohort. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 12.	3.0	46

#	ARTICLE	IF	CITATIONS
595	Mind the gap: from neurons to networks to outcomes in multiple sclerosis. <i>Nature Reviews Neurology</i> , 2021, 17, 173-184.	4.9	46
596	Measuring Resilience and Resistance in Aging and Alzheimer Disease Using Residual Methods. <i>Neurology</i> , 2021, 97, 474-488.	1.5	46
597	Comparison of a conventional cardiac-triggered dual spin-echo and a fast STIR sequence in detection of spinal cord lesions in multiple sclerosis. <i>European Radiology</i> , 2000, 10, 753-758.	2.3	45
598	Comparison of the Alzheimer's Disease Assessment Scale Cognitive Subscale and the Vascular Dementia Assessment Scale in Differentiating Elderly Individuals with Different Degrees of White Matter Changes. <i>Dementia and Geriatric Cognitive Disorders</i> , 2007, 24, 73-81.	0.7	45
599	Intercenter agreement of brain atrophy measurement in multiple sclerosis patients using manually edited SIENA and SIENAX. <i>Journal of Magnetic Resonance Imaging</i> , 2007, 26, 881-885.	1.9	45
600	Punctate lesion pattern suggestive of perivascular inflammation in acute natalizumab-associated progressive multifocal leukoencephalopathy: productive JC virus infection or preclinical PML-IRIS manifestation?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2013, 84, 1176-1177.	0.9	45
601	Cognitive reserve moderates long-term cognitive and functional outcome in cerebral small vessel disease. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, 1296-1302.	0.9	45
602	Central Review of Amyloid-Related Imaging Abnormalities in Two Phase III Clinical Trials of Bapineuzumab in Mild-To-Moderate Alzheimer's Disease Patients. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 557-573.	1.2	45
603	Grey Matter Atrophy in Multiple Sclerosis: Clinical Interpretation Depends on Choice of Analysis Method. <i>PLoS ONE</i> , 2016, 11, e0143942.	1.1	45
604	Secondary progressive multiple sclerosis: the relationship between short-term MRI activity and clinical features. <i>Brain</i> , 1998, 121, 225-231.	3.7	44
605	Isotropic 3D fast FLAIR imaging of the brain in multiple sclerosis patients: initial experience. <i>European Radiology</i> , 2002, 12, 559-567.	2.3	44
606	Thallium-201 Single-Photon Emission Computed Tomography As an Early Predictor of Outcome in Recurrent Glioma. <i>Journal of Clinical Oncology</i> , 2003, 21, 3559-3565.	0.8	44
607	Use of ultrasmall superparamagnetic particles of iron oxide (USPIO)-enhanced MRI to demonstrate diffuse inflammation in the normal-appearing white matter (NAWM) of multiple sclerosis (MS) patients: An exploratory study. <i>Journal of Magnetic Resonance Imaging</i> , 2009, 29, 774-779.	1.9	44
608	Interferon β -1 neutralizing antibodies 5 years after clinically isolated syndrome. <i>Neurology</i> , 2011, 77, 835-843.	1.5	44
609	Improvement of White Matter Changes on Neuroimaging Modalities After Stem Cell Transplant in Metachromatic Leukodystrophy. <i>JAMA Neurology</i> , 2013, 70, 779.	4.5	44
610	Molecular mechanism underlying the impact of vitamin D on disease activity of MS. <i>Annals of Clinical and Translational Neurology</i> , 2014, 1, 605-617.	1.7	44
611	Multi-parametric structural magnetic resonance imaging in relation to cognitive dysfunction in long-standing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 608-619.	1.4	44
612	APOE ϵ 4 status is associated with white matter hyperintensities volume accumulation rate independent of AD diagnosis. <i>Neurobiology of Aging</i> , 2017, 53, 67-75.	1.5	44

#	ARTICLE	IF	CITATIONS
613	Gray matter network measures are associated with cognitive decline in mild cognitive impairment. <i>Neurobiology of Aging</i> , 2018, 61, 198-206.	1.5	44
614	The P2X7 receptor tracer [11C]SMW139 as an in vivo marker of neuroinflammation in multiple sclerosis: a first-in man study. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2020, 47, 379-389.	3.3	44
615	Application of the ATN classification scheme in a population without dementia: Findings from the EPAD cohort. <i>Alzheimer's and Dementia</i> , 2021, 17, 1189-1204.	0.4	44
616	Comparison of four potential MR parameters for severe tissue destruction in multiple sclerosis lesions. <i>Magnetic Resonance Imaging</i> , 1997, 15, 155-162.	1.0	43
617	Two-year follow-up study of primary and transitional progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2002, 8, 108-114.	1.4	43
618	CTLA-4 and CD28 gene polymorphisms in susceptibility, clinical course and progression of multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2003, 140, 188-193.	1.1	43
619	Magnetization transfer ratio measurement in multiple sclerosis normal-appearing brain tissue: limited differences with controls but relationships with clinical and MR measures of disease. <i>Multiple Sclerosis Journal</i> , 2007, 13, 708-716.	1.4	43
620	Assessing the reproducibility of the SienaX and Siena brain atrophy measures using the ADNI back-to-back MP-RAGE MRI scans. <i>Psychiatry Research - Neuroimaging</i> , 2011, 193, 182-190.	0.9	43
621	Cardiovascular and Interventional Radiological Society of Europe Commentary on the Treatment of Chronic Cerebrospinal Venous Insufficiency. <i>CardioVascular and Interventional Radiology</i> , 2011, 34, 1-2.	0.9	43
622	Morphological features of MS lesions on FLAIR* at 7T and their relation to patient characteristics. <i>Journal of Neurology</i> , 2014, 261, 1356-1364.	1.8	43
623	7T T2*-weighted magnetic resonance imaging reveals cortical phase differences between early- and late-onset Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 20-26.	1.5	43
624	Multiple Sclerosis-Secondary Progressive Multi-Arm Randomisation Trial (MS-SMART): a multiarm phase IIb randomised, double-blind, placebo-controlled clinical trial comparing the efficacy of three neuroprotective drugs in secondary progressive multiple sclerosis. <i>BMJ Open</i> , 2018, 8, e021944.	0.8	43
625	Inclusion of optic nerve involvement in dissemination in space criteria for multiple sclerosis. <i>Neurology</i> , 2018, 91, e1130-e1134.	1.5	43
626	Precision prevention of Alzheimer's and other dementias: Anticipating future needs in the control of risk factors and implementation of disease-modifying therapies. <i>Alzheimer's and Dementia</i> , 2020, 16, 1457-1468.	0.4	43
627	Exploratory treatment trials in multiple sclerosis using MRI: sample size calculations for relapsing-remitting and secondary progressive subgroups using placebo controlled parallel groups. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64, 50-55.	0.9	42
628	Seasonal variation in immune measurements and MRI markers of disease activity in MS. <i>Neurology</i> , 2002, 58, 1077-1080.	1.5	42
629	The changing face of multiple sclerosis clinical trial populations. <i>Current Medical Research and Opinion</i> , 2011, 27, 1529-1537.	0.9	42
630	Thinner temporal and parietal cortex is related to incident clinical progression to dementia in patients with subjective cognitive decline. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2016, 5, 43-52.	1.2	42

#	ARTICLE	IF	CITATIONS
631	Development of the SIOPE DIPG network, registry and imaging repository: a collaborative effort to optimize research into a rare and lethal disease. <i>Journal of Neuro-Oncology</i> , 2017, 132, 255-266.	1.4	42
632	Diagnostic Accuracy of Neuroimaging to Delineate Diffuse Gliomas within the Brain: A Meta-Analysis. <i>American Journal of Neuroradiology</i> , 2017, 38, 1884-1891.	1.2	42
633	Cerebral amyloid burden is associated with white matter hyperintensity location in specific posterior white matter regions. <i>Neurobiology of Aging</i> , 2019, 84, 225-234.	1.5	42
634	Multi-study validation of data-driven disease progression models to characterize evolution of biomarkers in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 24, 101954.	1.4	42
635	<i>APOE</i> and cortical superficial siderosis in CAA. <i>Neurology</i> , 2019, 93, e358-e371.	1.5	42
636	SVM recursive feature elimination analyses of structural brain MRI predicts near-term relapses in patients with clinically isolated syndromes suggestive of multiple sclerosis. <i>NeuroImage: Clinical</i> , 2019, 24, 102011.	1.4	42
637	Genome-wide association study of Alzheimer's disease CSF biomarkers in the EMIF-AD Multimodal Biomarker Discovery dataset. <i>Translational Psychiatry</i> , 2020, 10, 403.	2.4	42
638	In vivo imaging of chronic active lesions in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 683-690.	1.4	42
639	Hippocampal sulcus width and cavities: comparison between patients with Alzheimer disease and nondemented elderly subjects. <i>American Journal of Neuroradiology</i> , 2006, 27, 2141-5.	1.2	42
640	Parametric fMRI analysis of visual encoding in the human medial temporal lobe. , 1999, 9, 637-643.		41
641	Persistent T1 hypointensity as an MRI marker for treatment efficacy in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2008, 14, 764-769.	1.4	41
642	Visual ratings of atrophy in MCI: prediction of conversion and relationship with CSF biomarkers. <i>Neurobiology of Aging</i> , 2013, 34, 73-82.	1.5	41
643	The influence of patient demographics, disease characteristics and treatment on brain volume loss in Trial Assessing Injectable Interferon vs FTY720 Oral in Relapsing"Remitting Multiple Sclerosis (TRANSFORMS), a phase 3 study of fingolimod in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1704-1713.	1.4	41
644	Unraveling the neuroimaging predictors for motor dysfunction in long-standing multiple sclerosis. <i>Neurology</i> , 2015, 85, 248-255.	1.5	41
645	Association of CSF, Plasma, and Imaging Markers of Neurodegeneration With Clinical Progression in People With Subjective Cognitive Decline. <i>Neurology</i> , 2022, 98, .	1.5	41
646	Lesional magnetization transfer ratio: a feasible outcome for remyelinating treatment trials in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2010, 16, 660-669.	1.4	40
647	Correlating Quantitative MR Imaging with Histopathology in X-Linked Adrenoleukodystrophy. <i>American Journal of Neuroradiology</i> , 2011, 32, 481-489.	1.2	40
648	Longitudinal gray matter changes in multiple sclerosis"Differential scanner and overall disease"-related effects. <i>Human Brain Mapping</i> , 2012, 33, 1225-1245.	1.9	40

#	ARTICLE	IF	CITATIONS
649	An MRI Rating Scale for Amyloid-Related Imaging Abnormalities with Edema or Effusion. American Journal of Neuroradiology, 2013, 34, 1550-1555.	1.2	40
650	Cerebrospinal fluid levels of Alzheimer's disease biomarkers in middle-aged patients with type 1 diabetes. Diabetologia, 2014, 57, 2208-2214.	2.9	40
651	Regional cortical thinning in multiple sclerosis and its relation with cognitive impairment: A multicenter study. Multiple Sclerosis Journal, 2016, 22, 901-909.	1.4	40
652	Different patterns of cortical gray matter loss over time in behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2016, 38, 21-31.	1.5	40
653	A more randomly organized grey matter network is associated with deteriorating language and global cognition in individuals with subjective cognitive decline. Human Brain Mapping, 2018, 39, 3143-3151.	1.9	40
654	Associations between quantitative [18F]florbetapir tau PET and atrophy across the Alzheimer's disease spectrum. Alzheimer's Research and Therapy, 2019, 11, 60.	3.0	40
655	Lifespan normative data on rates of brain volume changes. Neurobiology of Aging, 2019, 81, 30-37.	1.5	40
656	Predicting clinical progression in multiple sclerosis after 6 and 12 years. European Journal of Neurology, 2019, 26, 893-902.	1.7	40
657	Patterns of white matter hyperintensities associated with cognition in middle-aged cognitively healthy individuals. Brain Imaging and Behavior, 2020, 14, 2012-2023.	1.1	40
658	Efficacy and safety of temelimab in multiple sclerosis: Results of a randomized phase 2b and extension study. Multiple Sclerosis Journal, 2022, 28, 429-440.	1.4	40
659	Spatial-Temporal Patterns of β -Amyloid Accumulation. Neurology, 2022, 98, .	1.5	40
660	The role of MRI as a surrogate outcome measure in multiple sclerosis. Multiple Sclerosis Journal, 2002, 8, 40-51.	1.4	39
661	Multislice T1 relaxation time measurements in the brain using IR-EPI: Reproducibility, normal values, and histogram analysis in patients with multiple sclerosis. Journal of Magnetic Resonance Imaging, 2003, 18, 656-664.	1.9	39
662	Oral interferon beta-1a in relapsing-remitting multiple sclerosis: a double-blind randomized study. Multiple Sclerosis Journal, 2003, 9, 342-348.	1.4	39
663	Motor evoked potential: A reliable and objective measure to document the functional consequences of multiple sclerosis? Relation to disability and MRI. Clinical Neurophysiology, 2007, 118, 1332-1340.	0.7	39
664	Improved reliability of hippocampal atrophy rate measurement in mild cognitive impairment using fluid registration. NeuroImage, 2007, 34, 1036-1041.	2.1	39
665	N-acetylaspartic acid in cerebrospinal fluid of multiple sclerosis patients determined by gas-chromatography-mass spectrometry. Journal of Neurology, 2007, 254, 631-637.	1.8	39
666	The pilot European Alzheimer's Disease Neuroimaging Initiative of the European Alzheimer's Disease Consortium. , 2008, 4, 255-264.		39

#	ARTICLE	IF	CITATIONS
667	White matter hyperintensities and medial temporal lobe atrophy in clinical subtypes of mild cognitive impairment: the DESCRIPA study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2009, 80, 1069-1074.	0.9	39
668	Translating pathology in multiple sclerosis: the combination of postmortem imaging, histopathology and clinical findings. <i>Acta Neurologica Scandinavica</i> , 2009, 119, 349-355.	1.0	39
669	Lower cerebral blood flow in subjects with Alzheimer's dementia, mild cognitive impairment, and subjective cognitive decline using two-dimensional phase-contrast magnetic resonance imaging. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2017, 9, 76-83.	1.2	39
670	Gray matter networks and cognitive impairment in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2019, 25, 382-391.	1.4	39
671	Cytokine producing CD8+ T cells are correlated to MRI features of tissue destruction in MS. <i>Journal of Neuroimmunology</i> , 2003, 142, 141-148.	1.1	38
672	Raloxifene Treatment Enhances Brain Activation during Recognition of Familiar Items: a Pharmacological fMRI Study in Healthy Elderly Males. <i>Neuropsychopharmacology</i> , 2006, 31, 1508-1518.	2.8	38
673	Short-term adaptation to a simple motor task: A physiological process preserved in multiple sclerosis. <i>NeuroImage</i> , 2009, 45, 500-511.	2.1	38
674	Accurate GM atrophy quantification in MS using lesion-filling with co-registered 2D lesion masks. <i>NeuroImage: Clinical</i> , 2014, 4, 366-373.	1.4	38
675	Joint assessment of white matter integrity, cortical and subcortical atrophy to distinguish AD from behavioral variant FTD: A two-center study. <i>NeuroImage: Clinical</i> , 2015, 9, 418-429.	1.4	38
676	Long-term motor and behavioral outcome after perinatal hypoxic-ischemic encephalopathy. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 354-359.	0.7	38
677	Test-retest reliability of the default mode network in a multi-centric fMRI study of healthy elderly: Effects of data-driven physiological noise correction techniques. <i>Human Brain Mapping</i> , 2016, 37, 2114-2132.	1.9	38
678	Subcutaneous interferon β -1a in the treatment of clinically isolated syndromes: 3-year and 5-year results of the phase III dosing frequency-blind multicentre REFLEXION study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2017, 88, 285-294.	0.9	38
679	Five-class differential diagnostics of neurodegenerative diseases using random undersampling boosting. <i>NeuroImage: Clinical</i> , 2017, 15, 613-624.	1.4	38
680	Linking late cognitive outcome with glioma surgery location using resection cavity maps. <i>Human Brain Mapping</i> , 2018, 39, 2064-2074.	1.9	38
681	Performance of five automated white matter hyperintensity segmentation methods in a multicenter dataset. <i>Scientific Reports</i> , 2019, 9, 16742.	1.6	38
682	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated volumetry across different MRI sites and vendors. <i>NeuroImage</i> , 2020, 218, 116932.	2.1	38
683	No major association of A poE genotype with disease characteristics and MRI findings in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2004, 10, 272-277.	1.4	37
684	Raloxifene exposure enhances brain activation during memory performance in healthy elderly males; its possible relevance to behavior. <i>NeuroImage</i> , 2005, 25, 63-75.	2.1	37

#	ARTICLE	IF	CITATIONS
685	Progression of cerebral white matter lesions in Alzheimer's disease: a new window for therapy?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2005, 76, 1286-1288.	0.9	37
686	Amyloid and its association with default network integrity in Alzheimer's disease. <i>Human Brain Mapping</i> , 2014, 35, 779-791.	1.9	37
687	Impact of APOE-É4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. <i>Neurobiology of Aging</i> , 2016, 38, 14-20.	1.5	37
688	Arterial spin labeling-based Z-maps have high specificity and positive predictive value for neurodegenerative dementia compared to FDG-PET. <i>European Radiology</i> , 2017, 27, 4237-4246.	2.3	37
689	Clinically relevant cranio-caudal patterns of cervical cord atrophy evolution in MS. <i>Neurology</i> , 2019, 93, e1852-e1866.	1.5	37
690	Onset of clinical and MRI efficacy of ocrelizumab in relapsing multiple sclerosis. <i>Neurology</i> , 2019, 93, e1778-e1786.	1.5	37
691	AMYPAD Diagnostic and Patient Management Study: Rationale and design. <i>Alzheimer's and Dementia</i> , 2019, 15, 388-399.	0.4	37
692	White Matter Hyperintensities, Medial Temporal Lobe Atrophy, Cortical Atrophy, and Response to Electroconvulsive Therapy in Severely Depressed Elderly Patients. <i>Journal of Clinical Psychiatry</i> , 2011, 72, 104-112.	1.1	37
693	MR imaging in retinoblastoma. <i>European Radiology</i> , 1997, 7, 726-731.	2.3	36
694	Raloxifene Affects Brain Activation Patterns in Postmenopausal Women during Visual Encoding. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1422-1422.	1.8	36
695	Amyloid-related imaging abnormalities-haemosiderin (ARIA-H) in patients with Alzheimer's disease treated with bapineuzumab: a historical, prospective secondary analysis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2016, 87, jnnp-2014-309493.	0.9	36
696	Personalized extended interval dosing of natalizumab in MS. <i>Neurology</i> , 2020, 95, e745-e754.	1.5	36
697	Immune signatures of prodromal multiple sclerosis in monozygotic twins. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2020, 117, 21546-21556.	3.3	36
698	Optical coherence tomography in multiple sclerosis: A 3â€¦year prospective multicenter study. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 2235-2251.	1.7	36
699	Reversible cognitive disorders after sunitinib for advanced renal cell cancer in patients with preexisting arteriosclerotic leukoencephalopathy. <i>Annals of Oncology</i> , 2007, 18, 1747-1750.	0.6	35
700	Regional brain atrophy development is related to specific aspects of clinical dysfunction in multiple sclerosis. <i>NeuroImage</i> , 2007, 38, 529-537.	2.1	35
701	Primary progressive multiple sclerosis diagnostic criteria: a reappraisal. <i>Multiple Sclerosis Journal</i> , 2009, 15, 1459-1465.	1.4	35
702	Longâ€¦interval T2â€¦weighted subtraction magnetic resonance imaging: A powerful new outcome measure in multiple sclerosis trials. <i>Annals of Neurology</i> , 2010, 67, 667-675.	2.8	35

#	ARTICLE	IF	CITATIONS
703	Memantine and Brain Atrophy in Alzheimer's Disease: A 1-Year Randomized Controlled Trial. <i>Journal of Alzheimer's Disease</i> , 2012, 29, 459-469.	1.2	35
704	Multimodal Quantitative MR Imaging of the Thalamus in Multiple Sclerosis and Neuromyelitis Optica. <i>Radiology</i> , 2015, 277, 784-792.	3.6	35
705	High-resolution T1-relaxation time mapping displays subtle, clinically relevant, gray matter damage in long-standing multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1279-1288.	1.4	35
706	Association between tumor location and neurocognitive functioning using tumor localization maps. <i>Journal of Neuro-Oncology</i> , 2019, 144, 573-582.	1.4	35
707	Detecting frontotemporal dementia syndromes using MRI biomarkers. <i>NeuroImage: Clinical</i> , 2019, 22, 101711.	1.4	35
708	Modifiable risk factors for dementia and dementia risk profiling. A user manual for Brain Health Services—part 2 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 169.	3.0	35
709	Chemokine receptor expression on T cells is related to new lesion development in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 133, 225-232.	1.1	34
710	Behavioural and psychological symptoms are not related to white matter hyperintensities and medial temporal lobe atrophy in Alzheimer's disease. <i>International Journal of Geriatric Psychiatry</i> , 2008, 23, 387-392.	1.3	34
711	Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS. <i>Neurology</i> , 2010, 75, 1228-1233.	1.5	34
712	Longitudinal reproducibility of automatically segmented hippocampal subfields: A multisite European 3T study on healthy elderly. <i>Human Brain Mapping</i> , 2015, 36, 3516-3527.	1.9	34
713	Defining brain volume cutoffs to identify clinically relevant atrophy in RRMS. <i>Multiple Sclerosis Journal</i> , 2017, 23, 656-664.	1.4	34
714	Disclosure of amyloid positron emission tomography results to individuals without dementia: a systematic review. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 72.	3.0	34
715	Quantification of amyloid PET for future clinical use: a state-of-the-art review. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2022, 49, 3508-3528.	3.3	34
716	Serial Isotropic Three-Dimensional Fast FLAIR Imaging: Using Image Registration and Subtraction to Reveal Active Multiple Sclerosis Lesions. <i>American Journal of Roentgenology</i> , 2002, 179, 777-782.	1.0	33
717	The FAS ⁶⁷⁰ polymorphism influences susceptibility to multiple sclerosis. <i>Journal of Neuroimmunology</i> , 2002, 128, 95-100.	1.1	33
718	Association between MRI parameters and the MS severity scale: a 12-year follow-up study. <i>Multiple Sclerosis Journal</i> , 2009, 15, 632-637.	1.4	33
719	Quantitation of brain tissue changes associated with white matter hyperintensities by diffusion-weighted and magnetization transfer imaging: The LADIS (leukoaraiosis and disability in the) Tj ETQq1 1107843143gBT /Ore		
720	Cerebral atrophy as outcome measure in short-term phase 2 clinical trials in multiple sclerosis. <i>Neuroradiology</i> , 2010, 52, 875-881.	1.1	33

#	ARTICLE	IF	CITATIONS
721	Cognition in MS correlates with resting-state oscillatory brain activity: An explorative MEG source-space study. <i>NeuroImage: Clinical</i> , 2013, 2, 727-734.	1.4	33
722	The European DTI Study on Dementia – A multicenter DTI and MRI study on Alzheimer's disease and Mild Cognitive Impairment. <i>NeuroImage</i> , 2017, 144, 305-308.	2.1	33
723	Altered eigenvector centrality is related to local resting-state network functional connectivity in patients with longstanding type 1 diabetes mellitus. <i>Human Brain Mapping</i> , 2017, 38, 3623-3636.	1.9	33
724	Single Subject Classification of Alzheimer's Disease and Behavioral Variant Frontotemporal Dementia Using Anatomical, Diffusion Tensor, and Resting-State Functional Magnetic Resonance Imaging. <i>Journal of Alzheimer's Disease</i> , 2018, 62, 1827-1839.	1.2	33
725	Progressive brain rich-club network disruption from clinically isolated syndrome towards multiple sclerosis. <i>NeuroImage: Clinical</i> , 2018, 19, 232-239.	1.4	33
726	Gray matter T1 ρ /T2 ρ ratios are higher in Alzheimer's disease. <i>Human Brain Mapping</i> , 2019, 40, 3900-3909.	1.9	33
727	Prodromal Dementia With Lewy Bodies: Clinical Characterization and Predictors of Progression. <i>Movement Disorders</i> , 2020, 35, 859-867.	2.2	33
728	T1 hypointensities and axonal loss. <i>Neuroimaging Clinics of North America</i> , 2000, 10, 739-52 ,ix.	0.5	33
729	Patterns of Brain Magnetic Resonance Abnormalities on T ₂ -Weighted Spin Echo Images in Clinical Subgroups of Multiple Sclerosis: A Large Cross-Sectional Study. <i>European Neurology</i> , 1998, 40, 91-98.	0.6	32
730	Interindividual differences of medial temporal lobe activation during encoding in an elderly population studied by fMRI. <i>NeuroImage</i> , 2004, 21, 173-180.	2.1	32
731	Whole brain analysis of T2* weighted baseline FMRI signal in dementia. <i>Human Brain Mapping</i> , 2007, 28, 1313-1317.	1.9	32
732	Magnetic Resonance Imaging Predictors of Conversion to Multiple Sclerosis in the BENEFIT Study. <i>Archives of Neurology</i> , 2009, 66, 1345-52.	4.9	32
733	The distribution of new enhancing lesion counts in multiple sclerosis: further explorations. <i>Multiple Sclerosis Journal</i> , 2009, 15, 42-49.	1.4	32
734	Validation of the automated method VIENA: An accurate, precise, and robust measure of ventricular enlargement. <i>Human Brain Mapping</i> , 2014, 35, 1101-1110.	1.9	32
735	Rare Genetic Variant in SORL1 May Increase Penetrance of Alzheimer's Disease in a Family with Several Generations of APOE- ϵ 4 Homozygosity. <i>Journal of Alzheimer's Disease</i> , 2017, 56, 63-74.	1.2	32
736	Agreement of MSmetrix with established methods for measuring cross-sectional and longitudinal brain atrophy. <i>NeuroImage: Clinical</i> , 2017, 15, 843-853.	1.4	32
737	The quantitative neuroradiology initiative framework: application to dementia. <i>British Journal of Radiology</i> , 2019, 92, 20190365.	1.0	32
738	Longitudinal spinal cord atrophy in multiple sclerosis using the generalized boundary shift integral. <i>Annals of Neurology</i> , 2019, 86, 704-713.	2.8	32

#	ARTICLE	IF	CITATIONS
739	Serum Neurofilament Light Association With Progression in Natalizumab-Treated Patients With Relapsing-Remitting Multiple Sclerosis. <i>Neurology</i> , 2021, 97, e1898-e1905.	1.5	32
740	TADPOLE Challenge: Accurate Alzheimer's Disease Prediction Through Crowdsourced Forecasting of Future Data. <i>Lecture Notes in Computer Science</i> , 2019, 11843, 1-10.	1.0	32
741	Visual rating of hippocampal atrophy: correlation with volumetry. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1994, 57, 1015-1015.	0.9	31
742	Infratentorial Abnormalities in Vascular Dementia. <i>Stroke</i> , 2006, 37, 105-110.	1.0	31
743	Structural neuroimaging. , 2009, , 58-69.		31
744	MRI—the perfect surrogate marker for multiple sclerosis?. <i>Nature Reviews Neurology</i> , 2009, 5, 182-183.	4.9	31
745	Histone deacetylase gene variants predict brain volume changes in multiple sclerosis. <i>Neurobiology of Aging</i> , 2013, 34, 238-247.	1.5	31
746	Cortical imaging in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2013, 26, 345-352.	1.8	31
747	Ventral Striatum, but Not Cortical Volume Loss, Is Related to Cognitive Dysfunction in Type 1 Diabetic Patients With and Without Microangiopathy. <i>Diabetes Care</i> , 2014, 37, 2483-2490.	4.3	31
748	Regional atrophy is associated with impairment in distinct cognitive domains in Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2014, 10, S299-305.	0.4	31
749	Postmortem validation of MRI cortical volume measurements in MS. <i>Human Brain Mapping</i> , 2016, 37, 2223-2233.	1.9	31
750	Disrupted white matter structural networks in healthy older adult APOE ϵ 4 carriers – An international multicenter DTI study. <i>Neuroscience</i> , 2017, 357, 119-133.	1.1	31
751	Inflammatory natalizumab-associated PML: baseline characteristics, lesion evolution and relation with PML-IRIS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, 535-541.	0.9	31
752	Performance of the 2017 and 2010 Revised McDonald Criteria in Predicting MS Diagnosis After a Clinically Isolated Syndrome. <i>Neurology</i> , 2022, 98, .	1.5	31
753	Association of Slowly Expanding Lesions on MRI With Disability in People With Secondary Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	31
754	Evidence for Atrophy of the Corpus callosum in Alzheimer's Disease. <i>European Neurology</i> , 1994, 34, 83-86.	0.6	30
755	Antibody-mediated suppression of $\hat{V}^{2.5.2/5.3+T}$ cells in multiple sclerosis: Results from an MRI-monitored phase II clinical trial. <i>Annals of Neurology</i> , 2002, 51, 467-474.	2.8	30
756	Magnetic source imaging contributes to the presurgical identification of sensorimotor cortex in patients with frontal lobe epilepsy. <i>Clinical Neurophysiology</i> , 2003, 114, 221-232.	0.7	30

#	ARTICLE	IF	CITATIONS
757	HLA-DRB1*1501 and Spinal Cord Magnetic Resonance Imaging Lesions in Multiple Sclerosis. Archives of Neurology, 2009, 66, 1531-6.	4.9	30
758	Characteristics of Early MRI in Children and Adolescents with Vanishing White Matter. Neuropediatrics, 2012, 43, 022-026.	0.3	30
759	Quantification of cerebral blood flow in healthy volunteers and type 1 diabetic patients: Comparison of MRI arterial spin labeling and [¹⁵ O]H ₂ O positron emission tomography (PET). Journal of Magnetic Resonance Imaging, 2014, 40, 1300-1309.	1.9	30
760	Progression in disability and regional grey matter atrophy in relapsing/remitting multiple sclerosis. Multiple Sclerosis Journal, 2014, 20, 202-213.	1.4	30
761	Building a New Paradigm for the Early Recognition of Behavioral Variant Frontotemporal Dementia: Late Onset Frontal Lobe Syndrome Study. American Journal of Geriatric Psychiatry, 2014, 22, 735-740.	0.6	30
762	Differentiation of edema and glioma infiltration: proposal of a DTI-based probability map. Journal of Neuro-Oncology, 2014, 120, 187-198.	1.4	30
763	Diagnosis of asymptomatic natalizumab-associated PML: are we between a rock and a hard place?. Journal of Neurology, 2014, 261, 1139-1143.	1.8	30
764	Multicenter Validation of Mean Upper Cervical Cord Area Measurements from Head 3D T1-Weighted MR Imaging in Patients with Multiple Sclerosis. American Journal of Neuroradiology, 2016, 37, 749-754.	1.2	30
765	Personalized risk for clinical progression in cognitively normal subjects—the ABIDE project. Alzheimer's Research and Therapy, 2019, 11, 33.	3.0	30
766	Facing privacy in neuroimaging: removing facial features degrades performance of image analysis methods. European Radiology, 2020, 30, 1062-1074.	2.3	30
767	Wearable technologies to measure clinical outcomes in multiple sclerosis: A scoping review. Multiple Sclerosis Journal, 2021, 27, 1643-1656.	1.4	30
768	Diagnosis of Progressive Multiple Sclerosis From the Imaging Perspective. JAMA Neurology, 2021, 78, 351.	4.5	30
769	Single-dose gadolinium with magnetization transfer versus triple-dose gadolinium in the MR detection of multiple sclerosis lesions. American Journal of Neuroradiology, 1997, 18, 1279-85.	1.2	30
770	Diagnostic Accuracy of the Frontotemporal Dementia Consensus Criteria in the Late-Onset Frontal Lobe Syndrome. Dementia and Geriatric Cognitive Disorders, 2016, 41, 210-219.	0.7	29
771	Association of Progressive Multifocal Leukoencephalopathy Lesion Volume With JC Virus Polymerase Chain Reaction Results in Cerebrospinal Fluid of Natalizumab-Treated Patients With Multiple Sclerosis. JAMA Neurology, 2018, 75, 827.	4.5	29
772	Data-Driven Differential Diagnosis of Dementia Using Multiclass Disease State Index Classifier. Frontiers in Aging Neuroscience, 2018, 10, 111.	1.7	29
773	Gray Matter Network Disruptions and Regional Amyloid Beta in Cognitively Normal Adults. Frontiers in Aging Neuroscience, 2018, 10, 67.	1.7	29
774	Real-world keystroke dynamics are a potentially valid biomarker for clinical disability in multiple sclerosis. Multiple Sclerosis Journal, 2021, 27, 1421-1431.	1.4	29

#	ARTICLE	IF	CITATIONS
775	Quantitative amyloid PET in Alzheimer's disease: the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, 750-758.	0.4	29
776	Technical and clinical validation of commercial automated volumetric MRI tools for dementia diagnosis—a systematic review. <i>Neuroradiology</i> , 2021, 63, 1773-1789.	1.1	29
777	Vascular Cognitive Impairment in a Memory Clinic Population: Rationale and Design of the "Utrecht-Amsterdam Clinical Features and Prognosis in Vascular Cognitive Impairment" (TRACE-VCI) Study. <i>JMIR Research Protocols</i> , 2017, 6, e60.	0.5	29
778	Sagittal MR of multiple sclerosis in the spinal cord: fast versus conventional spin-echo imaging. <i>American Journal of Neuroradiology</i> , 1998, 19, 355-60.	1.2	29
779	Modelling new enhancing MRI lesion counts in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2001, 7, 298-304.	1.4	28
780	Asymptomatic Carotid Artery Stenosis: Past, Present and Future. <i>European Neurology</i> , 2006, 56, 139-154.	0.6	28
781	Determinants of Cerebral Atrophy Rate at the Time of Diagnosis of Multiple Sclerosis. <i>Archives of Neurology</i> , 2007, 64, 190.	4.9	28
782	Segmentation of Subtraction Images for the Measurement of Lesion Change in Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2008, 29, 340-346.	1.2	28
783	Quantitative MR Imaging and Spectroscopy in Congenital Cytomegalovirus Infection and Periventricular Leukomalacia Suggests a Comparable Neuropathological Substrate of the Cerebral White Matter Lesions. <i>Neuropediatrics</i> , 2009, 40, 168-173.	0.3	28
784	Unraveling pathology in juvenile Alexander disease: serial quantitative MR imaging and spectroscopy of white matter. <i>Neuroradiology</i> , 2009, 51, 669-675.	1.1	28
785	The Holy Grail in diagnostic neuroradiology: 3T or 3D?. <i>European Radiology</i> , 2011, 21, 449-456.	2.3	28
786	The Predictive Value of 3D Time-of-Flight MR Angiography in Assessment of Brain Arteriovenous Malformation Obliteration after Radiosurgery. <i>American Journal of Neuroradiology</i> , 2012, 33, 232-238.	1.2	28
787	Inflammation High-Field Magnetic Resonance Imaging. <i>Neuroimaging Clinics of North America</i> , 2012, 22, 135-157.	0.5	28
788	Brain volume and white matter hyperintensities as determinants of cerebral blood flow in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2665-2670.	1.5	28
789	Applying causal models to explore the mechanism of action of simvastatin in progressive multiple sclerosis. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2019, 116, 11020-11027.	3.3	28
790	Comparing Glioblastoma Surgery Decisions Between Teams Using Brain Maps of Tumor Locations, Biopsies, and Resections. <i>JCO Clinical Cancer Informatics</i> , 2019, 3, 1-12.	1.0	28
791	Smaller medial temporal lobe volumes in individuals with subjective cognitive decline and biomarker evidence of Alzheimer's disease—Data from three memory clinic studies. <i>Alzheimer's and Dementia</i> , 2019, 15, 185-193.	0.4	28
792	Improved performance of the 2017 McDonald criteria for diagnosis of multiple sclerosis in children in a real-life cohort. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1372-1380.	1.4	28

#	ARTICLE	IF	CITATIONS
793	Pathologic correlates of the magnetization transfer ratio in multiple sclerosis. <i>Neurology</i> , 2020, 95, e2965-e2976.	1.5	28
794	A randomized, placebo-controlled, phase 2 trial of laquinimod in primary progressive multiple sclerosis. <i>Neurology</i> , 2020, 95, e1027-e1040.	1.5	28
795	Association of Gray Matter Atrophy Patterns With Clinical Phenotype and Progression in Multiple Sclerosis. <i>Neurology</i> , 2021, 96, e1561-e1573.	1.5	28
796	<i>Bacillus cereus</i> meningoencephalitis in preterm infants: neuroimaging characteristics. <i>American Journal of Neuroradiology</i> , 2005, 26, 2137-43.	1.2	28
797	A phase II trial of anti-CD4 antibodies in the treatment of multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1996, 1, 339-342.	1.4	27
798	Spinal cord magnetic resonance imaging in suspected multiple sclerosis. <i>European Radiology</i> , 2000, 10, 368-376.	2.3	27
799	Sporadic Creutzfeldt-Jakob disease in a young Dutch valine homozygote: Atypical molecular phenotype. <i>Annals of Neurology</i> , 2001, 50, 258-261.	2.8	27
800	Is the whole brain periventricular?. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 143-144.	0.9	27
801	Shifting Paradigms in Dementia: Toward Stratification of Diagnosis and Treatment Using MRI. <i>Annals of the New York Academy of Sciences</i> , 2007, 1097, 215-224.	1.8	27
802	Future clinical challenges in multiple sclerosis. <i>Neurology</i> , 2011, 76, S28-37.	1.5	27
803	Indolent course of progressive multifocal leukoencephalopathy during natalizumab treatment in MS. <i>Neurology</i> , 2011, 76, 574-576.	1.5	27
804	Quantitative regional validation of the visual rating scale for posterior cortical atrophy. <i>European Radiology</i> , 2014, 24, 397-404.	2.3	27
805	The influence of genetic variants in SORL1 gene on the manifestation of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2015, 36, 1605.e13-1605.e20.	1.5	27
806	Can MS lesion stages be distinguished with MRI? A postmortem MRI and histopathology study. <i>Journal of Neurology</i> , 2015, 262, 1074-1080.	1.8	27
807	Performance of five research-domain automated WM lesion segmentation methods in a multi-center MS study. <i>NeuroImage</i> , 2017, 163, 106-114.	2.1	27
808	Modeling grey matter atrophy as a function of time, aging or cognitive decline show different anatomical patterns in Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2019, 22, 101786.	1.4	27
809	MRI-based prediction of conversion from clinically isolated syndrome to clinically definite multiple sclerosis using SVM and lesion geometry. <i>Brain Imaging and Behavior</i> , 2019, 13, 1361-1374.	1.1	27
810	White matter hyperintensities mediate gray matter volume and processing speed relationship in cognitively unimpaired participants. <i>Human Brain Mapping</i> , 2020, 41, 1309-1322.	1.9	27

#	ARTICLE	IF	CITATIONS
811	Molecular Imaging Approaches in Dementia. <i>Radiology</i> , 2021, 298, 517-530.	3.6	27
812	Voxel-based analysis of quantitative T1 maps demonstrates that multiple sclerosis acts throughout the normal-appearing white matter. <i>American Journal of Neuroradiology</i> , 2006, 27, 868-74.	1.2	27
813	The effects of high-dose methylprednisolone on gadolinium-enhanced magnetic resonance imaging and cerebrospinal fluid measurements in multiple sclerosis. <i>Journal of Neuroimmunology</i> , 1992, 40, 265-272.	1.1	26
814	Decreased vitamin B12 and folate levels in cerebrospinal fluid and serum of multiple sclerosis patients after high-dose intravenous methylprednisolone. <i>Journal of Neurology</i> , 1993, 240, 305-308.	1.8	26
815	Cerebrospinal Fluid IgM Index Correlates with Cranial MRI Lesion Load in Patients with Multiple Sclerosis. <i>European Neurology</i> , 2007, 58, 90-95.	0.6	26
816	Dementia Mimicking Alzheimer's Disease Owing to a Tau Mutation: CSF and PET Findings. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 303-307.	0.6	26
817	Leucoencephalopathy with brainstem and spinal cord involvement and high lactate: quantitative magnetic resonance imaging. <i>Brain</i> , 2011, 134, 3333-3341.	3.7	26
818	Spatiotemporal distribution of white matter lesions in relapsing/remitting and secondary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1577-1584.	1.4	26
819	Cardiovascular Risk Factors and White Matter Hyperintensities: Difference in Susceptibility in South Asians Compared With Europeans. <i>Journal of the American Heart Association</i> , 2018, 7, e010533.	1.6	26
820	Three-Tesla MRI does not improve the diagnosis of multiple sclerosis. <i>Neurology</i> , 2018, 91, e249-e257.	1.5	26
821	The Meta VCI Map consortium for meta-analyses on strategic lesion locations for vascular cognitive impairment using lesion-symptom mapping: Design and multicenter pilot study. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 310-326.	1.2	26
822	Hippocampal profiling: Localized magnetic resonance imaging volumetry and T2 relaxometry for hippocampal sclerosis. <i>Epilepsia</i> , 2020, 61, 297-309.	2.6	26
823	Brain Health Services: organization, structure, and challenges for implementation. A user manual for Brain Health Services—part 1 of 6. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 168.	3.0	26
824	Follow-up study of MS patients treated with high-dose intravenous methylprednisolone. <i>Acta Neurologica Scandinavica</i> , 1994, 90, 105-110.	1.0	25
825	A multicentre study of motor functional connectivity changes in patients with multiple sclerosis. <i>European Journal of Neuroscience</i> , 2011, 33, 1256-1263.	1.2	25
826	White Matter Hyperintensities and Cognitive Impairment During Electroconvulsive Therapy in Severely Depressed Elderly Patients. <i>American Journal of Geriatric Psychiatry</i> , 2014, 22, 157-166.	0.6	25
827	Diagnostic value of brain chronic black holes on T1-weighted MR images in clinically isolated syndromes. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1471-1477.	1.4	25
828	The structure of the geriatric depressed brain and response to electroconvulsive therapy. <i>Psychiatry Research - Neuroimaging</i> , 2014, 222, 1-9.	0.9	25

#	ARTICLE	IF	CITATIONS
829	Volumetric MRI data correlate to disease severity in metachromatic leukodystrophy. <i>Annals of Clinical and Translational Neurology</i> , 2015, 2, 932-940.	1.7	25
830	Disrupted subject-specific gray matter network properties and cognitive dysfunction in type 1 diabetes patients with and without proliferative retinopathy. <i>Human Brain Mapping</i> , 2016, 37, 1194-1208.	1.9	25
831	Amyloid-independent atrophy patterns predict time to progression to dementia in mild cognitive impairment. <i>Alzheimer's Research and Therapy</i> , 2017, 9, 73.	3.0	25
832	Bullseye's representation of cerebral white matter hyperintensities. <i>Journal of Neuroradiology</i> , 2018, 45, 114-122.	0.6	25
833	Resilience to cognitive impairment in the oldest-old: design of the EMIF-AD 90+ study. <i>BMC Geriatrics</i> , 2018, 18, 289.	1.1	25
834	Retinal thickness as a potential biomarker in patients with amyloid-proven early and late-onset Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2019, 11, 463-471.	1.2	25
835	Normal Aging Brain Collection Amsterdam (NABCA): A comprehensive collection of postmortem high-field imaging, neuropathological and morphometric datasets of non-neurological controls. <i>NeuroImage: Clinical</i> , 2019, 22, 101698.	1.4	25
836	Radiomics in multiple sclerosis and neuromyelitis optica spectrum disorder. <i>European Radiology</i> , 2019, 29, 4670-4677.	2.3	25
837	Accurate MR Image Registration to Anatomical Reference Space for Diffuse Glioma. <i>Frontiers in Neuroscience</i> , 2020, 14, 585.	1.4	25
838	Active MRI lesion appearance in MS patients is preceded by fluctuations in circulating T-helper 1 and 2 cells. <i>Journal of Neuroimmunology</i> , 2001, 118, 286-294.	1.1	24
839	β -Crystallin genotype has impact on the multiple sclerosis phenotype. <i>Neurology</i> , 2003, 61, 1245-1249.	1.5	24
840	Detection of Root Avulsion in the Dominant C7 Obstetric Brachial Plexus Lesion: Experience with Three-dimensional Constructive Interference in Steady-state Magnetic Resonance Imaging and Electrophysiology. <i>Neurosurgery</i> , 2005, 57, 930-940.	0.6	24
841	Corpus Callosum Tissue Loss and Development of Motor and Global Cognitive Impairment: The LADIS Study. <i>Dementia and Geriatric Cognitive Disorders</i> , 2011, 32, 279-286.	0.7	24
842	Episodic memory and the medial temporal lobe: not all it seems. Evidence from the temporal variants of frontotemporal dementia. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 1145-1148.	0.9	24
843	Disturbed oscillatory brain dynamics in subcortical ischemic vascular dementia. <i>BMC Neuroscience</i> , 2012, 13, 85.	0.8	24
844	The effect of galantamine on brain atrophy rate in subjects with mild cognitive impairment is modified by apolipoprotein E genotype: post-hoc analysis of data from a randomized controlled trial. <i>Alzheimer's Research and Therapy</i> , 2014, 6, 47.	3.0	24
845	Novel MRI and PET markers of neuroinflammation in multiple sclerosis. <i>Current Opinion in Neurology</i> , 2016, 29, 229-236.	1.8	24
846	Ultra-high field MTR and $qR2^*$ differentiates subpial cortical lesions from normal-appearing gray matter in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1306-1314.	1.4	24

#	ARTICLE	IF	CITATIONS
847	Cortical and subcortical gray matter structural alterations in normoglycemic obese and type 2 diabetes patients: relationship with adiposity, glucose, and insulin. <i>Metabolic Brain Disease</i> , 2018, 33, 1211-1222.	1.4	24
848	Metabolites predict lesion formation and severity in relapsing-remitting multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 491-500.	1.4	24
849	Different patterns of longitudinal brain and spinal cord changes and their associations with disability progression in NMO and MS. <i>European Radiology</i> , 2018, 28, 96-103.	2.3	24
850	Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2019, 92, e1558-e1566.	1.5	24
851	Histopathology-validated recommendations for cortical lesion imaging in multiple sclerosis. <i>Brain</i> , 2020, 143, 2988-2997.	3.7	24
852	Accuracy and reproducibility of automated white matter hyperintensities segmentation with lesion segmentation tool: A European multi-site 3T study. <i>Magnetic Resonance Imaging</i> , 2021, 76, 108-115.	1.0	24
853	Visual assessment of [18F]flutemetamol PET images can detect early amyloid pathology and grade its extent. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2169-2182.	3.3	24
854	Brain structural alterations in MOG antibody diseases: a comparative study with AQP4 seropositive NMOSD and MS. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 709-716.	0.9	24
855	Brain microstructural and metabolic alterations detected <i>in vivo</i> at onset of the first demyelinating event. <i>Brain</i> , 2021, 144, 1409-1421.	3.7	24
856	Cortical involvement determines impairment 30 years after a clinically isolated syndrome. <i>Brain</i> , 2021, 144, 1384-1395.	3.7	24
857	Blood Pressure, White Matter Lesions and Medial Temporal Lobe Atrophy: Closing the Gap between Vascular Pathology and Alzheimer's Disease?. <i>Dementia and Geriatric Cognitive Disorders</i> , 2005, 20, 331-337.	0.7	23
858	Efficacy of subcutaneous interferon β -1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2014, 85, 647-653.	0.9	23
859	Longitudinal absolute metabolite quantification of white and gray matter regions in healthy controls using proton MR spectroscopic imaging. <i>NMR in Biomedicine</i> , 2014, 27, 304-311.	1.6	23
860	Switching from branded to generic glatiramer acetate: 15-month GATE trial extension results. <i>Multiple Sclerosis Journal</i> , 2017, 23, 1909-1917.	1.4	23
861	Thinner cortex in patients with subjective cognitive decline is associated with steeper decline of memory. <i>Neurobiology of Aging</i> , 2018, 61, 238-244.	1.5	23
862	Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. <i>NeuroImage: Clinical</i> , 2018, 19, 625-632.	1.4	23
863	Automatically computed rating scales from MRI for patients with cognitive disorders. <i>European Radiology</i> , 2019, 29, 4937-4947.	2.3	23
864	Comparing lesion segmentation methods in multiple sclerosis: Input from one manually delineated subject is sufficient for accurate lesion segmentation. <i>NeuroImage: Clinical</i> , 2019, 24, 102074.	1.4	23

#	ARTICLE	IF	CITATIONS
865	TMEM106B and CPOX are genetic determinants of cerebrospinal fluid Alzheimer's disease biomarker levels. <i>Alzheimer's and Dementia</i> , 2021, 17, 1628-1640.	0.4	23
866	The natural history of primary progressive aphasia: beyond aphasia. <i>Journal of Neurology</i> , 2022, 269, 1375-1385.	1.8	23
867	Multiple Sclerosis Therapy. <i>Drugs</i> , 1995, 49, 200-212.	4.9	22
868	Statistical power of MRI monitored trials in multiple sclerosis: new data and comparison with previous results. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1999, 66, 465-469.	0.9	22
869	TNF \pm production by CD4 ⁺ T cells predicts long-term increase in lesion load on MRI in MS. <i>Neurology</i> , 2001, 57, 1129-1131.	1.5	22
870	LOW VITAMIN B6 LEVELS ARE ASSOCIATED WITH WHITE MATTER LESIONS IN ALZHEIMER'S DISEASE. <i>Journal of the American Geriatrics Society</i> , 2005, 53, 1073-1074.	1.3	22
871	Growth-associated protein 43 in lesions and cerebrospinal fluid in multiple sclerosis. <i>Neuropathology and Applied Neurobiology</i> , 2006, 32, 318-331.	1.8	22
872	Disrupted Module Efficiency of Structural and Functional Brain Connectomes in Clinically Isolated Syndrome and Multiple Sclerosis. <i>Frontiers in Human Neuroscience</i> , 2018, 12, 138.	1.0	22
873	Cortical cerebral blood flow in ageing: effects of haematocrit, sex, ethnicity and diabetes. <i>European Radiology</i> , 2019, 29, 5549-5558.	2.3	22
874	Impairment in complex activities of daily living is related to neurodegeneration in Alzheimer's disease—specific regions. <i>Neurobiology of Aging</i> , 2019, 75, 109-116.	1.5	22
875	Impact of 3 Tesla MRI on interobserver agreement in clinically isolated syndrome: A MAGNIMS multicentre study. <i>Multiple Sclerosis Journal</i> , 2019, 25, 352-360.	1.4	22
876	Infratentorial and spinal cord lesions: Cumulative predictors of long-term disability?. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1381-1391.	1.4	22
877	Determination of individual stimulus-response curves in the visual cortex. <i>Human Brain Mapping</i> , 2002, 17, 244-250.	1.9	21
878	The interleukin-1 gene family in multiple sclerosis susceptibility and disease course. <i>Multiple Sclerosis Journal</i> , 2003, 9, 535-539.	1.4	21
879	Motor Outcome at the Age of One after Perinatal Hypoxic-ischemic Encephalopathy. <i>Neuropediatrics</i> , 2007, 38, 71-77.	0.3	21
880	Preliminary evidence of hippocampal damage in chronic users of ecstasy. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2012, 83, 83-85.	0.9	21
881	Associations between Magnetic Resonance Imaging Measures and Neuropsychological Impairment in Early and Late Onset Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 35, 169-178.	1.2	21
882	Predictors of Progression from Mild Cognitive Impairment to Dementia in the Placebo-Arm of a Clinical Trial Population. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 79-85.	1.2	21

#	ARTICLE	IF	CITATIONS
883	Indicators for cognitive performance and subjective cognitive complaints in multiple sclerosis: a role for advanced MRI?. <i>Multiple Sclerosis Journal</i> , 2014, 20, 1131-1134.	1.4	21
884	Head Motion Parameters in fMRI Differ Between Patients with Mild Cognitive Impairment and Alzheimer Disease Versus Elderly Control Subjects. <i>Brain Topography</i> , 2014, 27, 801-807.	0.8	21
885	Early-Stage White Matter Lesions Detected by Multispectral MRI Segmentation Predict Progressive Cognitive Decline. <i>Frontiers in Neuroscience</i> , 2015, 9, 455.	1.4	21
886	Diagnostic performance of brain MRI in pharmacovigilance of natalizumab-treated MS patients. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1174-1183.	1.4	21
887	Disease trajectories in behavioural variant frontotemporal dementia, primary psychiatric and other neurodegenerative disorders presenting with behavioural change. <i>Journal of Psychiatric Research</i> , 2018, 104, 183-191.	1.5	21
888	Validation of mean upper cervical cord area (MUCCA) measurement techniques in multiple sclerosis (MS): High reproducibility and robustness to lesions, but large software and scanner effects. <i>NeuroImage: Clinical</i> , 2019, 24, 101962.	1.4	21
889	PET and CSF amyloid- β status are differently predicted by patient features: information from discordant cases. <i>Alzheimer's Research and Therapy</i> , 2019, 11, 100.	3.0	21
890	The sequence of structural, functional and cognitive changes in multiple sclerosis. <i>NeuroImage: Clinical</i> , 2021, 29, 102550.	1.4	21
891	Characterization of symptoms and determinants of disease burden in dementia with Lewy bodies: DEvELOP design and baseline results. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 53.	3.0	21
892	Relationship Between White Matter Lesions and Gray Matter Atrophy in Multiple Sclerosis. <i>Neurology</i> , 2022, 98, .	1.5	21
893	partially saturated fluid attenuated inversion recovery (FLAIR) sequences in multiple sclerosis: Comparison with fully relaxed FLAIR and conventional spin-echo. <i>Magnetic Resonance Imaging</i> , 1995, 13, 513-521.	1.0	20
894	Specific power calculations for magnetic resonance imaging (MRI) in monitoring active relapsing-remitting multiple sclerosis (MS): implications for phase II therapeutic trials. <i>Multiple Sclerosis Journal</i> , 1997, 2, 283-290.	1.4	20
895	Interobserver agreement for diagnostic MRI criteria in suspected multiple sclerosis. <i>Neuroradiology</i> , 1999, 41, 347-350.	1.1	20
896	The use of magnetic resonance imaging in multiple sclerosis treatment trials: power calculations for annual lesion load measurement. <i>Journal of Neurology</i> , 2000, 247, 34-40.	1.8	20
897	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. <i>Multiple Sclerosis Journal</i> , 2000, 6, 237-240.	1.4	20
898	Polymorphisms in the genes encoding interferon-gamma and interferon-gamma receptors in multiple sclerosis. <i>International Journal of Immunogenetics</i> , 2004, 31, 133-140.	1.2	20
899	Delineation of brain AVMs on MR-Angiography for the purpose of stereotactic radiosurgery. <i>International Journal of Radiation Oncology Biology Physics</i> , 2007, 67, 308-316.	0.4	20
900	Glucocorticoid receptor gene polymorphisms associated with more aggressive disease phenotype in MS. <i>Journal of Neuroimmunology</i> , 2007, 186, 150-155.	1.1	20

#	ARTICLE	IF	CITATIONS
901	Diffusion Magnetic Resonance Imaging in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2011, 21, 71-88.	0.5	20
902	Novel Hypomyelinating Leukoencephalopathy Affecting Early Myelinating Structures. <i>Archives of Neurology</i> , 2012, 69, 125.	4.9	20
903	Glutamate gene polymorphisms predict brain volumes in multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2013, 19, 281-288.	1.4	20
904	Disturbed phase relations in white matter hyperintensity based vascular dementia: An EEG directed connectivity study. <i>Clinical Neurophysiology</i> , 2015, 126, 497-504.	0.7	20
905	Reproducibility of hippocampal atrophy rates measured with manual, FreeSurfer, AdaBoost, FSL/FIRST and the MAPS-HBSI methods in Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2016, 252, 26-35.	0.9	20
906	4H Leukodystrophy: A Brain Magnetic Resonance Imaging Scoring System. <i>Neuropediatrics</i> , 2017, 48, 152-160.	0.3	20
907	White matter hyperintensities and vascular risk factors in monozygotic twins. <i>Neurobiology of Aging</i> , 2018, 66, 40-48.	1.5	20
908	Disease-related determinants are associated with mortality in dementia due to Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2018, 10, 23.	3.0	20
909	Brain reward responses to food stimuli among female monozygotic twins discordant for BMI. <i>Brain Imaging and Behavior</i> , 2018, 12, 718-727.	1.1	20
910	Manual and automated tissue segmentation confirm the impact of thalamus atrophy on cognition in multiple sclerosis: A multicenter study. <i>NeuroImage: Clinical</i> , 2021, 29, 102549.	1.4	20
911	Disability in multiple sclerosis is related to thalamic connectivity and cortical network atrophy. <i>Multiple Sclerosis Journal</i> , 2022, 28, 61-70.	1.4	20
912	Predicting disability progression and cognitive worsening in multiple sclerosis using patterns of grey matter volumes. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 995-1006.	0.9	20
913	Genome-Wide Association Study of Alzheimer's Disease Brain Imaging Biomarkers and Neuropsychological Phenotypes in the European Medical Information Framework for Alzheimer's Disease Multimodal Biomarker Discovery Dataset. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 840651.	1.7	20
914	Serial quantitative MR assessment of optic neuritis in a case of neuromyelitis optica, using Gadolinium-enhanced STIR imaging. <i>Neuroradiology</i> , 1991, 33, 70-71.	1.1	19
915	Agreement between different input image types in brain atrophy measurement in multiple sclerosis using SIENAX and SIENA. <i>Journal of Magnetic Resonance Imaging</i> , 2008, 28, 559-565.	1.9	19
916	MRI characteristics are predictive for CDMS in monofocal, but not in multifocal patients with a clinically isolated syndrome. <i>BMC Neurology</i> , 2009, 9, 19.	0.8	19
917	Clinical Characteristics of Patients With Frontotemporal Dementia With and Without Lobar Atrophy on MRI. <i>Alzheimer Disease and Associated Disorders</i> , 2010, 24, 242-247.	0.6	19
918	Coil-treated Aneurysms: Decision Making Regarding Additional Treatment Based on Findings of MR Angiography and Intraarterial DSA. <i>Radiology</i> , 2012, 265, 858-863.	3.6	19

#	ARTICLE	IF	CITATIONS
919	Interferon beta-1b reduces black holes in a randomised trial of clinically isolated syndrome. Multiple Sclerosis Journal, 2014, 20, 234-242.	1.4	19
920	Changes in MEG resting-state networks are related to cognitive decline in type 1 diabetes mellitus patients. NeuroImage: Clinical, 2014, 5, 69-76.	1.4	19
921	Pseudo-healthy Image Synthesis for White Matter Lesion Segmentation. Lecture Notes in Computer Science, 2016, , 87-96.	1.0	19
922	Accurate Delineation of Glioma Infiltration by Advanced PET/MR Neuro-Imaging (FRONTIER Study). Neurosurgery, 2016, 79, 535-540.	0.6	19
923	Cerebral rituximab uptake in multiple sclerosis: A ⁸⁹ Zr-immunoPET pilot study. Multiple Sclerosis Journal, 2018, 24, 543-545.	1.4	19
924	Differential brainstem atrophy patterns in multiple sclerosis and neuromyelitis optica spectrum disorders. Journal of Magnetic Resonance Imaging, 2018, 47, 1601-1609.	1.9	19
925	A novel partial volume correction method for accurate quantification of [18F] flortaucipir in the hippocampus. EJNMMI Research, 2018, 8, 79.	1.1	19
926	Evaluating combinations of diagnostic tests to discriminate different dementia types. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2018, 10, 509-518.	1.2	19
927	Clinical value of cerebrospinal fluid neurofilament light chain in semantic dementia. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 997-1004.	0.9	19
928	Automated fiber tract reconstruction for surgery planning: Extensive validation in language-related white matter tracts. NeuroImage: Clinical, 2019, 23, 101883.	1.4	19
929	Latent atrophy factors related to phenotypical variants of posterior cortical atrophy. Neurology, 2020, 95, e1672-e1685.	1.5	19
930	Mild progressive multifocal leukoencephalopathy after switching from natalizumab to ocrelizumab. Neurology: Neuroimmunology and NeuroInflammation, 2021, 8, .	3.1	19
931	Automated quantitative MRI volumetry reports support diagnostic interpretation in dementia: a multi-rater, clinical accuracy study. European Radiology, 2021, 31, 5312-5323.	2.3	19
932	Spatial concordance of DNA methylation classification in diffuse glioma. Neuro-Oncology, 2021, 23, 2054-2065.	0.6	19
933	Longitudinal Network Changes and Conversion to Cognitive Impairment in Multiple Sclerosis. Neurology, 2021, 97, e794-e802.	1.5	19
934	Imaging of remyelination. Multiple Sclerosis Journal, 1997, 3, 129-132.	1.4	18
935	Restricted Diffusion in Vanishing White Matter. Archives of Neurology, 2012, 69, 723-7.	4.9	18
936	The Association of Glucose Metabolism and Eigenvector Centrality in Alzheimer's Disease. Brain Connectivity, 2016, 6, 1-8.	0.8	18

#	ARTICLE	IF	CITATIONS
937	Functional brain network centrality is related to APOE genotype in cognitively normal elderly. <i>Brain and Behavior</i> , 2018, 8, e01080.	1.0	18
938	Performance of PML diagnostic criteria in natalizumab-associated PML: data from the Dutch-Belgian cohort. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2019, 90, 44-46.	0.9	18
939	Assessment of the appropriate use criteria for amyloid PET in an unselected memory clinic cohort: The ABIDE project. <i>Alzheimer's and Dementia</i> , 2019, 15, 1458-1467.	0.4	18
940	Outcomes of clinical utility in amyloid-PET studies: state of art and future perspectives. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2021, 48, 2157-2168.	3.3	18
941	Cerebrovascular disease, neurodegeneration, and clinical phenotype in dementia with Lewy bodies. <i>Neurobiology of Aging</i> , 2021, 105, 252-261.	1.5	18
942	Cerebral white matter abnormalities in 6p25 deletion syndrome. <i>American Journal of Neuroradiology</i> , 2006, 27, 586-8.	1.2	18
943	?Top of the basilar? syndrome: A comparison of clinical and MR findings. <i>Neuroradiology</i> , 1988, 30, 293-298.	1.1	17
944	Oral or intravenous methylprednisolone for acute relapses of MS?. <i>Lancet, The</i> , 1997, 349, 893-894.	6.3	17
945	The development of clinical activity in relapsing"remitting MS is associated with a decrease of FasL mRNA and an increase of Fas mRNA in peripheral blood. <i>Journal of Neuroimmunology</i> , 2003, 138, 123-131.	1.1	17
946	Callosal tissue loss parallels subtle decline in psychomotor speed. A longitudinal quantitative MRI study. <i>The LADIS Study. Neuropsychologia</i> , 2012, 50, 1650-1655.	0.7	17
947	Multicenter mapping in the healthy brain. <i>Magnetic Resonance in Medicine</i> , 2014, 71, 1103-1107.	1.9	17
948	Multi-scale MRI spectrum detects differences in myelin integrity between MS lesion types. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1569-1577.	1.4	17
949	Whole brain functional connectivity in clinically isolated syndrome without conventional brain MRI lesions. <i>European Radiology</i> , 2016, 26, 2982-2991.	2.3	17
950	Asymptomatic spinal cord lesions do not predict the time to disability in patients with early multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2018, 24, 481-490.	1.4	17
951	Can post-mortem MRI be used as a proxy for in vivo? A case study. <i>Brain Communications</i> , 2019, 1, fcz030.	1.5	17
952	Relationship between β^2 -amyloid and structural network topology in decedents without dementia. <i>Neurology</i> , 2020, 95, e532-e544.	1.5	17
953	Investigating the clinico-anatomical dissociation in the behavioral variant of Alzheimer disease. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 148.	3.0	17
954	Circulating metabolites are associated with brain atrophy and white matter hyperintensities. <i>Alzheimer's and Dementia</i> , 2021, 17, 205-214.	0.4	17

#	ARTICLE	IF	CITATIONS
955	DHA intake relates to better cerebrovascular and neurodegeneration neuroimaging phenotypes in middle-aged adults at increased genetic risk of Alzheimer disease. <i>American Journal of Clinical Nutrition</i> , 2021, 113, 1627-1635.	2.2	17
956	Smartphone-derived keystroke dynamics are sensitive to relevant changes in multiple sclerosis. <i>European Journal of Neurology</i> , 2022, 29, 522-534.	1.7	17
957	Association of Education and Intracranial Volume With Cognitive Trajectories and Mortality Rates Across the Alzheimer Disease Continuum. <i>Neurology</i> , 2022, 98, .	1.5	17
958	Slowly expanding lesions relate to persisting black-holes and clinical outcomes in relapse-onset multiple sclerosis. <i>NeuroImage: Clinical</i> , 2022, 35, 103048.	1.4	17
959	Inter-rater variability in reporting enhancing lesions present on standard and triple dose gadolinium scans of patients with multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 1997, 3, 226-230.	1.4	16
960	Prenatal Diagnosis of Aneurysms of the Vein of Galen (Vena Magna Cerebri) With Conventional Sonography, Three-dimensional Sonography, and Magnetic Resonance Imaging. <i>Journal of Ultrasound in Medicine</i> , 2003, 22, 1363-1368.	0.8	16
961	Diagnostic tools for the study of vascular cognitive dysfunction in hypertension and antihypertensive drug research. , 2006, 109, 274-283.		16
962	Increased plasma 8,12-iso-iPF2alpha-VI levels in relapsing multiple sclerosis patients are not predictive of disease progression. <i>Multiple Sclerosis Journal</i> , 2012, 18, 1092-1098.	1.4	16
963	Enhanced Axonal Metabolism during Early Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2015, 36, 1116-1123.	1.2	16
964	Subgenual Cingulate Cortex Functional Connectivity in Relation to Depressive Symptoms and Cognitive Functioning in Type 1 Diabetes Mellitus Patients. <i>Psychosomatic Medicine</i> , 2016, 78, 740-749.	1.3	16
965	White Matter Hyperintensities Potentiate Hippocampal Volume Reduction in Non-Demented Older Individuals with Abnormal Amyloid- β . <i>Journal of Alzheimer's Disease</i> , 2016, 55, 333-342.	1.2	16
966	Quantitative MRI in hypomyelinating disorders. <i>Neurology</i> , 2016, 87, 752-758.	1.5	16
967	Brain atrophy measurements should be used to guide therapy monitoring in MS – NO. <i>Multiple Sclerosis Journal</i> , 2016, 22, 1524-1526.	1.4	16
968	Long-term disease activity and disability progression in relapsing-remitting multiple sclerosis patients on natalizumab. <i>Multiple Sclerosis and Related Disorders</i> , 2019, 33, 82-87.	0.9	16
969	The Clinical Phenotype of Vascular Cognitive Impairment in Patients with Type 2 Diabetes Mellitus. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 311-322.	1.2	16
970	Robust Deep Learning-based Segmentation of Glioblastoma on Routine Clinical MRI Scans Using Sparsified Training. <i>Radiology: Artificial Intelligence</i> , 2020, 2, e190103.	3.0	16
971	Brain miliary enhancement. <i>Neuroradiology</i> , 2020, 62, 283-300.	1.1	16
972	Risk of dementia in ϵ APOE ϵ 4 carriers is mitigated by a polygenic risk score. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12229.	1.2	16

#	ARTICLE	IF	CITATIONS
973	White matter microstructure disruption in early stage amyloid pathology. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12124.	1.2	16
974	Plasma Proteomic Biomarkers Relating to Alzheimer's Disease: A Meta-Analysis Based on Our Own Studies. <i>Frontiers in Aging Neuroscience</i> , 2021, 13, 712545.	1.7	16
975	[¹⁸ F]Flortaucipir PET Across Various MAPT Mutations in Presymptomatic and Symptomatic Carriers. <i>Neurology</i> , 2021, 97, e1017-e1030.	1.5	16
976	Right temporal variant frontotemporal dementia is pathologically heterogeneous: a case-series and a systematic review. <i>Acta Neuropathologica Communications</i> , 2021, 9, 131.	2.4	16
977	Comparison of two MR sequences for the detection of multiple sclerosis lesions in the spinal cord. <i>American Journal of Neuroradiology</i> , 1996, 17, 1533-8.	1.2	16
978	Pre- and post-mortem MR imaging of unsuspected multiple sclerosis in a patient with Alzheimer's disease. <i>Journal of the Neurological Sciences</i> , 1993, 117, 175-178.	0.3	15
979	CSF biomarkers in frontotemporal lobar degeneration: relations with clinical characteristics, apolipoprotein E genotype, and neuroimaging. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2006, 77, 246-248.	0.9	15
980	Can rate of brain atrophy in multiple sclerosis be explained by clinical and MRI characteristics?. <i>Multiple Sclerosis Journal</i> , 2009, 15, 465-471.	1.4	15
981	T-cell subsets in the cerebrospinal fluid and peripheral blood of multiple sclerosis patients treated with high-dose intravenous methylprednisolone. <i>Acta Neurologica Scandinavica</i> , 1993, 88, 80-86.	1.0	15
982	One year activity on subtraction MRI predicts subsequent 4 year activity and progression in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2011, 82, 1125-1131.	0.9	15
983	Effect of prior treatment status and reasons for discontinuation on the efficacy and safety of fingolimod vs. interferon β -1a intramuscular: Subgroup analyses of the Trial Assessing Injectable Interferon vs. Fingolimod Oral in Relapsing/Remitting Multiple Sclerosis (TRANSFORMS). <i>Multiple Sclerosis and Related Disorders</i> , 2014, 3, 355-363.	0.9	15
984	Design of the ExCersion-VCI study: The effect of aerobic exercise on cerebral perfusion in patients with vascular cognitive impairment. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2017, 3, 157-165.	1.8	15
985	Multimodal characterization of gray matter alterations in neuromyelitis optica. <i>Multiple Sclerosis Journal</i> , 2018, 24, 1308-1316.	1.4	15
986	Retinal and Cerebral Microvasculopathy: Relationships and Their Genetic Contributions. , 2018, 59, 5025.		15
987	Generalised boundary shift integral for longitudinal assessment of spinal cord atrophy. <i>NeuroImage</i> , 2020, 209, 116489.	2.1	15
988	Cerebral blood flow and cognitive functioning in patients with disorders along the heart-brain axis. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2020, 6, e12034.	1.8	15
989	The relation between APOE genotype and cerebral microbleeds in cognitively unimpaired middle- and old-aged individuals. <i>Neurobiology of Aging</i> , 2020, 95, 104-114.	1.5	15
990	Diagnostic criteria for primary progressive multiple sclerosis: A position paper. <i>Annals of Neurology</i> , 2000, 47, 831-835.	2.8	15

#	ARTICLE	IF	CITATIONS
991	MRI in multiple sclerosis: correlation with expanded disability status scale (EDSS). <i>Multiple Sclerosis Journal</i> , 1999, 5, 283-286.	1.4	15
992	Identifying and evaluating clinical subtypes of Alzheimer's disease in care electronic health records using unsupervised machine learning. <i>BMC Medical Informatics and Decision Making</i> , 2021, 21, 343.	1.5	15
993	Early Reduction of MRI Activity During 6 Months of Treatment With Cladribine Tablets for Highly Active Relapsing Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	15
994	Expression of adhesion molecules on peripheral lymphocytes predicts future lesion development in MS. <i>Journal of Neuroimmunology</i> , 2005, 158, 222-230.	1.1	14
995	Motor testing at 1 year improves the prediction of motor and mental outcome at 2 years after perinatal hypoxic-ischaemic encephalopathy. <i>Developmental Medicine and Child Neurology</i> , 2010, 52, 54-59.	1.1	14
996	Bimonthly assessment of magnetization transfer magnetic resonance imaging parameters in multiple sclerosis: a 14-month, multicentre, follow-up study. <i>Multiple Sclerosis Journal</i> , 2010, 16, 325-331.	1.4	14
997	2010 revisions to McDonald criteria for diagnosis of multiple sclerosis: Impact of 3 Tesla magnetic resonance imaging. <i>Annals of Neurology</i> , 2011, 70, 182-183.	2.8	14
998	Integrating Biomarkers for Underlying Alzheimer's Disease in Mild Cognitive Impairment in Daily Practice: Comparison of a Clinical Decision Support System with Individual Biomarkers. <i>Journal of Alzheimer's Disease</i> , 2016, 50, 261-270.	1.2	14
999	Language comprehension in nonspeaking children with severe cerebral palsy: Neuroanatomical substrate?. <i>European Journal of Paediatric Neurology</i> , 2015, 19, 510-520.	0.7	14
1000	Preoperative Resectability Estimates of Nonenhancing Glioma by Neurosurgeons and a Resection Probability Map. <i>Neurosurgery</i> , 2019, 85, E304-E313.	0.6	14
1001	What Determines Cognitive Functioning in the Oldest-Old? The EMIF-AD 90+ Study. <i>Journals of Gerontology - Series B Psychological Sciences and Social Sciences</i> , 2021, 76, 1499-1511.	2.4	14
1002	Tau PET and relative cerebral blood flow in dementia with Lewy bodies: A PET study. <i>NeuroImage: Clinical</i> , 2020, 28, 102504.	1.4	14
1003	Reduced accuracy of MRI deep grey matter segmentation in multiple sclerosis: an evaluation of four automated methods against manual reference segmentations in a multi-center cohort. <i>Journal of Neurology</i> , 2020, 267, 3541-3554.	1.8	14
1004	Distinct influence of different vascular risk factors on white matter brain lesions in multiple sclerosis. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2020, 91, 388-391.	0.9	14
1005	Quantifying eloquent locations for glioblastoma surgery using resection probability maps. <i>Journal of Neurosurgery</i> , 2021, 134, 1091-1101.	0.9	14
1006	Strategies to reduce sample sizes in Alzheimer's disease primary and secondary prevention trials using longitudinal amyloid PET imaging. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 82.	3.0	14
1007	Amyloid-driven disruption of default mode network connectivity in cognitively healthy individuals. <i>Brain Communications</i> , 2021, 3, fcab201.	1.5	14
1008	Single-subject gray matter networks predict future cortical atrophy in preclinical Alzheimer's disease. <i>Neurobiology of Aging</i> , 2020, 94, 71-80.	1.5	14

#	ARTICLE	IF	CITATIONS
1009	Regional analysis of volumes and reproducibilities of automatic and manual hippocampal segmentations. PLoS ONE, 2017, 12, e0166785.	1.1	14
1010	An International Standardized Magnetic Resonance Imaging Protocol for Diagnosis and Follow-up of Patients with Multiple Sclerosis. International Journal of MS Care, 2020, 22, 226-232.	0.4	14
1011	Radiotherapy response of cerebral metastases quantified by serial MR imaging. Journal of Neuro-Oncology, 1994, 21, 171-176.	1.4	13
1012	Choosing Drug Therapy for Multiple Sclerosis. Drugs, 1998, 56, 555-569.	4.9	13
1013	Value of fluid-attenuated inversion recovery sequences in early MRI of the brain in neonates with a perinatal hypoxic-ischemic encephalopathy. European Radiology, 2000, 10, 1594-1601.	2.3	13
1014	Differences between subgroups of MS: MRI findings and correlation with histopathology. Journal of the Neurological Sciences, 2003, 206, 173-174.	0.3	13
1015	Thallium-201 SPECT: the optimal prediction of response in glioma therapy. European Journal of Nuclear Medicine and Molecular Imaging, 2006, 33, 222-227.	3.3	13
1016	Multiple Sclerosis and Chronic Cerebrospinal Venous Insufficiency: The Neuroimaging Perspective. American Journal of Neuroradiology, 2011, 32, 424-427.	1.2	13
1017	Patient subgroup analyses of the treatment effect of subcutaneous interferon β -1a on development of multiple sclerosis in the randomized controlled REFLEX study. Journal of Neurology, 2014, 261, 490-499.	1.8	13
1018	Harmonization of neuroimaging biomarkers for neurodegenerative diseases: A survey in the imaging community of perceived barriers and suggested actions. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2019, 11, 69-73.	1.2	13
1019	A multi-shell multi-tissue diffusion study of brain connectivity in early multiple sclerosis. Multiple Sclerosis Journal, 2020, 26, 774-785.	1.4	13
1020	Spinal cord atrophy in a primary progressive multiple sclerosis trial: Improved sample size using GBSI. NeuroImage: Clinical, 2020, 28, 102418.	1.4	13
1021	Validation of Plasma Proteomic Biomarkers Relating to Brain Amyloid Burden in the EMIF-Alzheimer's Disease Multimodal Biomarker Discovery Cohort. Journal of Alzheimer's Disease, 2020, 74, 213-225.	1.2	13
1022	Differential patterns of gray matter volumes and associated gene expression profiles in cognitively-defined Alzheimer's disease subgroups. NeuroImage: Clinical, 2021, 30, 102660.	1.4	13
1023	Replication study of plasma proteins relating to Alzheimer's pathology. Alzheimer's and Dementia, 2021, 17, 1452-1464.	0.4	13
1024	Serum contactin-1 as a biomarker of long-term disease progression in natalizumab-treated multiple sclerosis. Multiple Sclerosis Journal, 2022, 28, 102-110.	1.4	13
1025	Non-invasively measured brain activity and radiological progression in diffuse glioma. Scientific Reports, 2021, 11, 18990.	1.6	13
1026	Degenerative adversarial neuroimage nets for brain scan simulations: Application in ageing and dementia. Medical Image Analysis, 2022, 75, 102257.	7.0	13

#	ARTICLE	IF	CITATIONS
1027	MR outcome parameters in multiple sclerosis: comparison of surface-based thresholding segmentation and magnetization transfer ratio histographic analysis in relation to disability (a) Tj ETQq1 1 0.7843142rgBT /Overlock 10	1.4	10
1028	B Cells in the CNS at Postmortem Are Associated With Worse Outcome and Cell Types in Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	13
1029	The protective gene dose effect of the <i>APOE</i> $\epsilon 2$ allele on gray matter volume in cognitively unimpaired individuals. <i>Alzheimer's and Dementia</i> , 2022, 18, 1383-1395.	0.4	13
1030	Exploring in vivo multiple sclerosis brain microstructural damage through T1w/T2w ratio: a multicentre study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 741-752.	0.9	13
1031	Disappearance of multiple sclerosis lesions with severely prolonged T1 on images obtained by a flair pulse sequence. <i>Magnetic Resonance Imaging</i> , 1996, 14, 209-213.	1.0	12
1032	Magnetization transfer contrast (MTC) and long repetition time spin-echo MR imaging in multiple sclerosis. <i>Magnetic Resonance Imaging</i> , 1998, 16, 351-358.	1.0	12
1033	Multiple sclerosis: interobserver agreement in reporting active lesions on serial brain MRI using conventional spin echo, fast spin echo, fast fluid-attenuated inversion recovery and post-contrast T1-weighted images. <i>Journal of Neurology</i> , 1999, 246, 920-925.	1.8	12
1034	Assessment of spinal cord damage in MS using MRI. <i>Journal of the Neurological Sciences</i> , 2000, 172, S36-S39.	0.3	12
1035	Magnetic resonance image registration in multiple sclerosis: Comparison with repositioning error and observer-based variability. <i>Journal of Magnetic Resonance Imaging</i> , 2002, 15, 505-510.	1.9	12
1036	How to use spinal cord magnetic resonance imaging in the McDonald diagnostic criteria for multiple sclerosis. <i>Annals of Neurology</i> , 2005, 57, 606-607.	2.8	12
1037	Classification of multiple sclerosis patients by latent class analysis of magnetic resonance imaging characteristics. <i>Multiple Sclerosis Journal</i> , 2006, 12, 565-572.	1.4	12
1038	Interobserver agreement on the radiological criteria of the International Panel on the diagnosis of multiple sclerosis. <i>European Radiology</i> , 2007, 17, 67-71.	2.3	12
1039	The SIENA/FSL whole brain atrophy algorithm is no more reproducible at 3 T than 1.5 T for Alzheimer's disease. <i>Psychiatry Research - Neuroimaging</i> , 2014, 224, 14-21.	0.9	12
1040	Cortical phase changes measured using 7T MRI in subjects with subjective cognitive impairment, and their association with cognitive function. <i>NMR in Biomedicine</i> , 2016, 29, 1289-1294.	1.6	12
1041	Impact of Imaging and Cerebrospinal Fluid Biomarkers on Behavioral Variant Frontotemporal Dementia Diagnosis within a Late-Onset Frontal Lobe Syndrome Cohort. <i>Dementia and Geriatric Cognitive Disorders</i> , 2016, 41, 16-26.	0.7	12
1042	Medial temporal lobe atrophy and posterior atrophy scales normative values. <i>NeuroImage: Clinical</i> , 2019, 24, 101936.	1.4	12
1043	High-dimensional detection of imaging response to treatment in multiple sclerosis. <i>Npj Digital Medicine</i> , 2019, 2, 49.	5.7	12
1044	Are Apathy and Depressive Symptoms Related to Vascular White Matter Hyperintensities in Severe Late Life Depression?. <i>Journal of Geriatric Psychiatry and Neurology</i> , 2021, 34, 21-28.	1.2	12

#	ARTICLE	IF	CITATIONS
1045	Relationships Between White Matter Hyperintensities, Cerebral Amyloid Angiopathy and Dementia in a Population-based Sample of the Oldest Old. <i>Current Alzheimer Research</i> , 2013, 10, 1090-1097.	0.7	12
1046	Amyloid- β , p-tau and reactive microglia are pathological correlates of MRI cortical atrophy in Alzheimer's disease. <i>Brain Communications</i> , 2021, 3, fcab281.	1.5	12
1047	Body mass index as a predictor of MS activity and progression among participants in BENEFIT. <i>Multiple Sclerosis Journal</i> , 2022, 28, 1277-1285.	1.4	12
1048	Genetically identical twins show comparable tau PET load and spatial distribution. <i>Brain</i> , 2022, 145, 3571-3581.	3.7	12
1049	Hypointense multiple sclerosis lesions on T1-weighted spin echo magnetic resonance images: their contribution in understanding multiple sclerosis evolution. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 1998, 64 Suppl 1, S77-9.	0.9	12
1050	Comparison of film-screen combination and digital fluorography in gastrointestinal barium examinations in a clinical setting. <i>European Journal of Radiology</i> , 1996, 22, 232-235.	1.2	11
1051	Improved interobserver agreement for visual detection of active T2 lesions on serial MR scans in multiple sclerosis using image registration. <i>Journal of Neurology</i> , 2001, 248, 789-794.	1.8	11
1052	Monocyte activation and disease activity in multiple sclerosis. A longitudinal analysis of serum MRP8/14 levels. <i>Journal of Neuroimmunology</i> , 2004, 148, 172-177.	1.1	11
1053	Assessing treatment effects on axonal loss?evidence from MRI monitored clinical trials. <i>Journal of Neurology</i> , 2004, 251, IV6-12.	1.8	11
1054	Relationship between brain MRI lesion load and short-term disease evolution in non-disabling MS: a large-scale, multicentre study. <i>Multiple Sclerosis Journal</i> , 2011, 17, 319-326.	1.4	11
1055	Genetic Correlations of Brain Lesion Distribution in Multiple Sclerosis: An Exploratory Study. <i>American Journal of Neuroradiology</i> , 2011, 32, 695-703.	1.2	11
1056	Prognostic value of Alzheimer's biomarkers in mild cognitive impairment: the effect of age at onset. <i>Journal of Neurology</i> , 2019, 266, 2535-2545.	1.8	11
1057	CSF cutoffs for MCI due to AD depend on APOE ϵ 4 carrier status. <i>Neurobiology of Aging</i> , 2020, 89, 55-62.	1.5	11
1058	Brain structural and functional alterations in MOG antibody disease. <i>Multiple Sclerosis Journal</i> , 2021, 27, 1350-1363.	1.4	11
1059	Ongoing microstructural changes in the cervical cord underpin disability progression in early primary progressive multiple sclerosis. <i>Multiple Sclerosis Journal</i> , 2021, 27, 28-38.	1.4	11
1060	Clinical evaluation of automated quantitative MRI reports for assessment of hippocampal sclerosis. <i>European Radiology</i> , 2021, 31, 34-44.	2.3	11
1061	MRI Natural History of the Leukodystrophy Vanishing White Matter. <i>Radiology</i> , 2021, 300, 671-680.	3.6	11
1062	Cortico-hippocampal communication by way of parallel parahippocampal-subicular pathways. <i>Hippocampus</i> , 2000, 10, 398-410.	0.9	11

#	ARTICLE	IF	CITATIONS
1063	Raloxifene Affects Brain Activation Patterns in Postmenopausal Women during Visual Encoding. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2001, 86, 1422-1422.	1.8	11
1064	Amiloride, fluoxetine or riluzole to reduce brain volume loss in secondary progressive multiple sclerosis: the MS-SMART four-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-72.	0.9	11
1065	Differences in topological progression profile among neurodegenerative diseases from imaging data. <i>ELife</i> , 2019, 8, .	2.8	11
1066	Gender-Related Association Between the $TGFB1+869$ Polymorphism and Multiple Sclerosis. <i>Journal of Interferon and Cytokine Research</i> , 2004, 24, 536-542.	0.5	11
1067	MAGNIMS recommendations for harmonization of MRI data in MS multicenter studies. <i>NeuroImage: Clinical</i> , 2022, 34, 102972.	1.4	11
1068	White-Matter Changes on MRI as Surrogate Marker. <i>International Psychogeriatrics</i> , 2003, 15, 261-265.	0.6	10
1069	ASSOCIATION BETWEEN VITAMIN B6 AND WHITE MATTER HYPERINTENSITIES IN PATIENTS WITH ALZHEIMER'S DISEASE NOT MEDIATED BY HOMOCYSTEINE METABOLISM. <i>Journal of the American Geriatrics Society</i> , 2007, 55, 956-958.	1.3	10
1070	A Randomized Trial of High-Dose Vitamin D2 in Relapsing-remitting Multiple Sclerosis. <i>Neurology</i> , 2012, 78, 840-841.	1.5	10
1071	Contribution of white matter hyperintensities, medial temporal lobe atrophy and cortical atrophy on outcome, seven to twelve years after ECT in severely depressed geriatric patients. <i>Journal of Affective Disorders</i> , 2015, 185, 144-148.	2.0	10
1072	White Matter Diffusion Changes during the First Year of Natalizumab Treatment in Relapsing-Remitting Multiple Sclerosis. <i>American Journal of Neuroradiology</i> , 2016, 37, 1030-1037.	1.2	10
1073	Validation of an MRI Rating Scale for Amyloid-Related Imaging Abnormalities. <i>Journal of Neuroimaging</i> , 2017, 27, 318-325.	1.0	10
1074	Interaction of Vascular Damage and Alzheimer Dementia: Focal Damage and Disconnection. <i>Radiology</i> , 2017, 282, 311-313.	3.6	10
1075	Exploring resting state connectivity in patients with psychotic depression. <i>PLoS ONE</i> , 2019, 14, e0209908.	1.1	10
1076	Single-subject structural cortical networks in clinically isolated syndrome. <i>Multiple Sclerosis Journal</i> , 2020, 26, 1392-1401.	1.4	10
1077	Methylphenidate and galantamine in patients with vascular cognitive impairment—the proof-of-principle study STREAM-VCI. <i>Alzheimer's Research and Therapy</i> , 2020, 12, 10.	3.0	10
1078	NAA is a Marker of Disability in Secondary-Progressive MS: A Proton MR Spectroscopic Imaging Study. <i>American Journal of Neuroradiology</i> , 2020, 41, 2209-2218.	1.2	10
1079	The Right Temporal Variant of Frontotemporal Dementia Is Not Genetically Sporadic: A Case Series. <i>Journal of Alzheimer's Disease</i> , 2021, 79, 1195-1201.	1.2	10
1080	Ocrelizumab after natalizumab in JC-virus positive relapsing remitting multiple sclerosis patients. <i>Multiple Sclerosis Journal - Experimental, Translational and Clinical</i> , 2021, 7, 205521732110138.	0.5	10

#	ARTICLE	IF	CITATIONS
1081	Tau-related grey matter network breakdown across the Alzheimer's disease continuum. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 138.	3.0	10
1082	Grey matter network trajectories across the Alzheimer's disease continuum and relation to cognition. <i>Brain Communications</i> , 2020, 2, fcaa177.	1.5	10
1083	Effects of Insulin Detemir and NPH Insulin on Body Weight and Appetite-Regulating Brain Regions in Human Type 1 Diabetes: A Randomized Controlled Trial. <i>PLoS ONE</i> , 2014, 9, e94483.	1.1	10
1084	Opportunities for Understanding MS Mechanisms and Progression With MRI Using Large-Scale Data Sharing and Artificial Intelligence. <i>Neurology</i> , 2021, 97, 989-999.	1.5	10
1085	Association of the ATN Research Framework With Clinical Profile, Cognitive Decline, and Mortality in Patients With Dementia With Lewy Bodies. <i>Neurology</i> , 2022, 98, .	1.5	10
1086	Magnetic Resonance Imaging Hyperintensities in Alzheimer's Disease-Reply. <i>Archives of Neurology</i> , 1991, 48, 469-470.	4.9	9
1087	Magnetic resonance (MR) imaging as a marker for multiple sclerosis. <i>Biomedicine and Pharmacotherapy</i> , 1999, 53, 351-357.	2.5	9
1088	Quantitative MR Imaging and Spectroscopy in Congenital Cytomegalovirus Infection and Periventricular Leukomalacia Suggests a Comparable Neuropathological Substrate of the Cerebral White Matter Lesions. <i>Neuropediatrics</i> , 2009, 40, 173-173.	0.3	9
1089	Performance of the Swanton multiple sclerosis criteria for dissemination in space. <i>Multiple Sclerosis Journal</i> , 2010, 16, 985-987.	1.4	9
1090	Novel Infantile-Onset Leukoencephalopathy With High Lactate Level and Slow Improvement. <i>Archives of Neurology</i> , 2012, 69, 718-22.	4.9	9
1091	Accelerated executive functions decline and gray matter structural changes in middle-aged type 1 diabetes mellitus patients with proliferative retinopathy. <i>Journal of Diabetes</i> , 2018, 10, 835-846.	0.8	9
1092	Non-linear registration improves statistical power to detect hippocampal atrophy in aging and dementia. <i>NeuroImage: Clinical</i> , 2019, 23, 101902.	1.4	9
1093	Effect of HLA-DRB1 alleles and genetic variants on the development of neutralizing antibodies to interferon beta in the BEYOND and BENEFIT trials. <i>Multiple Sclerosis Journal</i> , 2019, 25, 565-573.	1.4	9
1094	Nutritional status and structural brain changes in Alzheimer's disease: The NUDAD project. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12063.	1.2	9
1095	Pharmacovigilance during treatment of multiple sclerosis: early recognition of CNS complications. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 177-188.	0.9	9
1096	Amyloid β , cortical thickness, and subsequent cognitive decline in cognitively normal oldest-old. <i>Annals of Clinical and Translational Neurology</i> , 2021, 8, 348-358.	1.7	9
1097	Linear brain atrophy measures in multiple sclerosis and clinically isolated syndromes: a 30-year follow-up. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2021, 92, 839-846.	0.9	9
1098	Glioblastoma Surgery Imaging Reporting and Data System: Validation and Performance of the Automated Segmentation Task. <i>Cancers</i> , 2021, 13, 4674.	1.7	9

#	ARTICLE	IF	CITATIONS
1099	Differential trajectories of hypometabolism across cognitively-defined Alzheimer's disease subgroups. <i>NeuroImage: Clinical</i> , 2021, 31, 102725.	1.4	9
1100	Learning to Segment When Experts Disagree. <i>Lecture Notes in Computer Science</i> , 2020, , 179-190.	1.0	9
1101	Impact of white matter hyperintensity location on depressive symptoms in memory-clinic patients: a lesion-symptom mapping study. <i>Journal of Psychiatry and Neuroscience</i> , 2019, 44, E1-E10.	1.4	9
1102	A deep learning algorithm for white matter hyperintensity lesion detection and segmentation. <i>Neuroradiology</i> , 2022, 64, 727-734.	1.1	9
1103	Meningeal Gd-DTPA enhancement in multiple sclerosis. <i>American Journal of Neuroradiology</i> , 1992, 13, 397-400.	1.2	9
1104	Effects of Dapagliflozin and Combination Therapy With Exenatide on Food-Cue Induced Brain Activation in Patients With Type 2 Diabetes. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2022, 107, e2590-e2599.	1.8	9
1105	Rare variants in IFFO1, DTNB, NLRC3 and SLC22A10 associate with Alzheimer's disease CSF profile of neuronal injury and inflammation. <i>Molecular Psychiatry</i> , 2022, 27, 1990-1999.	4.1	9
1106	Regional associations of white matter hyperintensities and early cortical amyloid pathology. <i>Brain Communications</i> , 2022, 4, .	1.5	9
1107	The Open-Access European Prevention of Alzheimer's Dementia (EPAD) MRI dataset and processing workflow. <i>NeuroImage: Clinical</i> , 2022, 35, 103106.	1.4	9
1108	Nonlinear Changes in Brain Activity During Continuous Word Repetition: An Event-Related Multiparametric Functional MR Imaging Study. <i>American Journal of Neuroradiology</i> , 2007, 28, 1715-1721.	1.2	8
1109	Can leptomeningeal enhancement be linked to multiple sclerosis?. <i>Neurology</i> , 2015, 84, 762-763.	1.5	8
1110	Imaging Phenotypes in Multiple Sclerosis. <i>Neuroimaging Clinics of North America</i> , 2015, 25, 83-96.	0.5	8
1111	Causes, effects and connectivity changes in MS-related cognitive decline. <i>Dementia E Neuropsychologia</i> , 2016, 10, 2-11.	0.3	8
1112	Neuroimaging in Dementia. , 2016, , 79-85.		8
1113	The value of subtraction MRI in detection of amyloid-related imaging abnormalities with oedema or effusion in Alzheimer's patients: An interobserver study. <i>European Radiology</i> , 2018, 28, 1215-1226.	2.3	8
1114	Computer-assisted prediction of clinical progression in the earliest stages of AD. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 726-736.	1.2	8
1115	Direct comparison of [11C] choline and [18F] FET PET to detect glioma infiltration: a diagnostic accuracy study in eight patients. <i>EJNMMI Research</i> , 2019, 9, 57.	1.1	8
1116	The presence of cerebral white matter lesions and lower skin microvascular perfusion predicts lower cognitive performance in type 1 diabetes patients with retinopathy but not in healthy controls: A longitudinal study. <i>Microcirculation</i> , 2019, 26, e12530.	1.0	8

#	ARTICLE	IF	CITATIONS
1117	Why Is Amyloid- β PET Requested After Performing CSF Biomarkers?. <i>Journal of Alzheimer's Disease</i> , 2020, 73, 559-569.	1.2	8
1118	Evaluating severity of white matter lesions from computed tomography images with convolutional neural network. <i>Neuroradiology</i> , 2020, 62, 1257-1263.	1.1	8
1119	Cerebral effects of glucagon-like peptide-1 receptor blockade before and after Roux-Y gastric bypass surgery in obese women: A proof-of-concept resting-state functional MRI study. <i>Diabetes, Obesity and Metabolism</i> , 2021, 23, 415-424.	2.2	8
1120	Uncertainty analysis of MR-PET image registration for precision neuro-PET imaging. <i>NeuroImage</i> , 2021, 232, 117821.	2.1	8
1121	Quantification of Cervical Cord Cross-Sectional Area: Which Acquisition, Vertebra Level, and Analysis Software? A Multicenter Repeatability Study on a Traveling Healthy Volunteer. <i>Frontiers in Neurology</i> , 2021, 12, 693333.	1.1	8
1122	Structural and functional hippocampal alterations in Multiple sclerosis and neuromyelitis optica spectrum disorder. <i>Multiple Sclerosis Journal</i> , 2022, 28, 707-717.	1.4	8
1123	Neuropsychological impairment in multiple sclerosis patients: the role of (juxta)cortical lesion on FLAIR. <i>Multiple Sclerosis Journal</i> , 2000, 6, 280-285.	1.4	8
1124	Using Unsupervised Learning to Identify Clinical Subtypes of Alzheimer's Disease in Electronic Health Records. <i>Studies in Health Technology and Informatics</i> , 2020, 270, 499-503.	0.2	8
1125	Structural neuroimaging outcomes in clinical dementia trials, with special reference to disease modifying designs. <i>Journal of Nutrition, Health and Aging</i> , 2006, 10, 123-8; discussion 129-30.	1.5	8
1126	A more unstable resting-state functional network in cognitively declining multiple sclerosis. <i>Brain Communications</i> , 2022, 4, .	1.5	8
1127	A Beginner's Guide to Arterial Spin Labeling (ASL) Image Processing. <i>Frontiers in Radiology</i> , 0, 2, .	1.2	8
1128	The Effect of Smoking on Long-term Gray Matter Atrophy and Clinical Disability in Patients with Relapsing-Remitting Multiple Sclerosis. <i>Neurology: Neuroimmunology and NeuroInflammation</i> , 2022, 9, .	3.1	8
1129	A randomized trial predicting response to cognitive rehabilitation in multiple sclerosis: Is there a window of opportunity?. <i>Multiple Sclerosis Journal</i> , 2022, 28, 2124-2136.	1.4	8
1130	Severe Irreversible Optic Neuritis Following Mantoux Tuberculin Skin Test in a Child with Multiple Sclerosis - A Case Report. <i>Neuropediatrics</i> , 1997, 28, 338-340.	0.3	7
1131	Guidelines for Brain Imaging in Vascular Dementia Clinical Trials. <i>International Psychogeriatrics</i> , 2003, 15, 273-276.	0.6	7
1132	Language Comprehension in Young People with Severe Cerebral Palsy in Relation to Language Tracts: A Diffusion Tensor Imaging Study. <i>Neuropediatrics</i> , 2013, 44, 286-290.	0.3	7
1133	The effect of amyloid pathology and glucose metabolism on cortical volume loss over time in Alzheimer's disease. <i>European Journal of Nuclear Medicine and Molecular Imaging</i> , 2014, 41, 1190-8.	3.3	7
1134	Impact of Gradient Number and Voxel Size on Diffusion Tensor Imaging Tractography for Resective Brain Surgery. <i>World Neurosurgery</i> , 2017, 105, 923-934.e2.	0.7	7

#	ARTICLE	IF	CITATIONS
1135	Microbleeds are associated with depressive symptoms in Alzheimer's disease. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2018, 10, 112-120.	1.2	7
1136	Evaluation of prospective motion correction of high-resolution 3D-T2-FLAIR acquisitions in epilepsy patients. <i>Journal of Neuroradiology</i> , 2018, 45, 368-373.	0.6	7
1137	Prion disease diagnosis using subject-specific imaging biomarkers within a multi-kernel Gaussian process. <i>NeuroImage: Clinical</i> , 2019, 24, 102051.	1.4	7
1138	Associations of Brain Pathology Cognitive and Physical Markers With Age in Cognitively Normal Individuals Aged 60â€“102 Years. <i>Journals of Gerontology - Series A Biological Sciences and Medical Sciences</i> , 2020, 75, 1609-1617.	1.7	7
1139	Small vessel disease lesion type and brain atrophy: The role of co-occurring amyloid. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12060.	1.2	7
1140	Dickkopf-1 Overexpression in vitro Nominates Candidate Blood Biomarkers Relating to Alzheimerâ€™s Disease Pathology. <i>Journal of Alzheimer's Disease</i> , 2020, 77, 1353-1368.	1.2	7
1141	Selection of memory clinic patients for CSF biomarker assessment can be restricted to a quarter of cases by using computerized decision support, without compromising diagnostic accuracy. <i>PLoS ONE</i> , 2020, 15, e0226784.	1.1	7
1142	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2021, 13, e12216.	1.2	7
1143	Parametric imaging of dual-time window [18F]flutemetamol and [18F]florbetaben studies. <i>NeuroImage</i> , 2021, 234, 117953.	2.1	7
1144	Subtyping relapsingâ€“remitting multiple sclerosis using structural MRI. <i>Journal of Neurology</i> , 2021, 268, 1808-1817.	1.8	7
1145	Demyelinating Diseases of the CNS (Brain and Spine). <i>IDKD Springer Series</i> , 2020, , 165-176.	0.8	7
1146	Gadopentetate dimeglumine enhancement of multiple sclerosis lesions on long TR spin-echo images at 0.6 T. <i>American Journal of Neuroradiology</i> , 1992, 13, 1257-9.	1.2	7
1147	A systematic review on the use of quantitative imaging to detect cancer therapy adverse effects in normal-appearing brain tissue. <i>Magnetic Resonance Materials in Physics, Biology, and Medicine</i> , 2022, 35, 163-186.	1.1	7
1148	Serum neurofilament as a predictor of 10-year grey matter atrophy and clinical disability in multiple sclerosis: a longitudinal study. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2022, 93, 849-857.	0.9	7
1149	Classification of patients with a clinically isolated syndrome based on signs and symptoms is supported by magnetic resonance imaging results. <i>Multiple Sclerosis Journal</i> , 2007, 13, 717-721.	1.4	6
1150	A search for new MRI criteria for dissemination in space in subjects with a clinically isolated syndrome. <i>European Radiology</i> , 2009, 19, 2244-2248.	2.3	6
1151	Neurological Signs in Relation to White Matter Hyperintensity Volumes in Memory Clinic Patients. <i>Dementia and Geriatric Cognitive Disorders</i> , 2010, 29, 301-308.	0.7	6
1152	CCSVI deconstructed and discarded. <i>Nature Reviews Neurology</i> , 2013, 9, 661-662.	4.9	6

#	ARTICLE	IF	CITATIONS
1153	Spinal cord MRI should always be performed in clinically isolated syndrome patients: Yes. Multiple Sclerosis Journal, 2014, 20, 1688-1689.	1.4	6
1154	Differential impact of subclinical carotid artery disease on cerebral structure and functioning in type 1 diabetes patients with versus those without proliferative retinopathy. Cardiovascular Diabetology, 2014, 13, 58.	2.7	6
1155	Minimal supportive treatment in natalizumab-related PML in a MS patient. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 354-355.	0.9	6
1156	A novel <i>CCM2</i> variant in a family with non- ϵ progressive cognitive complaints and cerebral microbleeds. American Journal of Medical Genetics Part B: Neuropsychiatric Genetics, 2017, 174, 220-226.	1.1	6
1157	Gray matter network differences between behavioral variant frontotemporal dementia and Alzheimer's disease. Neurobiology of Aging, 2017, 50, 77-86.	1.5	6
1158	Spinal cord atrophy rates. Neurology, 2018, 91, 157-158.	1.5	6
1159	Comorbid amyloid β pathology affects clinical and imaging features in VCD. Alzheimer's and Dementia, 2020, 16, 354-364.	0.4	6
1160	Damage in the Thalamocortical Tracts is Associated With Subsequent Thalamus Atrophy in Early Multiple Sclerosis. Frontiers in Neurology, 2020, 11, 575611.	1.1	6
1161	Biomarker testing in MCI patients—deciding who to test. Alzheimer's Research and Therapy, 2021, 13, 14.	3.0	6
1162	FLAIR-only joint volumetric analysis of brain lesions and atrophy in clinically isolated syndrome (CIS) suggestive of multiple sclerosis. NeuroImage: Clinical, 2021, 29, 102542.	1.4	6
1163	Modelling new enhancing MRI lesion counts in multiple sclerosis. Multiple Sclerosis Journal, 2001, 7, 298-304.	1.4	6
1164	Magnetic resonance imaging of epilepsy in multiple sclerosis: a case control study. Implications for treatment trials with 4-aminopyridine. Multiple Sclerosis Journal, 1996, 1, 213-7.	1.4	6
1165	Evolution from a first clinical demyelinating event to multiple sclerosis in the REFLEX trial: Regional susceptibility in the conversion to multiple sclerosis at disease onset and its amenability to subcutaneous interferon beta β 1a. European Journal of Neurology, 2022, 29, 2024-2035.	1.7	6
1166	Impact of cerebral blood flow and amyloid load on SUVR bias. EJNMMI Research, 2022, 12, 29.	1.1	6
1167	Targeted Screening for Alzheimer's Disease Clinical Trials Using Data-Driven Disease Progression Models. Frontiers in Artificial Intelligence, 2022, 5, .	2.0	6
1168	Description of a European memory clinic cohort undergoing amyloid β PET: The AMYPAD Diagnostic and Patient Management Study. Alzheimer's and Dementia, 2023, 19, 844-856.	0.4	6
1169	Database for serial magnetic resonance imaging in multiple sclerosis. Neuroradiology, 1993, 35, 362-366.	1.1	5
1170	SPECT, CT and MRI in a Turkish family with huntington's disease. Neuroradiology, 1993, 35, 525-528.	1.1	5

#	ARTICLE	IF	CITATIONS
1171	Methylprednisolone treatment in multiple sclerosis: effect of treatment, pharmacokinetics, future. Multiple Sclerosis Journal, 1996, 1, 327-328.	1.4	5
1172	At the heart of primary progressive multiple sclerosis: three cases with diffuse MRI abnormalities only. Multiple Sclerosis Journal, 2008, 14, 428-430.	1.4	5
1173	Normal Ageing. , 2011, , 43-57.		5
1174	Suspected early dementia. BMJ: British Medical Journal, 2011, 343, d5568-d5568.	2.4	5
1175	Localisation of the central sulcus region in glioma patients with three-dimensional fluid-attenuated inversion recovery and volume rendering: comparison with functional and conventional magnetic resonance. British Journal of Neurosurgery, 2011, 25, 210-217.	0.4	5
1176	Diagnostic relevance of high field MRI in clinical neuroradiology: the advantages and challenges of driving a sports car. European Radiology, 2012, 22, 2304-2306.	2.3	5
1177	Laminar cortical damage in multiple sclerosis. Brain, 2015, 138, 828-829.	3.7	5
1178	Mapping Deep Gray Matter Iron in Multiple Sclerosis by Using Quantitative Magnetic Susceptibility. Radiology, 2018, 289, 497-498.	3.6	5
1179	Exploring effects of Souvenaid on cerebral glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia: Translational Research and Clinical Interventions, 2019, 5, 492-500.	1.8	5
1180	Voxelwise statistical methods to localize practice variation in brain tumor surgery. PLoS ONE, 2019, 14, e0222939.	1.1	5
1181	Prediction of poor clinical outcome in vascular cognitive impairment: TRACEâ€VCI study. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2020, 12, e12077.	1.2	5
1182	Grey zone amyloid burden affects memory function: the SCIENCE project. European Journal of Nuclear Medicine and Molecular Imaging, 2021, 48, 747-756.	3.3	5
1183	Glioblastoma Surgery Imagingâ€”Reporting and Data System: Standardized Reporting of Tumor Volume, Location, and Resectability Based on Automated Segmentations. Cancers, 2021, 13, 2854.	1.7	5
1184	Fingolimod Treatment Increases the Proportion of Patients Who Are Free from Disease Activity in Multiple Sclerosis Compared to IFN-b1a: Results from a Phase 3, Active-Controlled Study (TRANSFORMS) (PD5.006). Neurology, 2012, 78, PD5.006-PD5.006.	1.5	5
1185	The wearing-off phenomenon of ocrelizumab in patients with multiple sclerosis. Multiple Sclerosis and Related Disorders, 2022, 57, 103364.	0.9	5
1186	Subjective cognitive decline and selfâ€ereported sleep problems: The SCIENCE project. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2022, 14, .	1.2	5
1187	Quantitative computer-assisted analysis vs. visual estimation of MR imaging response of brain metastases to radiotherapy. Magnetic Resonance Imaging, 1997, 15, 99-106.	1.0	4
1188	Whole-brain T 1 -relaxation time measurements in multiple sclerosis. Journal of Neurology, 2002, 249, 1451-1452.	1.8	4

#	ARTICLE	IF	CITATIONS
1189	Multi-Contrast, Isotropic, Single-Slab 3D MR Imaging in Multiple Sclerosis. <i>Neuroradiology Journal</i> , 2009, 22, 33-42.	0.6	4
1190	Making better use of our brain MRI research data. <i>European Radiology</i> , 2012, 22, 1395-1396.	2.3	4
1191	Design of the NIGMA study: Exploring the effect of Souvenaid on cerebral glucose metabolism in early Alzheimer's disease. <i>Alzheimer's and Dementia: Translational Research and Clinical Interventions</i> , 2016, 2, 233-240.	1.8	4
1192	The optic nerve should be included as one of the typical CNS regions for establishing dissemination in space when diagnosing MS – Commentary. <i>Multiple Sclerosis Journal</i> , 2018, 24, 125-126.	1.4	4
1193	P2505: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITY CORRELATES WITH COGNITION IN THE ALFA COHORT. <i>Alzheimer's and Dementia</i> , 2018, 14, P925.	0.4	4
1194	Earliest radiological progression in glioblastoma by multidisciplinary consensus review. <i>Journal of Neuro-Oncology</i> , 2018, 139, 591-598.	1.4	4
1195	How Do Different Forms of Vascular Brain Injury Relate to Cognition in a Memory Clinic Population: The TRACE-VCI Study. <i>Journal of Alzheimer's Disease</i> , 2019, 68, 1273-1286.	1.2	4
1196	Sex differences in memory clinic patients with possible vascular cognitive impairment. <i>Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring</i> , 2020, 12, e12090.	1.2	4
1197	Converging evidence for a "gray zone" of amyloid burden and its relevance. <i>Alzheimer's and Dementia</i> , 2020, 16, e044786.	0.4	4
1198	Timing of glioblastoma surgery and patient outcomes: a multicenter cohort study. <i>Neuro-Oncology Advances</i> , 2021, 3, v00053.	0.4	4
1199	Transient Cognitive Impairment and White Matter Hyperintensities in Severely Depressed Older Patients Treated With Electroconvulsive Therapy. <i>American Journal of Geriatric Psychiatry</i> , 2021, 29, 1117-1128.	0.6	4
1200	Visual Function and Brief Cognitive Assessment for Multiple Sclerosis in Optic Neuritis Clinically Isolated Syndrome Patients. <i>Journal of Neuro-Ophthalmology</i> , 2022, 42, e22-e31.	0.4	4
1201	The utility of MRI in suspected MS: Report of the Therapeutics and Technology Assessment Subcommittee. <i>Neurology</i> , 2004, 63, 1140-1140.	1.5	4
1202	The effect of gadolinium-based contrast-agents on automated brain atrophy measurements by FreeSurfer in patients with multiple sclerosis. <i>European Radiology</i> , 2022, 32, 3576-3587.	2.3	4
1203	Grey matter network markers identify individuals with prodromal Alzheimer's disease who will show rapid clinical decline. <i>Brain Communications</i> , 2022, 4, f00026.	1.5	4
1204	Designing Multi-arm Multistage Adaptive Trials for Neuroprotection in Progressive Multiple Sclerosis. <i>Neurology</i> , 2022, 98, 754-764.	1.5	4
1205	Upper cervical cord atrophy is independent of cervical cord lesion volume in early multiple sclerosis: A two-year longitudinal study. <i>Multiple Sclerosis and Related Disorders</i> , 2022, 60, 103713.	0.9	4
1206	Post-mortem correlates of Virchow-Robin spaces detected on <i>in vivo</i> MRI. <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2022, 42, 1224-1235.	2.4	4

#	ARTICLE	IF	CITATIONS
1207	Cerebrospinal fluid proteomic profiling of individuals with mild cognitive impairment and suspected non- β -Alzheimer's disease pathophysiology. <i>Alzheimer's and Dementia</i> , 2023, 19, 807-820.	0.4	4
1208	Quantifying spinal cord demyelination with magnetic transfer imaging. <i>Neurology</i> , 2005, 64, 1677-1678.	1.5	3
1209	The role of spinal cord imaging in the diagnosis of multiple sclerosis. <i>Nature Clinical Practice Neurology</i> , 2006, 2, 283-286.	2.7	3
1210	Modeling MR Imaging Enhancing-Lesion Volumes in Multiple Sclerosis: Application in Clinical Trials. <i>American Journal of Neuroradiology</i> , 2011, 32, 2093-2097.	1.2	3
1211	Highly accurate volumetry of the spinal cord. , 2015, , .		3
1212	P1-401: INVESTIGATING ARTERIAL SPIN LABELING AS A LARGE VESSEL CORRELATE OF SVD, AD, AND PD. <i>Alzheimer's and Dementia</i> , 2018, 14, P456.	0.4	3
1213	Multiple Sclerosis and Variants. , 2018, , 1-41.		3
1214	Novel imaging phantom for accurate and robust measurement of brain atrophy rates using clinical MRI. <i>NeuroImage: Clinical</i> , 2019, 21, 101667.	1.4	3
1215	The role of pontine lesion location in differentiating multiple sclerosis from vascular risk factor-related small vessel disease. <i>Multiple Sclerosis Journal</i> , 2021, 27, 968-972.	1.4	3
1216	Development and evaluation of a manual segmentation protocol for deep grey matter in multiple sclerosis: Towards accelerated semi-automated references. <i>NeuroImage: Clinical</i> , 2021, 30, 102659.	1.4	3
1217	Cognitive Functioning and Hippocampal Connectivity in Patients With Longstanding Type 1 Diabetes and Apolipoprotein E ϵ 4. <i>Diabetes Care</i> , 2021, 44, 2388-2396.	4.3	3
1218	Linomide in the treatment of multiple sclerosis: MRI results from prematurely terminated phase-III trials. <i>Multiple Sclerosis Journal</i> , 2000, 6, 99-104.	1.4	3
1219	Symptomatic Treatment of Vascular Cognitive Impairment (STREAM-VCI): Protocol for a Cross-Over Trial. <i>JMIR Research Protocols</i> , 2018, 7, e80.	0.5	3
1220	Characterizing 1-year development of cervical cord atrophy across different MS phenotypes: A voxel-wise, multicentre analysis. <i>Multiple Sclerosis Journal</i> , 2022, 28, 885-899.	1.4	3
1221	Evaluating robustness of the Centiloid scale against variations in amyloid PET image resolution. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	3
1222	Reproducibility of $3T$ APT-CEST in Healthy Volunteers and Patients With Brain Glioma. <i>Journal of Magnetic Resonance Imaging</i> , 2023, 57, 206-215.	1.9	3
1223	Clinical applicability of quantitative atrophy measures on MRI in patients suspected of Alzheimer's disease. <i>European Radiology</i> , 2022, 32, 7789-7799.	2.3	3
1224	Ibuprofen does not suppress active multiple sclerosis lesions on gadolinium-enhanced MR images. <i>Annals of Neurology</i> , 1997, 42, 982-982.	2.8	2

#	ARTICLE	IF	CITATIONS
1225	Association of APOE polymorphisms with disease severity in MS is limited to women. <i>Neurology</i> , 2004, 63, 1139-1139.	1.5	2
1226	No influence of <i>KIF1B</i> on neurodegenerative markers in multiple sclerosis. <i>Neurology</i> , 2011, 76, 1843-1845.	1.5	2
1227	Fetal Origin of Brain Damage in 2 Infants with aCOL4A1Mutation: Fetal and Neonatal MRI. <i>Neuropediatrics</i> , 2011, 42, e1-e1.	0.3	2
1228	Diagnostic algorithm for relapsing demyelinating syndromes of the CNS in children. <i>Lancet, The</i> , 2017, 389, S41.	6.3	2
1229	ICâ€Pâ€192: DISEASEâ€STAGE SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P158.	0.4	2
1230	Quantitative PET and Histology of Brain Biopsy Reveal Lack of Selective Pittsburgh Compound-B Binding to Intracerebral Amyloidoma. <i>Journal of Alzheimer's Disease</i> , 2018, 65, 71-77.	1.2	2
1231	Clinico-radiological dissociation of disease activity in MS patients: frequency and clinical relevance. <i>Journal of Neurology</i> , 2020, 267, 3287-3291.	1.8	2
1232	lbudilast. <i>Neurology</i> , 2021, 96, 141-142.	1.5	2
1233	The bvFTD phenocopy syndrome: a case study supported by repeated MRI, [18F]FDG-PET and pathological assessment. <i>Neurocase</i> , 2021, 27, 181-189.	0.2	2
1234	On the cutting edge of glioblastoma surgery: where neurosurgeons agree and disagree on surgical decisions. <i>Journal of Neurosurgery</i> , 2022, 136, 45-55.	0.9	2
1235	Fetal Familial Cerebral Cavernous Malformation With a Novel Heterozygous KRIT1 Pathogenic Variant. <i>Neurology</i> , 2021, 97, 10.1212/WNL.0000000000012852.	1.5	2
1236	Visual association encoding activates the medial temporal lobe: A functional magnetic resonance imaging study. <i>Hippocampus</i> , 1997, 7, 594-601.	0.9	2
1237	A Semi-supervised Large Margin Algorithm for White Matter Hyperintensity Segmentation. <i>Lecture Notes in Computer Science</i> , 2016, , 104-112.	1.0	2
1238	The precision of T1 hypointense lesion volume quantification in multiple sclerosis treatment trials: a multicenter study. <i>Multiple Sclerosis Journal</i> , 2000, 6, 237-240.	1.4	2
1239	Presumed small vessel disease, imaging and cognition markers in the Alzheimerâ€™s Disease Neuroimaging Initiative. <i>Brain Communications</i> , 2021, 3, fcab226.	1.5	2
1240	Vascular Cognitive Impairment and cognitive decline; a longitudinal study comparing different types of vascular brain injury - The TRACE-VCI study. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100141.	0.4	2
1241	Advanced quantitative evaluation of PET systems using the ACR phantom and NiftyPET software. <i>Medical Physics</i> , 2022, , .	1.6	2
1242	Quantitative amyloid PET in the AMYPAD diagnostic and patient management study. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2

#	ARTICLE	IF	CITATIONS
1243	Data-driven evidence for three distinct patterns of amyloid ^β accumulation. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	2
1244	Familial British dementia: a clinical and multi-modal imaging case study. <i>Journal of Neurology</i> , 2022, 269, 3926-3930.	1.8	2
1245	Opportunities for Molecular Imaging in Multiple Sclerosis Management: Linking Probe to Treatment. <i>Radiology</i> , 2022, 303, 486-497.	3.6	2
1246	Determining the Minimal Important Change of Everyday Functioning in Dementia. <i>Neurology</i> , 2022, 99, .	1.5	2
1247	Accumulation of hypointense lesions (‘black holes’) on T1 weighted images of multiple sclerosis patients correlates with disease progression in secondary progressive MS patients. <i>Journal of Neuroimmunology</i> , 1995, 56-63, 8-8.	1.1	1
1248	Methylprednisolone for Acute Relapses of Multiple Sclerosis. <i>CNS Drugs</i> , 1998, 10, 233-238.	2.7	1
1249	Feature Extraction and Strategy of Analyzing Structural Neuroimaging in Dementia. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2008, 89, 75-86.	1.0	1
1250	Segmental muscular atrophy of the distal upper extremity (Hirayama disease): An atypical case with anterior dural detachment. <i>European Journal of Radiology Extra</i> , 2009, 72, e53-e55.	0.1	1
1251	Imaging of gray matter lesions in multiple sclerosis. , 2011, , 165-174.		1
1252	Imaging Alzheimer in 2011. <i>Neuroradiology</i> , 2011, 53, 145-147.	1.1	1
1253	IC-P-072: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY. , 2014, 10, P40-P40.		1
1254	Daclizumab in multiple sclerosis: a high-yield extension study. <i>Lancet Neurology</i> , The, 2014, 13, 443-444.	4.9	1
1255	P1-258: CORTICAL PHASE CHANGES AT 7T MRI IN SUBJECTIVE COGNITIVE IMPAIRMENT AND THEIR ASSOCIATION WITH COGNITIVE FUNCTION. , 2014, 10, P402-P402.		1
1256	P2-192: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P541-P542.		1
1257	O4-07-05: ADDED VALUE OF MRI BIOMARKERS TO NEUROPSYCHOLOGICAL TEST PERFORMANCE FOR PREDICTION OF AD IN SUBJECTS WITH MCI. , 2014, 10, P265-P265.		1
1258	IC-P-076: WHITE MATTER HYPERINTENSITIES PREDICT MILD COGNITIVE IMPAIRMENT AND DEMENTIA IN PATIENTS WITH SUBJECTIVE COGNITIVE COMPLAINTS. , 2014, 10, P42-P43.		1
1259	P1-255: PREDICTION OF PRODROMAL AD IN MCI SUBJECTS USING MULTICENTER DTI AND MRI DATA AND MULTIPLE KERNELS SVM: AN EDSD STUDY. , 2014, 10, P400-P401.		1
1260	IC-P-109: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY: A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER DISEASE. , 2014, 10, P61-P61.		1

#	ARTICLE	IF	CITATIONS
1261	P2-196: RESTING STATE CEREBRAL PERFUSION AND METABOLISM IN SUBJECTIVE MEMORY COMPLAINTS: ALZHEIMER'S DISEASE AND FRONTOTEMPORAL DEMENTIA-TWO SIDES OF THE SAME COIN?. , 2014, 10, P543-P543.		1
1262	P4-089: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P806-P807.		1
1263	IC-P-153: Thinner Cortical Thickness in Patients With Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. , 2016, 12, P113-P114.		1
1264	O5-07-02: Personalized Risk Estimates for Mci Patients: Taking Biomarkers Into the Clinic. , 2016, 12, P393-P393.		1
1265	[P3â€“386]: COMPUTED RATING SCALES FOR COGNITIVE DISORDERS FROM MRI. Alzheimer's and Dementia, 2017, 13, P1108.	0.4	1
1266	[P1â€“395]: AMYPAD: A EUROPEAN PUBLICâ€“PRIVATE PARTNERSHIP TO INVESTIGATE THE VALUE OF Î²â€“AMYLOID BRAIN SCANS AS A DIAGNOSTIC AND THERAPEUTIC MARKER FOR ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P420.	0.4	1
1267	[P2â€“212]: EUROPEAN MEDICAL INFORMATION FRAMEWORK FOR ALZHEIMER'S DISEASE (EMIFâ€“AD): THE BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2017, 13, P691.	0.4	1
1268	ICâ€“Pâ€“182: EVENTâ€“BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€“AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P152.	0.4	1
1269	ICâ€“Pâ€“092: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. Alzheimer's and Dementia, 2018, 14, P76.	0.4	1
1270	P4â€“106: DECLINE IN GREY MATTER CONNECTIVITY OVER TIME IS RELATED TO CLINICAL PROGRESSION IN MCI DUE TO AD. Alzheimer's and Dementia, 2018, 14, P1479.	0.4	1
1271	P2â€“445: EVENTâ€“BASED MODELING OF THE TEMPORAL ORDERING OF REGIONAL Î²â€“AMYLOID DEPOSITION IN THE BRAIN. Alzheimer's and Dementia, 2018, 14, P887.	0.4	1
1272	Neuromyelitis Optica Spectrum Disorders (NMOSD). , 2019, , 769-785.		1
1273	Neuroimaging in Normal Brain Aging. , 2019, , 1277-1293.		1
1274	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2019, , 1251-1275.		1
1275	Neuromyelitis Optica Spectrum Disorders (NMOSD). , 2019, , 1-17.		1
1276	Mild cognitive impairment with Lewy bodies: Clinical characteristics and risk factors for progression. Alzheimer's and Dementia, 2020, 16, e039094.	0.4	1
1277	Dynamic PET imaging reduces sample sizes to detect longitudinal amyloid accumulation. Alzheimer's and Dementia, 2020, 16, e042623.	0.4	1
1278	Baseline features of the AMYPAD Diagnostic and Patient Management Study (DPMS) participants. Alzheimer's and Dementia, 2020, 16, e042628.	0.4	1

#	ARTICLE	IF	CITATIONS
1279	Early Detection of Incipient Alzheimer Pathology. <i>Neurology</i> , 2021, 96, 647-648.	1.5	1
1280	Disorders Mainly Affecting White Matter. , 2011, , 177-242.		1
1281	Magnetic Resonance and Dementia. , 2002, , 1-4.		1
1282	Seeing more with less: virtual gadolinium-enhanced glioma imaging. <i>The Lancet Digital Health</i> , 2021, 3, e754-e755.	5.9	1
1283	Differential Dementia Diagnosis on Incomplete Data with Latent Trees. <i>Lecture Notes in Computer Science</i> , 2016, , 44-52.	1.0	1
1284	ATN classification in dementia with Lewy bodies: Association with clinical profile, cognitive decline and survival. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
1285	What do data-driven Alzheimer's disease subtypes tell us about white matter pathology and clinical progression?. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
1286	Associations between gut microbiota composition and AD biomarkers. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	1
1287	White matter lesions on MRI in older individuals: Alzheimer's disease?. <i>Clinical Neurology and Neurosurgery</i> , 1991, 93, 356-357.	0.6	0
1288	6. Atrophy of the medial temporal lobes as early marker in Alzheimer's disease: a MRI study. <i>Clinical Neurology and Neurosurgery</i> , 1992, 94, 82.	0.6	0
1289	12. A correlative triad of clinical, gadolinium-DTPA-enhanced MRI and CSF myelin basic protein in multiple sclerosis patients treated with high dose intravenous methylprednisolone. <i>Clinical Neurology and Neurosurgery</i> , 1992, 94, 78.	0.6	0
1290	Correspondence. <i>Magnetic Resonance Imaging</i> , 1999, 17, 1236-1237.	1.0	0
1291	Erratum to "Magnetization transfer histogram parameters reflect all dimensions of MS pathology, including atrophy" [J. Neurol. Sci. 184 (2001) 155-162]. <i>Journal of the Neurological Sciences</i> , 2001, 187, 111.	0.3	0
1292	Assessing Treatment Effects on Axonal Loss - Evidence from MRI Monitored Clinical Trials. <i>The Neuroradiology Journal</i> , 2005, 18, 486-492.	0.1	0
1293	NINDS AIREN neuroimaging criteria do not distinguish stroke patients with and without dementia. <i>Neurology</i> , 2005, 65, 1341-1341.	1.5	0
1294	Heterogeneity of White Matter Hyperintensities in Alzheimer's Disease: Post-Mortem Quantitative MRI and Neuropathology. <i>Neuroradiology Journal</i> , 2009, 22, 51-63.	0.6	0
1295	PS1 - 4. Widespread decreased white matter tract integrity in T1DM patients with microangiopathy and its relation to cognitive functions. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2011, 9, 93-93.	0.0	0
1296	PS11 - 50. Depressive symptoms exacerbate the negative effects of type 1 diabetes and microangiopathy on brain functioning. <i>Nederlands Tijdschrift Voor Diabetologie</i> , 2012, 10, 133-133.	0.0	0

#	ARTICLE	IF	CITATIONS
1297	Reply:. American Journal of Neuroradiology, 2012, 33, E98-E98.	1.2	0
1298	O4â€³â€¹: Differential impact of apolipoprotein E genotype on distributions of amyloid load and glucose metabolism in Alzheimer's disease. Alzheimer's and Dementia, 2012, 8, P618.	0.4	0
1299	Demyelinating Diseases. , 2012, , 50-57.		0
1300	Efficient use of MRI for dose finding in multiple sclerosis. Lancet Neurology, The, 2013, 12, 730-731.	4.9	0
1301	PS12 - 6. Selective cognitive decline is related to focal brain volume loss in type 1 diabetes patients with microangiopathy: a 4 year follow-up. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 179-180.	0.0	0
1302	P16.12 * BRAIN LOCATIONS INVOLVED IN BASELINE COGNITIVE FUNCTIONING OF PATIENTS WITH GLIOMA BEFORE THERAPY. Neuro-Oncology, 2014, 16, ii80-ii81.	0.6	0
1303	O5-02-02: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P291-P292.		0
1304	O2-13-03: MILD COGNITIVE IMPAIRMENT WITH SUSPECTED NON AD PATHOLOGY (SNAP): PREDICTION OF PROGRESSION TO DEMENTIA. , 2014, 10, P194-P195.		0
1305	P1-223: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P385-P386.		0
1306	IC-P-085: COMPARING ATROPHY PATTERNS IN EARLY CLINICAL STAGES ACROSS DISTINCT PHENOTYPES OF ALZHEIMER'S DISEASE. , 2014, 10, P48-P49.		0
1307	IC-P-067: ADVANCED DIFFUSION WEIGHTING IMAGING (DWI) TRACTOGRAPHY OF THE LIMBIC SYSTEM: NOVEL BIOMARKERS OF NEURODEGENERATIVE CHANGES DURING PROGRESSION/CONVERSION FROM COGNITIVE NORMALITY TO AD DEMENTIA. , 2014, 10, P37-P37.		0
1308	P1-235: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P390-P391.		0
1309	P1-385: RATIONALE AND DESIGN OF THE NL-ENIGMA STUDY, A DUTCH 24-WEEK RANDOMISED CONTROLLED STUDY TO EXPLORE THE EFFECT OF A NUTRITIONAL INTERVENTION ON BRAIN GLUCOSE METABOLISM IN EARLY ALZHEIMER'S DISEASE. , 2014, 10, P455-P456.		0
1310	O2-07-04: COGNITIVE SUBTYPES IN DEMENTIA DUE TO ALZHEIMER'S DISEASE IDENTIFIED BY LATENT CLASS ANALYSIS. , 2014, 10, P178-P179.		0
1311	O5-05-04: MATRIX METALLOPROTEINASES IN RELATION TO ALZHEIMER'S DISEASE AND CAA. , 2014, 10, P300-P300.		0
1312	IC-P-057: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POST MORTEM CONFIRMED DEMENTIAS. , 2014, 10, P32-P33.		0
1313	IC-P-077: LOBAR MICROBLEEDS PREDICT STROKE IN PATIENTS WITH ALZHEIMER'S DISEASE: THE MISTRAL STUDY. , 2014, 10, P43-P44.		0
1314	IC-P-224: THE HIPPOCAMPAL BOUNDARY SHIFT INTEGRAL IS 70% MORE REPRODUCIBLE THAN OTHER ATROPHY ALGORITHMS. , 2014, 10, P120-P121.		0

#	ARTICLE	IF	CITATIONS
1315	IC-P-056: MORE ATROPHY OF DEEP GRAY MATTER STRUCTURES IN BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA COMPARED TO ALZHEIMER'S DISEASE. , 2014, 10, P31-P32.		0
1316	P1-233: MULTIMODAL BRAIN NETWORK ALTERATIONS IN ALZHEIMER'S DISEASE AND MILD COGNITIVE IMPAIRMENT PATIENTS. , 2014, 10, P389-P390.		0
1317	O1-02-04: 7T T2*-WEIGHTED MRI REVEALS CORTICAL PHASE DIFFERENCES BETWEEN EARLY- AND LATE-ONSET AD. , 2014, 10, P132-P133.		0
1318	IC-P-179: REDUCED CALLOSAL WHITE MATTER INTEGRITY SURPASSES CEREBROSPINAL FLUID AND ATROPHY MARKERS AS PREDICTOR OF DECLINE IN SUBJECTS WITH MILD COGNITIVE IMPAIRMENT: A COMBINED VOLUMETRY AND DTI STUDY. , 2014, 10, P100-P100.		0
1319	P1-174: CEREBROVASCULAR DISEASE IN LATE ONSET FRONTAL LOBE SYNDROME. , 2014, 10, P363-P363.		0
1320	P1-415: STUDY PROTOCOL: THE EFFECT OF PHYSICAL EXERCISE ON CEREBRAL BLOOD FLOW AND COGNITION IN PATIENTS WITH MILD VASCULAR COGNITIVE IMPAIRMENT. , 2014, 10, P465-P466.		0
1321	P2-190: CLASSIFICATION OF PATHOLOGY USING BRAIN SUBSTRUCTURE VOLUMES IN POSTMORTEM CONFIRMED DEMENTIAS. , 2014, 10, P540-P541.		0
1322	IC-P-106: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set. , 2015, 11, P72-P73.		0
1323	Effect of fingolimod versus interferon-beta1a on neda-4 (no evidence of disease activity or worsening) in the transforms study. Journal of the Neurological Sciences, 2015, 357, e315-e316.	0.3	0
1324	Radiologically isolated syndrome. Journal of the Neurological Sciences, 2015, 357, e462-e463.	0.3	0
1325	P3-158: Grey matter network disruptions are related to amyloid beta in cognitively healthy elderly. , 2015, 11, P689-P689.		0
1326	P3-146: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study. , 2015, 11, P682-P682.		0
1327	IC-P-124: Classification of resting-state cerebral perfusion maps from patients with Alzheimer's disease and patients with frontotemporal dementia. , 2015, 11, P85-P85.		0
1328	P4-088: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P806-P806.		0
1329	P1-180: Hypometabolism of the posterior cingulate cortex is not restricted to Alzheimer's disease. , 2015, 11, P414-P414.		0
1330	SUSTAINED LOW RATE BRAIN VOLUME LOSS IN LONG TERM FINGOLIMOD TREATMENT. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.19-e4.	0.9	0
1331	IC-P-079: Lower cerebral blood flow is associated with cognitive decline in patients with Alzheimer's disease. , 2015, 11, P57-P57.		0
1332	IC-04-03: Grey matter network disruptions are related to amyloid-beta in cognitively healthy elderly. , 2015, 11, P11-P11.		0

#	ARTICLE	IF	CITATIONS
1333	IC-P-092: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P64-P64.		0
1334	IC-P-062: Lower cerebral blood flow is related to more severe cognitive impairment in patients with dementia due to Alzheimer's disease. , 2015, 11, P46-P47.		0
1335	EFFECT OF FINGOLIMOD VS. IFN-BETA1A ON NO EVIDENCE OF DISEASE ACTIVITY. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, e4.18-e4.	0.9	0
1336	F2-03-03: Characterization of the behavioral and dysexecutive variants of Alzheimer's disease. , 2015, 11, P168-P168.		0
1337	IC-P-089: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P62-P62.		0
1338	IC-P-093: Distinct patterns of atrophy in postmortem confirmed dementias. , 2015, 11, P64-P65.		0
1339	IC-P-105: Basal forebrain and hippocampus as predictors of conversion to Alzheimer's disease in patients with mild cognitive impairment: A multicenter DTI and volumetry study. , 2015, 11, P72-P72.		0
1340	IC-P-108: Impact of ApoE-ε4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P73-P73.		0
1341	P3-170: Reproducibility of hippocampal atrophy rate at 1.5T and 3T for freesurfer and MAPS-HBSI using the ADNI1 data set. , 2015, 11, P694-P695.		0
1342	P4-100: Vascular and amyloid pathologies in memory clinic patients: Synergetic or independent?. , 2015, 11, P814-P814.		0
1343	O1-07-02: Alzheimer's disease core biomarkers and prediction of dementia in MCI: The effect of age at onset. , 2015, 11, P140-P142.		0
1344	O2-09-01: Impact of ApoE-ε4 and family history of dementia on gray matter atrophy in cognitively healthy middle-aged adults. , 2015, 11, P194-P194.		0
1345	O3-14-02: Assessing underlying Alzheimer's disease pathology in MCI patients from the amsterdam dementia cohort by use of the predictad software tool. , 2015, 11, P254-P255.		0
1346	O4-08-05: Distinct patterns of atrophy in postmortem-confirmed dementias. , 2015, 11, P288-P289.		0
1347	O4-08-06: Visual assessment in postmortem-proven dementias: Clinical expertise versus machine learning. , 2015, 11, P289-P289.		0
1348	O5-02-03: Reduced cortical thickness in patients with subjective cognitive decline is related to clinical progression. , 2015, 11, P317-P317.		0
1349	Transient gadolinium leakage in natalizumab-treated multiple sclerosis: Figure 1. Journal of Neurology, Neurosurgery and Psychiatry, 2015, 86, 475-476.	0.9	0
1350	IC-03-02: Grey Matter Connectivity is Associated with Clinical Progression in Non-Demented, Amyloid Positive Patients. , 2016, 12, P9-P10.		0

#	ARTICLE	IF	CITATIONS
1351	P2â€221: Cerebral Blood Flow Measured with Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P706.	0.4	0
1352	O3â€08â€01: Grey Matter Connectivity is Associated with Time to Clinical Progression in Mild Cognitive Impairment, Independent of Amyloid Status. Alzheimer's and Dementia, 2016, 12, P303.	0.4	0
1353	P1â€178: Impact of Coâ€Morbidity on Clinical Phenotype of Patients with Vascular Cognitive Disorders. Alzheimer's and Dementia, 2016, 12, P472.	0.4	0
1354	IC-02-04: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. , 2016, 12, P7-P8.		0
1355	P1â€284: Grey Matter Connectivity is Associated With Clinical Progression in Nonâ€Demented, Amyloid Positive Patients. Alzheimer's and Dementia, 2016, 12, P528.	0.4	0
1356	P1-327: Cross-Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. , 2016, 12, P552-P553.		0
1357	ICâ€Pâ€103: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Nonâ€Demented Stages of Alzheimerâ€™s Disease. Alzheimer's and Dementia, 2016, 12, P78.	0.4	0
1358	ICâ€Pâ€106: Crossâ€Sectional Modeling of Regional Perfusion and Gray Matter Volume in Alzheimer's Disease. Alzheimer's and Dementia, 2016, 12, P80.	0.4	0
1359	ICâ€Pâ€108: Cerebral Blood Flow Measured With Phaseâ€Contrast MRI in AD, MCI and Controls. Alzheimer's and Dementia, 2016, 12, P82.	0.4	0
1360	ICâ€Pâ€133: The Measurement of Hippocampal Atrophy Rates With MRI for A 3â€Year Study Appears to be at Least 3 Times More Sensitive Than A 1â€Year Study Based on Backâ€toâ€Back Reproducibility. Alzheimer's and Dementia, 2016, 12, P99.	0.4	0
1361	ICâ€Pâ€147: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P109.	0.4	0
1362	P3â€144: Cognitive Subtypes Identified Using Nonnegative Matrix Factorisation in Four Large Alzheimer's Disease Dementia Cohorts. Alzheimer's and Dementia, 2016, 12, P873.	0.4	0
1363	P3â€269: Correlation of Cortical Thickness in Cognitively Healthy Elderly Monozygotic Twin Pairs. Alzheimer's and Dementia, 2016, 12, P935.	0.4	0
1364	P4â€191: A Novel Neuroimaging Approach to Capture Cognitive Reserve. Alzheimer's and Dementia, 2016, 12, P1095.	0.4	0
1365	P4â€220: The Measurement of Hippocampal Atrophy Rates With MRI for A 3â€Year Study Appears to Be at Least 3 Times More Sensitive Than A 1â€Year Study Based on Backâ€toâ€Back Reproducibility. Alzheimer's and Dementia, 2016, 12, P1112.	0.4	0
1366	O1-01-01: Active and Passive Reserve Differentially Mitigate Cognitive Symptoms in Demented and Non-Demented Stages of Alzheimerâ€™s Disease. , 2016, 12, P169-P170.		0
1367	O4â€02â€04: Atrophy Patterns Predicting Cognitive Decline in Nonâ€Demented Subjects are Independent of Amyloid Pathology. Alzheimer's and Dementia, 2016, 12, P335.	0.4	0
1368	O4-09-04: Towards Data-Driven Medicine in Differential Diagnostics of Neurodegenerative Diseases. , 2016, 12, P355-P355.		0

#	ARTICLE	IF	CITATIONS
1369	P1174: Cost-efficient Differential Diagnostics of Neurodegenerative Diseases Using A Stratified Approach. Alzheimer's and Dementia, 2016, 12, P469.	0.4	0
1370	P2250: Reduced White Matter Integrity of the Rostral Limbic System Pathways in Healthy Elderly APOE E4 Allele Carriers. Alzheimer's and Dementia, 2016, 12, P721.	0.4	0
1371	P2342: Thinner Cortical Thickness in Patients with Subjective Cognitive Decline is Related to Poor Memory Performance and Faster Decline of Executive Function. Alzheimer's and Dementia, 2016, 12, P774.	0.4	0
1372	ALEMTUZUMAB PERSISTENTLY SLOWS BRAIN VOLUME LOSS IN RRMS. Journal of Neurology, Neurosurgery and Psychiatry, 2016, 87, e1.30-e1.	0.9	0
1373	P07.08: Higher functional hub load at diagnosis is associated with shorter survival in glioma patients. Neuro-Oncology, 2016, 18, iv35-iv35.	0.6	0
1374	Comparing quality of glioblastoma resections between care teams. European Journal of Cancer, 2017, 72, S46-S47.	1.3	0
1375	[ICAP130]: MRI-BASED CLASSIFICATION ACCURACY OF DEMENTIA TYPE IS DETERMINED BY MRI MODALITY. Alzheimer's and Dementia, 2017, 13, P98.	0.4	0
1376	[P1392]: AUTOMATED SELECTION OF MULTIMODAL MRI BIOMARKERS FOR DIAGNOSIS OF DEMENTIA. Alzheimer's and Dementia, 2017, 13, P417.	0.4	0
1377	[P2245]: AMYLOID VISUALIZATION IN THE RETINA OF ALZHEIMER'S DISEASE PATIENTS WITH CURCUMIN. Alzheimer's and Dementia, 2017, 13, P705.	0.4	0
1378	[P2399]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P783.	0.4	0
1379	[P2418]: METHODOLOGICAL AND LOGISTIC STRATEGIES FOR A LARGE MULTI-CENTER 12-AMYLOID PET EUROPEAN PROJECT: AMYLOID IMAGING TO PREVENT ALZHEIMER'S DISEASE (AMYPAD). Alzheimer's and Dementia, 2017, 13, P794.	0.4	0
1380	[P3062]: ACROSS-SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTI-SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P954.	0.4	0
1381	[P3375]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P1102.	0.4	0
1382	[P3389]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK-TO-BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS?. Alzheimer's and Dementia, 2017, 13, P1109.	0.4	0
1383	[P3422]: CLINICAL AND RADIOLOGICAL FINDINGS IN PATIENTS WITH PATHOLOGICALLY CONFIRMED CAA. Alzheimer's and Dementia, 2017, 13, P1127.	0.4	0
1384	[P4226]: BEST COMBINATORIAL LOW-COST MARKERS TO PREDICT MCI CONVERSION: AN EMIFAD FEDERATION STUDY. Alzheimer's and Dementia, 2017, 13, P1356.	0.4	0
1385	[ICAP036]: CORRELATION OF GREY MATTER NETWORK MEASURES IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P32.	0.4	0
1386	[ICAP053]: EARLY ALTERATIONS IN RESTING-STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P43.	0.4	0

#	ARTICLE	IF	CITATIONS
1387	[ICâ€Pâ€055]: EFFECT OF APOEâ€µ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P45.	0.4	0
1388	[ICâ€Pâ€065]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P53.	0.4	0
1389	[ICâ€Pâ€085]: GREY MATTER CONNECTIVITY IS ASSOCIATED WITH THE RATE OF COGNITIVE DECLINE IN MILD COGNITIVE IMPAIRMENT. Alzheimer's and Dementia, 2017, 13, P69.	0.4	0
1390	[ICâ€Pâ€095]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P74.	0.4	0
1391	[ICâ€Pâ€106]: PREDICTING PROGRESSION IN PREâ€DEMENTIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P81.	0.4	0
1392	[ICâ€Pâ€110]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P87.	0.4	0
1393	[ICâ€Pâ€132]: WHEN MEASURING HIPPOCAMPAL ATROPHY, DO THE SEGMENTATION NOISE DISTRIBUTIONS OF METHODS, AS DETERMINED BY THE BACK TO BACK REPRODUCIBILITY, HAVE GAUSSIAN DISTRIBUTIONS?. Alzheimer's and Dementia, 2017, 13, P99.	0.4	0
1394	[ICâ€Pâ€167]: ACROSSâ€SESSION REPRODUCIBILITY OF AUTOMATIC WHITE MATTER HYPERINTENSITIES SEGMENTATION: A EUROPEAN MULTIâ€SITE 3T STUDY. Alzheimer's and Dementia, 2017, 13, P126.	0.4	0
1395	[P1â€289]: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN (CSF AÎ² OR AMYLOIDâ€PET) IN THE EMIFâ€AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2017, 13, P361.	0.4	0
1396	[P1â€400]: USING SUBTRACTION MRI TO IMPROVE THE DETECTION OF AMYLOIDâ€RELATED IMAGING ABNORMALITIES WITH EDEMA OR EFFUSION (ARIAâ€E) IN PATIENTS AFFECTED BY ALZHEIMER'S DISEASE RECEIVING IMMUNOTHERAPY: AN INTERâ€OBSERVER STUDY. Alzheimer's and Dementia, 2017, 13, P425.	0.4	0
1397	[P1â€404]: EARLY ALTERATIONS IN RESTINGâ€STATE FUNCTIONAL CONNECTIVITY IS ASSOCIATED WITH AMYLOID PATHOLOGY IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWINS. Alzheimer's and Dementia, 2017, 13, P429.	0.4	0
1398	[P1â€411]: WHITE MATTER HYPERINTENSITIES AND VASCULAR RISK FACTORS IN COGNITIVELY HEALTHY ELDERLY MONOZYGOTIC TWIN PAIRS. Alzheimer's and Dementia, 2017, 13, P433.	0.4	0
1399	[P1â€440]: GREY MATTER CONNECTIVITY IS RELATED TO A STEEPER LOSS OF MEMORY AND LANGUAGE FUNCTIONING OVER TIME IN PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P451.	0.4	0
1400	[P2â€335]: EFFECT OF APOE Îµ2 ON REGIONAL GRAY MATTER ATROPHY AND CLINICAL PHENOTYPE IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P748.	0.4	0
1401	[F1â€03â€04]: BIOMARKERâ€BASED PERSONALIZED RISK ESTIMATES FOR PATIENTS WITH SUBJECTIVE COGNITIVE DECLINE. Alzheimer's and Dementia, 2017, 13, P177.	0.4	0
1402	[O1â€01â€02]: MICROBLEEDS ARE ASSOCIATED WITH DEPRESSIVE SYMPTOMS IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P182.	0.4	0
1403	[O2â€01â€01]: CHARACTERIZING INDIVIDUALS WITH SUBJECTIVE COGNITIVE DECLINE: THE SUBJECTIVE COGNITIVE IMPAIRMENT COHORT (SCIENCE). Alzheimer's and Dementia, 2017, 13, P547.	0.4	0
1404	[O2â€10â€06]: PROGNOSIS OF CLINICAL PROGRESSION IN SUBJECTIVE COGNITIVE DECLINE USING A CLINICAL DECISION SUPPORT SYSTEM. Alzheimer's and Dementia, 2017, 13, P579.	0.4	0

#	ARTICLE	IF	CITATIONS
1405	[O2â€“11â€“03]: PREDICTING PROGRESSION IN PREâ€“DEMENCIA STAGES OF ALZHEIMER'S DISEASE WITH A NEUROIMAGING MEASURE OF COGNITIVE RESERVE. Alzheimer's and Dementia, 2017, 13, P581.	0.4	0
1406	[P4â€“524]: WHITE MATTER HYPERINTENSITIES ARE ASSOCIATED WITH HIPPOCAMPAL ATROPHY RATES AFTER ADJUSTING FOR OTHER VASCULAR MARKERS IN PREDEMENCIA DISEASE STAGES. Alzheimer's and Dementia, 2017, 13, P1547.	0.4	0
1407	[P4â€“526]: HARMONIZATION OF NEUROIMAGING BIOMARKERS FOR NEURODEGENERATIVE DISEASES: A SURVEY FOR BEST PRACTICE GUIDELINES. Alzheimer's and Dementia, 2017, 13, P1549.	0.4	0
1408	[DTâ€“01â€“02]: THE IMPACT OF AMYLOID PET ON DIAGNOSIS AND PATIENT MANAGEMENT IN AN UNSELECTED MEMORY CLINIC COHORT: THE ABIDE PROJECT. Alzheimer's and Dementia, 2017, 13, P1474.	0.4	0
1409	Arterial spin labeled cerebral perfusion in cognitively normal monozygotic twins. Journal of the Neurological Sciences, 2017, 381, 804.	0.3	0
1410	HOUT-14. TIME TO PROGRESSION AND VOLUME AT PROGRESSION DEPEND ON DEFINITION OF PROGRESSION IN GLIOBLASTOMA. Neuro-Oncology, 2017, 19, vi108-vi109.	0.6	0
1411	Peri-hippocampal developmental venous anomalies and memory loss: more than a normal variant?. Neuroradiology, 2018, 60, 579-582.	1.1	0
1412	P3â€“403: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1257.	0.4	0
1413	O3â€“13â€“01: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1054.	0.4	0
1414	P1â€“476: CORTICAL T1â€“W/T2â€“W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P506.	0.4	0
1415	O1â€“14â€“04: IMPACT OF WHITE MATTER HYPERINTENSITY LOCATION ON DEPRESSIVE SYMPTOMS IN MEMORY CLINIC PATIENTS: A LESIONâ€“SYMPTOM MAPPING STUDY. Alzheimer's and Dementia, 2018, 14, P259.	0.4	0
1416	P3â€“216: IS THE RELATION BETWEEN BLOOD PRESSURE AND COGNITION DEPENDENT ON AMYLOID PATHOLOGY OR PHYSICAL PERFORMANCE? RESULTS OF THE EMIFâ€“AD 90+ STUDY. Alzheimer's and Dementia, 2018, 14, P1153.	0.4	0
1417	ICâ€“Pâ€“222: [18F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. Alzheimer's and Dementia, 2018, 14, P180.	0.4	0
1418	ICâ€“Pâ€“066: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. Alzheimer's and Dementia, 2018, 14, P59.	0.4	0
1419	P3â€“233: PLASMA PRIMARY FATTY AMIDES ASSOCIATE TO CSF AMYLOID LEVELS AND ALZHEIMER'S DISEASE PROGRESSION IN THE EMIFâ€“AD BIOMARKER DISCOVERY COHORT. Alzheimer's and Dementia, 2018, 14, P1161.	0.4	0
1420	P1â€“016: METHYLPHENIDATE IMPROVES EXECUTIVE FUNCTIONING IN PATIENTS WITH VASCULAR COGNITIVE IMPAIRMENT: FIRST RESULTS OF THE STREAMâ€“VCI STUDY. Alzheimer's and Dementia, 2018, 14, P270.	0.4	0
1421	ICâ€“Pâ€“119: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION. Alzheimer's and Dementia, 2018, 14, P101.	0.4	0
1422	ICâ€“06â€“05: LOSS OF GREY MATTER CONNECTIVITY IN THE PRECUNEUS IS ASSOCIATED WITH FASTER ATROPHY RATES IN PRECLINICAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P13.	0.4	0

#	ARTICLE	IF	CITATIONS
1423	P1â€418: WHITE MATTER MICROSTRUCTURE AND AMYLOID AGGREGATION IN COGNITIVELY HEALTHY, ELDERLY IDENTICAL TWINS. <i>Alzheimer's and Dementia</i> , 2018, 14, P465.	0.4	0
1424	P1â€297: METABOLIC BLOODâ€BASED BIOMARKERS RELATE TO BRAIN ATROPHY AND WHITE MATTER HYPERINTENSITIES IN ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P401.	0.4	0
1425	P1â€478: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOIDâ€BETA LOAD IN CORTEX OF NONâ€NEUROLOGICAL AGED DONORS. <i>Alzheimer's and Dementia</i> , 2018, 14, P508.	0.4	0
1426	P2â€349: DIFFERENT COMBINATIONS OF DIAGNOSTIC TESTS DISCRIMINATE SPECIFIC SUBTYPES OF DEMENTIA. <i>Alzheimer's and Dementia</i> , 2018, 14, P820.	0.4	0
1427	P2â€363: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P830.	0.4	0
1428	F1â€02â€04: GENOMICS AND EPIGENOMICS ANALYSES IN THE EMIFâ€AD MULTIMODAL BIOMARKER DISCOVERY STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P204.	0.4	0
1429	P3â€436: MECHANISTIC PROFILES OF NEURODEGENERATION: A STUDY IN ALZHEIMER'S DISEASE, HEALTHY AGEING AND PRIMARY PROGRESSIVE MULTIPLE SCLEROSIS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1280.	0.4	0
1430	P2â€360: [¹⁸ F]AV1451 PET IN RELATION TO ATROPHY ACROSS THE ALZHEIMER'S DISEASE SPECTRUM. <i>Alzheimer's and Dementia</i> , 2018, 14, P827.	0.4	0
1431	P3â€264: UNBIASED METHOD TO DETERMINE CUTâ€POINTS FOR CSF TOTAL TAU LEVELS REVEALS PRESENCE OF BIOLOGICAL SUBTYPES IN A LARGE ALZHEIMER'S DISEASE POPULATION. <i>Alzheimer's and Dementia</i> , 2018, 14, P1176.	0.4	0
1432	O2â€03â€03: COGNITIVELY DEFINED SUBTYPES OF ALZHEIMER'S DISEASE ARE ASSOCIATED WITH DISTINCT PATTERNS OF ATROPHY. <i>Alzheimer's and Dementia</i> , 2018, 14, P615.	0.4	0
1433	P01.062 Probability maps of glioblastoma indicate variation in surgical decisions between twelve surgical teams. <i>Neuro-Oncology</i> , 2018, 20, iii243-iii244.	0.6	0
1434	O2â€14â€04: IDENTIFYING BEHAVIORAL VARIANT FRONTOTEMPORAL DEMENTIA AMONG PATIENTS WITH A LATEâ€ONSET FRONTAL LOBE SYNDROME: SUMMARY RESULTS OF THE LOF STUDY. <i>Alzheimer's and Dementia</i> , 2018, 14, P657.	0.4	0
1435	ICâ€Pâ€093: LATENT ATROPHY FACTORS IN POSTERIOR CORTICAL ATROPHY RELATE TO SPECIFIC COGNITIVE IMPAIRMENTS. <i>Alzheimer's and Dementia</i> , 2018, 14, P79.	0.4	0
1436	ICâ€Pâ€033: LONGITUDINAL CHANGES IN GREY MATTER CONNECTIVITY ARE RELATED TO COGNITIVE DECLINE IN PRODROMAL ALZHEIMER'S DISEASE. <i>Alzheimer's and Dementia</i> , 2018, 14, P37.	0.4	0
1437	P3â€342: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P1214.	0.4	0
1438	ICâ€Pâ€032: INFLUENCE OF NETWORK CONSTRUCTION METHODS ON PATH LENGTH VALUES IN ALZHEIMER'S DISEASE: A MULTIâ€STUDY ANALYSIS OF MRI CONNECTIVITY STUDIES. <i>Alzheimer's and Dementia</i> , 2018, 14, P36.	0.4	0
1439	P3â€277: IMPAIRMENT IN COMPLEX ACTIVITIES OF DAILY LIVING IS RELATED TO NEURODEGENERATION IN ALZHEIMER'S DISEASE SPECIFIC REGIONS. <i>Alzheimer's and Dementia</i> , 2018, 14, P1183.	0.4	0
1440	THUR 174â€...The magnify-ms study: mavenclad® tablets in active rms. <i>Journal of Neurology, Neurosurgery and Psychiatry</i> , 2018, 89, A23.1-A23.	0.9	0

#	ARTICLE	IF	CITATIONS
1441	P3â€³48: POSTERIOR ATROPHY SCALE: NORMATIVE VALUES FOR ITALIAN POPULATION. Alzheimer's and Dementia, 2018, 14, P1217.	0.4	0
1442	ICâ€³122: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS. Alzheimer's and Dementia, 2018, 14, P103.	0.4	0
1443	ICâ€³110: PATTERNS OF GLUCOSE HYPOMETABOLISM, SUBCORTICAL ATROPHY AND WHITE MATTER HYPERINTENSITIES IN THE BEHAVIORAL VARIANT OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P94.	0.4	0
1444	F5â€³04: THE USE OF RESIDUAL METHODS TO CAPTURE COGNITIVE RESERVE AND STUDY CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1633.	0.4	0
1445	P1â€³67: DISEASEâ€³STAGEâ€³SPECIFIC RELATIONSHIP BETWEEN COGNITIVE RESERVE AND CLINICAL PROGRESSION IN ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P500.	0.4	0
1446	O2â€³05: EXTENSION AND VALIDATION OF AN AMYLOID STAGING MODEL: ASSOCIATIONS WITH CLINICAL MEASURES. Alzheimer's and Dementia, 2018, 14, P643.	0.4	0
1447	P3â€³22: PROTOCOL HARMONISATION AND INâ€³VIVO COMPARISON OF ARTERIAL SPIN LABELLING PERFUSION MRI FOR MULTICENTER CLINICAL TRIALS. Alzheimer's and Dementia, 2018, 14, P1269.	0.4	0
1448	O2â€³15â€³04: ROBUST INDIVIDUALIZED PREDICTION MODELS WHICH ARE APPLICABLE ACROSS DIFFERENT COHORTS. Alzheimer's and Dementia, 2018, 14, P661.	0.4	0
1449	O5â€³01â€³03: ATROPHY SUBTYPES IN ALZHEIMER'S DISEASE IDENTIFIED THROUGH NONâ€³NEGATIVE MATRIX FACTORIZATION. Alzheimer's and Dementia, 2018, 14, P1638.	0.4	0
1450	ICâ€³005: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€³QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P16.	0.4	0
1451	O2â€³13â€³03: REGIONAL DISTRIBUTION OF WHITE MATTER HYPERINTENSITIES RELATED TO ALZHEIMER'S DISEASE RISK FACTORS IN THE ALFA COHORT. Alzheimer's and Dementia, 2018, 14, P653.	0.4	0
1452	219 Probability Maps of Glioblastoma Indicate Variation in Surgical Decisions Between 10 Surgical Teams. Neurosurgery, 2018, 65, 122.	0.6	0
1453	F1â€³02â€³02: DISCOVERY, REPLICATION AND EXTENSION STUDY OF PLASMA PROTEOMIC BIOMARKERS RELATING TO BRAIN AMYLOID BURDEN AND ALZHEIMER'S DISEASE PROGRESSION. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
1454	ICâ€³053: LOWER STRUCTURAL DEGREE AND HIGHER LOCAL EFFICIENCY RELATED TO DIFFUSE AMYLOIDâ€³BETA LOAD IN CORTEX OF NONâ€³NEUROLOGICAL AGED DONORS. Alzheimer's and Dementia, 2018, 14, P51.	0.4	0
1455	P3â€³355: ASSESSMENT OF EARLY AMYLOID PATHOLOGY USING [¹⁸ F]FLUTEMETAMOL POSITRON EMISSION TOMOGRAPHY: COMPARING VISUAL READ, SEMIâ€³QUANTITATIVE AND QUANTITATIVE METHODS. Alzheimer's and Dementia, 2018, 14, P1221.	0.4	0
1456	P2â€³477: THE NORMAL AGING BRAIN COLLECTION AMSTERDAM (NABCA): A COMPREHENSIVE COLLECTION OF POSTMORTEM IMAGING, NEUROPATHOLOGICAL AND MORPHOMETRIC DATASETS. Alzheimer's and Dementia, 2018, 14, P907.	0.4	0
1457	F1â€³02â€³01: RELATING CSF MARKERS NEUROGRANIN, NEUROFILAMENTâ€³LIGHT AND YKLâ€³40 TO AÎ², APOE Î¼4 AND COGNITION: RESULTS FROM THE EMIFâ€³AD MULTIMODAL BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P201.	0.4	0
1458	Neuroimaging in Dementia. , 2018, , 1-31.		0

#	ARTICLE	IF	CITATIONS
1459	P2â€Pâ€458: PREDICTING COGNITIVE DECLINE THROUGH STRUCTURAL MRI BIOMARKERS: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P895.	0.4	0
1460	F1â€Pâ€02â€03: MRI PREDICTORS OF AMYLOID PATHOLOGY: RESULTS FROM THE EMIFâ€AD BIOMARKER DISCOVERY STUDY. Alzheimer's and Dementia, 2018, 14, P202.	0.4	0
1461	ICâ€Pâ€187: CORTICAL T1â€W/T2â€W RATIO VALUES ARE HIGHER IN ALZHEIMER'S DISEASE COMPARED TO CONTROLS. Alzheimer's and Dementia, 2018, 14, P156.	0.4	0
1462	Neurodegenerative Disorders: Classification and Imaging Strategy. , 2018, , 1-26.		0
1463	Neuroimaging in Normal Brain Aging. , 2018, , 1-17.		0
1464	Leukodystrophies and Inherited Metabolic Conditions. , 2019, , 1641-1675.		0
1465	Multiple Sclerosis and Variants. , 2019, , 727-767.		0
1466	Neuroimaging in Dementia. , 2019, , 1295-1325.		0
1467	Reproducing Fingerprints: A Step toward Clinical Adoption. Radiology, 2019, 292, 438-439.	3.6	0
1468	IDEAS becoming reality on the roadmap for biomarker validation in Alzheimer's disease. Lancet Neurology, The, 2019, 18, 519-520.	4.9	0
1469	ICâ€Pâ€159: AMYLOIDâ€BETA ACCUMULATION AFFECTS IN VIVO STAGING OF TAU DEPOSITION IN COGNITIVELY IMPAIRED INDIVIDUALS. Alzheimer's and Dementia, 2019, 15, P127.	0.4	0
1470	ICâ€Pâ€025: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P32.	0.4	0
1471	ICâ€Pâ€01: GREY MATTER CONNECTIVITY TRAJECTORIES ACROSS THE ALZHEIMER'S DISEASE CONTINUUM AND ASSOCIATIONS WITH COGNITIVE DECLINE. Alzheimer's and Dementia, 2019, 15, P1.	0.4	0
1472	ICâ€Pâ€076: FDGâ€PET REVEALS DISTINCT HYPOMETABOLIC TRAJECTORIES IN COGNITIVELYâ€DEFINED SUBGROUPS OF ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P68.	0.4	0
1473	ICâ€Pâ€015: VOXELâ€BASED AMYLOID PET STAGING FOR THE WHOLE ALZHEIMER'S DISEASE <i>CONTINUUM</i>. Alzheimer's and Dementia, 2019, 15, P24.	0.4	0
1474	ICâ€Pâ€097: DIFFERENTIATING THE BEHAVIOURAL VARIANT OF ALZHEIMER'S DISEASE FROM BEHAVIOURAL VARIANT FRONTOTEMPORAL DEMENTIA AND TYPICAL ALZHEIMER'S DISEASE: THE VALUE OF NEUROIMAGING. Alzheimer's and Dementia, 2019, 15, P84.	0.4	0
1475	MS-SMART study: systematic sampling bias concerns â€“ Authors' reply. Lancet Neurology, The, 2020, 19, 479-480.	4.9	0
1476	Operationalization of the ATN classification scheme in preclinical AD: Findings from EPAD V500.0 data release. Alzheimer's and Dementia, 2020, 16, e037912.	0.4	0

#	ARTICLE	IF	CITATIONS
1477	Amygdalar nuclei and hippocampal subfields on MRI: Test-retest reliability of automated segmentation in old and young healthy volunteers. <i>Alzheimer's and Dementia</i> , 2020, 16, e040322.	0.4	0
1478	Amyloid β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e040991.	0.4	0
1479	ExploreQC: A toolbox for MRI quality control in the EPAD multicentre study. <i>Alzheimer's and Dementia</i> , 2020, 16, e041952.	0.4	0
1480	Polygenic risk score for Alzheimer's disease is related to amyloid positivity in subjective cognitive decline: The SCIENCE project. <i>Alzheimer's and Dementia</i> , 2020, 16, e042116.	0.4	0
1481	Differential diagnosis of dementia combining web-based cognitive testing and MRI. <i>Alzheimer's and Dementia</i> , 2020, 16, e042626.	0.4	0
1482	Examining centiloid quantification against visual assessment using [18F]flutemetamol PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e042653.	0.4	0
1483	Computerized decision support to select memory clinic patients for amyloid PET: Which patient to test?. <i>Alzheimer's and Dementia</i> , 2020, 16, e042687.	0.4	0
1484	Biomarker testing in MCI patients: Deciding who to tap. <i>Alzheimer's and Dementia</i> , 2020, 16, e042735.	0.4	0
1485	Neurofilament light and cognitive performance: Associations with amyloid and vascular pathologies in individuals with mild cognitive impairment. <i>Alzheimer's and Dementia</i> , 2020, 16, e042739.	0.4	0
1486	Amyloid β deposition in cognitively normal oldest-old is associated with cortical thinning and faster memory decline. <i>Alzheimer's and Dementia</i> , 2020, 16, e042768.	0.4	0
1487	Gray matter atrophy, but not vascular brain injury is related to cognitive impairment in patients with heart failure. <i>Alzheimer's and Dementia</i> , 2020, 16, e042892.	0.4	0
1488	A multi-centre study analysis of the spatial-temporal progression of amyloid deposition and its utility for longitudinal studies. <i>Alzheimer's and Dementia</i> , 2020, 16, e044707.	0.4	0
1489	Current status and quantitative results of the AMYPAD prognostic and natural history study. <i>Alzheimer's and Dementia</i> , 2020, 16, e044711.	0.4	0
1490	Amyloid-independent association of grey matter network disruptions with phospho-tau in preclinical Alzheimer's disease. <i>Alzheimer's and Dementia</i> , 2020, 16, e044739.	0.4	0
1491	Amyloid pathology, but not vascular pathology, is associated with risk of incident dementia in non-demented memory clinic participants. <i>Alzheimer's and Dementia</i> , 2020, 16, e045196.	0.4	0
1492	Grey zone amyloid burden heralds future memory decline: The SCIENCE Project. <i>Alzheimer's and Dementia</i> , 2020, 16, e045210.	0.4	0
1493	Regional tau pathology is associated with loss of synapses and reduced synaptic activity: A combined [18 F]flortaucipir, [11 C]UCB and magnetoencephalography study. <i>Alzheimer's and Dementia</i> , 2020, 16, e045806.	0.4	0
1494	Regional distribution of tau pathology in cognitively unimpaired, genetically identical twins. <i>Alzheimer's and Dementia</i> , 2020, 16, e045876.	0.4	0

#	ARTICLE	IF	CITATIONS
1495	Associations of brain connectivity with disease progression and cognitive dysfunction in autosomalâ€dominant Alzheimer disease depend on imaging modality. <i>Alzheimer's and Dementia</i> , 2020, 16, e045942.	0.4	0
1496	Comparison of static and dynamic analysis techniques for longitudinal analysis of amyloid PET. <i>Alzheimer's and Dementia</i> , 2020, 16, e045991.	0.4	0
1497	Response: Brain military enhancement. <i>Neuroradiology</i> , 2020, 62, 547-547.	1.1	0
1498	Author response: Clinical relevance of acute cerebral microinfarcts in vascular cognitive impairment. <i>Neurology</i> , 2020, 94, 330-330.	1.5	0
1499	Magnetic Resonance: Applications in Dementia. , 2002, , 5-25.		0
1500	Neurodegenerative Disorders. , 2002, , 31-138.		0
1501	Disorders Primarily Affecting White Matter. , 2002, , 139-230.		0
1502	Neuroprotective Treatment in Primary Progressive Multiple Sclerosis: a Phase I/II Study with Riluzole. , 2004, , 41-47.		0
1503	5 Beeldvormend onderzoek. , 2009, , 43-51.		0
1504	Primary Grey Matter Loss. , 2011, , 59-135.		0
1505	Introduction to â€œQuantitative MRI of the Spinal Cordâ€, 2014, , xvii.		0
1506	Imaging biomarkers for the diagnosis of Prion disease. , 2018, , .		0
1507	Staying Connected: The Relevance of Motor-specific Transcallosal Fibers. <i>Radiology</i> , 2021, , 212510.	3.6	0
1508	Decreased integrity of the monoaminergic tract is associated with a positive response to MPH in patients with vascular cognitive impairment - proof of principle study STREAM-VCI. <i>Cerebral Circulation - Cognition and Behavior</i> , 2022, 3, 100128.	0.4	0
1509	Response to the â€˜Letter to the editorâ€™ 10.1007/s00234-022â€02906-z. <i>Neuroradiology</i> , 2022, 64, 849.	1.1	0
1510	A stepwise approach towards diagnostic workup in dementia using online cognitive tools. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
1511	Mapping associations across multiple aspects of Alzheimer disease and the role of CSF biomarkers in individuals without dementia. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0
1512	Tau and synaptic biomarkers but not amyloidâ€ β are associated with cerebral perfusion in the Alzheimerâ€™s disease spectrum. <i>Alzheimer's and Dementia</i> , 2021, 17, .	0.4	0

#	ARTICLE	IF	CITATIONS
1513	Prediction of amyloid pathology in cognitively unimpaired individuals using structural MRI. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1514	Tau deposition is associated with grey matter network breakdown across different stages of the Alzheimer's disease continuum. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1515	Baseline MRI and CSF measurements in cognitively normal individuals as prognostic markers of progression to mild cognitive impairment. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1516	Automatic brain extraction using deep learning. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1517	Residual approaches to capture resilience and resistance in aging and Alzheimer's disease: A meta-analysis. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1518	Regional amyloid accumulation predicts memory decline in initially cognitively unimpaired individuals. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1519	Genetically identical twins are highly similar in levels and spatial distribution of tau pathology: A [¹⁸ F]flortaucipir PET study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1520	Subjective cognitive decline and self-reported sleep at a memory clinic: The SCIENCE project. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1521	Cognitive decline in possible vascular cognitive impairment (VCI): Does the form of vascular brain injury matter?. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1522	Neuroimaging-derived phenotypes in the European Prevention of Alzheimer Dementia (EPAD) Cohort Study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1523	Current status and quantitative results of the AMYPAD prognostic and natural history study. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1524	Differential gray matter connectivity correlates of CSF biomarkers: Results from the EPAD Cohort. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1525	Predicting institutionalization and mortality across the spectrum of Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.4	0
1526	Title is missing!. , 2020, 15, e0226784.		0
1527	Title is missing!. , 2020, 15, e0226784.		0
1528	Title is missing!. , 2020, 15, e0226784.		0
1529	Title is missing!. , 2020, 15, e0226784.		0
1530	Cerebrospinal fluid proteomic profiling of individuals with prodromal Alzheimer's disease classified using two different neurodegenerative biomarkers (N) in A/T/N classification. Alzheimer's and Dementia, 2021, 17, e053030.	0.4	0

#	ARTICLE	IF	CITATIONS
1531	Glioma perfusion quantification with ASL and DSC: head-to-head comparison with 15O-H2O PET. Nuklearmedizin - NuclearMedicine, 2022, 61, .	0.3	0